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ABSTRACT
FIBRINOGEN-CONJUGATED GOLD-COATED MAGNETITE NANOPARTICLES FOR
TARGETING ACTIVATED PLATELETS IN A WHOLE BLOOD SYSTEM
by
Cammy Truong
The University of Wisconsin-Milwaukee, 2020
Under the Supervision of Professor Julie Oliver
Activated platelets are a key component of the arterial thrombi responsible for heart
attack and stroke. Tissue plasminogen activator (tPA) is currently the only FDA-approved drug
for ischemic stroke. It works by dissolving fibrin, thus breaking down the clot and restoring
blood flow to the brain. However, it must be administered within 4.5 hours of the onset of stroke.
This leaves a significant number of patients who are ineligible for intervention and who have
poor clinical outcomes. Additionally, tPA is not injury site-specific; consequently, the side
effects range from mild to severe. We are investigating targeting activated platelets in occlusive
thrombi for magnetically-induced hyperthermia as an alternative therapy for ischemic stroke.
The binding of plasma fibrinogen to its platelet surface receptor is dependent on cell
activation and could therefore function in selective targeting of activated platelets. When
fibrinogen receptors are cross-linked by ligand, they engage the actin cytoskeleton and clear
from the edges of platelets or groups of platelets, thereby exposing additional unoccupied
receptors. We propose that fibrinogen-conjugated nanoparticles can be used to target activated
platelets rather than fibrin within an existing occlusive clot as a means to restore blood flow in
the vessel. In our model, selection for activated platelets over quiescent circulating platelets is
critical in order to minimize bleeding complications that are especially dangerous in ischemic
brain. We hypothesize that fibrinogen-conjugated, gold-coated magnetite nanoparticles can
ii

specifically target activated platelets and disrupt occlusive thrombi when exposed to an
oscillating magnetic field. We tested this using an in vitro model system of thrombosis that
allows platelet activation and fibrin formation in platelet-rich plasma or whole blood. Exposing
labeled samples to an oscillating magnetic field will cause hyperthermia and disrupt clots. Dense
fibrin networks make nanoparticle penetration into the clots very difficult, so we have described
clot structure and quantified nanoparticle access to the clot interior using the robust gold
nanoparticle system. Our experiments found nanoparticles interact with both activated platelets,
and fibrin, giving us multiple targets; clot structure influences how well the nanoparticles are
incorporated; and multiple applications of nanoparticles may increase the power of clot busting.
These results show our specific cell targeting with hyperthermia can be developed into a viable
therapy for ischemic stroke.
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Chapter 1- A Novel Treatment for Ischemic Stroke: Specific Cell Targeting with
Nanoparticles for Hyperthermia

1

Impact of stroke worldwide and in the United States of America:
Worldwide, an estimated 11.6 million incident ischemic strokes and 5.3 million incident
hemorrhagic strokes occur each year. Of the 16.9 million total, 6.1 million people died and about
5 million survivors were left disabled. In fact, strokes are the second leading cause of death and
the third leading cause of disability in the world (1, 2).
In America, each year nearly 795,000 people experience a new or recurrent stroke. Of
these, 610,000 of these are first attacks, and 185,000 are recurrent. Of the strokes in America,
87% are ischemic and 13% are hemorrhagic. Although less common, hemorrhage strokes have a
higher mortality rate compared with ischemic strokes. Approximately 8% to 12% of ischemic
strokes and 37% to 38% of hemorrhage strokes result in death within 30 days of stroke onset.
Every 40 seconds, someone in America has a stroke. On average, every 3 minutes and 35
seconds someone dies of a stroke. Strokes account for 1 in every 19 deaths in America. When
considered separate from other cardiovascular diseases, strokes rank fifth among all causes of
death, behind diseases of the heart, cancer, chronic lower respiratory diseases and unintentional
accidents (1). In addition, stroke is the leading cause of serious long-term disability in America
(1, 3). In 2014 to 2015, the average annual cost of strokes in the US was $45.5 billion. $28
billion of which were direct medical costs, including outpatient or office-based provider visits,
hospital inpatient stays, emergency department visits, prescribed medicines, and at home health
care (1, 4).
Strokes appear to be a huge burden for not only our nation’s people and its economy, but
also people and economies worldwide. Despite the enormous impact of strokes, there are still
very few treatments currently available. Thus, new approaches to therapy are needed.
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Pathology underlying stroke:
A stroke is defined simply as a “brain attack” or a “cerebrovascular accident”. Blood
vessels that deliver blood to the brain or other parts of the body from the heart are called arteries.
A stroke is a disease that affects the arteries leading to and within the brain. The brain needs a
constant supply of blood carrying the oxygen and nutrients it needs to function. Specific arteries
provide blood to specific areas of the brain. A stroke occurs when the blood vessels flowing to
the brain either become blocked or ruptured. When the blood supply to the brain is cut off, the
brain cells do not receive enough oxygen and nutrients. If the deprivation of oxygen and
nutrients lasts long enough, these brain cells will start to die. When the cells begin to die, the
functions controlled by that area of the brain, such as memory or muscle control, can be lost. The
ultimate effect of the stroke on the patient primarily depends on several factors including the
location of the obstruction or rupture, and how much the brain tissue is damaged (5-8). For
example, if a stroke happens in the occipital lobe, it’s likely that a disability involving vision will
result. Also, as sides of the brain have contralateral control of the body, a stroke on one side of
the brain will cause neurological complications on the opposing side of the body.
Anyone can have a stroke at any age. Stroke risk factors include underlying medical
conditions, lifestyle choices, genetics, age, sex, and ethnicity. Strokes are classified into two
broad categories; ischemic (clots) and hemorrhagic (bleeds).
Hemorrhagic strokes account for 13% of all stroke cases (1). There are two main types of
hemorrhagic stroke; intracranial hemorrhages happen when the bleeding occurs inside the brain
and subarachnoid hemorrhages happen when the bleeding occurs between the brain and the
meningeal membranes that cover it. Hemorrhagic stroke is usually the result of a weakened
vessel, or aneurysm, that ruptures and bleeds into the surrounding brain. Thus, it allows blood to
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leak and accumulate inside the brain. The sudden increase in pressure within the brain causes
compression of the surrounding brain tissue and leads to neural damage. In addition, when
neurons are exposed to high concentrations of the blood coagulation protease thrombin, it causes
apoptosis via signaling through members of the protease activated receptor (PAR) family (9, 10).
The available treatments for hemorrhagic stroke depend on what caused it, its location, and the
size of the hemorrhage. Treatments include interventional radiology or neurosurgical procedures
such as surgical clipping or coil embolization. Neurosurgical procedures are performed to stop
the bleeding and reduce the pressure in the brain. Additionally, medications can be given to
reduce swelling, pain, and prevent seizures. The best treatment for hemorrhagic stroke is
detection of the aneurysm before it bursts and to undergo a surgical repair of the vessel. After
rupture occurs, treatment becomes more difficult and outcomes can be poor (11).
The majority of strokes are ischemic. They account for 87% of all stroke incidences (1).
Thus, it is implied that ischemic strokes are responsible for the majority of disabilities suffered
by stroke victims. Ischemic strokes are caused by occlusive clots in arteries, where high shear
rate contributes to platelet activation and fibrin formation. This results in rich-platelet thrombi
that reduces blood supply to the brain and leads to a hypoxic condition and a lack of nutrients
downstream of the blockage (12-14). Types of ischemic strokes can be further broken down by
the cause of the occlusion. The most common type of ischemic stroke, known as a cerebral
thrombosis, is a thrombus that develops at a fatty plaque build up within the blood vessel.
Another type of ischemic stroke is called a cerebral embolism. It is a blood clot that forms at
another location in the circulatory system, such as the heart or large artery of the upper chest and
neck. Then, part of the blood clot breaks loose, enters the bloodstream, and travels through the
brain’s blood vessels until it reaches vessels too small to pass through. The embolism usually
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originated in the heart in an unclosed foramen ovale or damaged heart valve, or in atherosclerotic
arteries (15-17).
Both types of ischemic stroke have the same outcome of occluding the vessel and
obstructing the flow of blood to the brain tissue supplied by the occluded artery. When blood
stops flowing to brain tissues, it will develop two different areas of injury. The zone closest to
the artery that has been blocked off is called the ischemic core. The zone on the periphery of the
core is called the ischemic penumbra. During ischemic stroke, neurons and their supporting cells
located within the ischemic core will die off quickly due to the deprivation of oxygen and
nutrients, causing a metabolic drop in these cells because of the deregulation of cellular K+ and
Ca2+ ion gradients (18-20). Neurons and their supporting cells in the ischemic penumbra can live
a little longer than those in the core because they get some blood supplied from surrounding
arteries. However, these neurons still become silent due to reduced metabolism and are at risk of
degradation as the ischemic stroke progresses. They eventually will die off if blood flow is not
reestablished. The penumbra is the area where treatments are most likely to be effective
compared to the ischemic core. Thus, if the blood flow can be restored safely into the ischemic
area in a timely manner, neurons in the penumbra may regain normal function and damage to
brain tissue can be minimized. As a result, a great interest lies in the quick reperfusion of the
penumbra (21, 22).

Current treatment for ischemic stroke:
The only FDA-approved drug for ischemic stroke is recombinant tissue plasminogen
activator (tPA), a clot-dissolving medication. The first-generation product on the market carries
the generic name alteplase (Activase®, Genetech). This medication, administered intravenously
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or directly to the site of the blockage, has to be provided within the first 4.5 hours of a stroke.
tPA benefits patients through limiting the amount of brain tissue that dies by dissolving the blood
clot in the brain and restoring blood flow to the affected brain territory before it sustains
irreversible damage. Because the benefit of tPA is time dependent, it is critical to treat patients as
quickly as possible. tPA is classified as a serine protease and is one of the essential components
of the fibrinolysis pathway, which is an important first step in the wound healing process. tPA’s
primary function includes initiating fibrinolysis by catalyzing the conversion of plasminogen to a
serine protease plasmin, the primary enzyme involved in dissolving blood clots (23, 24). Plasmin
is the major protease responsible for local fibrinolysis and leads to the decrease in size of fibrin
strands (Figure 1), causing fibrin to lose its function of trapping clot components such as
platelets and red blood cells (RBCs). Thus, dissolution of the clot occurs, and blood flow is
restored to the surrounding tissue and perfused ischemic neurons.
Since approval of tPA as a therapeutic for ischemic strokes in 1996, it has been found to
be and is now considered a double-edged sword. tPA is not injury site-specific and can cause
bleeding complications at sites outside of the occlusion. In some instance, administering tPA can
be considered more dangerous than the stroke itself because it can cause brain hemorrhages.
According to alteplase guidelines, the drug is only approved in patients suffering from an acute
ischemic stroke. In order to receive tPA, patient criteria such as time restrictions, potential
bleeding complications, medical history, and age issues have to align. If the potential benefit of
tPA therapy is greater than the risk of side effects such as bleeding, the providers will administer
tPA. In fact, the strict eligibility criteria for this medication lead to low rates of alteplase
treatment (25, 26). Moreover, up to 2/3rds of stroke patients that received tPA treatment with
large-vessel occlusions did not achieve recanalization. In addition, less than 50% of those treated
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with tPA achieved a complete reperfusion by 24 hours and about 40% of the stroke patients
remained severely disabled or died (27, 28). Thus, there is a need to develop a combinational
therapy that could offset tPA side effects and improve efficacy in clinical practice or develop a
new therapeutic as an alternative to tPA treatment for ischemic stroke.
Although tPA works well in dissolving smaller clots in narrower vessels, a safe dose of
tPA administered by intravenous infusion often does not last long enough in the bloodstream to
break down large clots. In fact, tPA has been shown to be ineffective against larger blood clots
(29, 30). And since increasing the dose of tPA raises the risk of bleeding complications, raising
tPA dosage is not a viable option. In addition to improving recanalization and reducing
hemorrhage risk by limiting use of thrombolytics, there has been an explosion of interest into
endovascular mechanical thrombectomy as a potential treatment for stroke (31-33). Mechanical
thrombectomy is a minimally invasive procedure. During a mechanical thrombectomy
procedure, neurovascular surgeons make a small incision either at the wrist or the abdomen to
gain the access to an artery. Using fluoroscopy to observe real-time images of the blood vessels,
the surgeon threads a catheter through the artery to the clot. Then, the clot can be removed from
the body by suction or stent retriever. Studies have shown that patients that were treated with
mechanical thrombectomy recover faster and with an improved quality of life compared to those
patients using clot-busting tPA (31, 33-38). In 2004, the mechanical embolus removal in cerebral
ischemia (MERCI) retriever became the first FDA approved device to be cleared for
thrombectomy in acute ischemic stroke (31, 33). Since then, there have been multiple devices
tested for this purpose including the Penumbra system, the Neuronet, the Catch device, the
Phenox Clot Retriever system, and the Alligator Retriever device. Two newer devices that are
robust and most successful at revascularization are the Trevo device and the Solotaire (39-45).
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Despite advancements that have expanded the time window for ischemic stroke treatment
to between 6 and 24 hours after onset and an ability to remove larger clots found in large artery
occlusions, some issues that may limit the widespread clinical use of mechanical thrombectomy
remain. First, time restrictions are still a problem with a majority of patients. It is estimated that
only 10% of patients with acute ischemic stroke have a proximal large artery occlusion and
present early enough to qualify for mechanical thrombectomy within 6 hours (46-49), and only
9% of patients presenting in the 6 to 24 hour time window qualify for mechanical clot removal
(50). Second, it is worth mentioning that only health centers with advanced imaging facilities and
well-experienced doctors can perform mechanical thrombectomies (51, 52). Third, like all
surgical interventions, mechanical clot removal carries the risk of complications such as vascular
injury, emboli, vasospasms and symptomatic hemorrhaging (28, 53).
So far, there are still very few FDA approved therapies for ischemic stroke. While tPA
can be used to treat the majority of ischemic strokes occurring in smaller vessels, mechanical
thrombectomy might be performed on thrombi occurring in relatively large vessels. However,
both treatments still have strict limitations on which patients are eligible to receive them. In this
regard, an alternative therapy for ischemic stroke may yet provide additional benefits to stroke
patients that existing treatments do not.

Platelets as a potential target for ischemic stroke treatment:
There are very limited choices for treating ischemic stroke. However, evidence points to
tPA as being the most effective and, at present, gold standard treatment for ischemic stroke (54).
Despite approval more than 20 years ago, tPA administration does not help every patient who
receives it.
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Ischemic stroke caused by an arterial blood clot interrupts the delivery of oxygen and
nutrients to tissue downstream of the blockage. This clot is mainly composed of fibrin and
activated platelets. Since targeting fibrin using tPA seems not to be a universal treatment for all
ischemic stroke patients, targeting platelets in an occlusive clot could be a viable option.
In mammals, platelets are small non-nucleated cells in circulation with a diameter of 1-2μm and
are derived from megakaryocytes in the bone marrow. Platelets were first identified in 1874 by
Osler (55) and their role in both physiological hemostasis and pathological thrombosis was
established by Bizzozero in 1881 (56). In non-mammalian vertebrates, hemostasis is mediated by
nucleated cells called thrombocytes (57). In fact, platelets are more effective than thrombocytes
in forming occlusive clots under arterial shear stress (58). Platelets usually live between 7-10
days in humans and approximately 5 days in mice. The regulation of platelet production is
exercised at the level of megakaryocytes.
Hemostasis is a critical physiological process to stop bleeding upon vascular injury. At
the site of injury, endothelial cells are disrupted and expose subendothelial matrix proteins such
as collagen, the most thrombogenic component of sub-endothelium (59-61). In physiological
conditions, collagen initiates platelet adhesion, aggregation, degranulation, and subsequent
recruitment of platelets to the injury site, producing an initial platelet plug that is the first wave
of hemostasis. Soluble mediators released from activated platelets play a major role in platelet
recruitment. Simultaneous activation of the coagulation system results in the generation of
thrombin, the most potent agonist for platelet activation in vivo (62,63), and the protease that
converts fibrinogen to fibrin. The second wave of hemostasis occurs as the fibrin polymers begin
to form. They wrap around the platelet plug, stabilize it, and trap more platelets, red blood cells
(RBCs) and white blood cells to form a whole blood clot (Figure 2). Thus, platelets play an
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important role in hemostasis. However, the same normal processes that occur during hemostasis
may also cause thrombosis and vessel occlusion if the platelet plug formation and blood
coagulation processes are inappropriate. These circumstances lead to pathological conditions
including strokes and heart attacks. Over the years, antiplatelet drugs have evolved to inhibit
platelet adherence, aggregation, and activation. These are used to prevent further thrombotic
events in patients who have already had an ischemic stroke or heart attack (Figure 3).
Upon platelet adherence and aggregation, platelets secrete thromboxane A2 (TXA-2)
causing platelet recruitment and activation. TXA-2 is a product of arachidonic acid metabolism
and synthesis within activated platelets. TXA-2 formation is catalyzed by the enzyme
cyclooxygenase-1 (COX-1). Aspirin, also known as acetylsalicylic acid, is an irreversible COX-1
inhibitor that affects platelets for their entire lifespan, thereby completely abolishing platelet
TXA-2 formation and causing reduced platelet function. Aspirin is commonly used to reduce the
risk of death from heart attacks or the risk of strokes in people who are at high risk or who have
cardiovascular disease (64-67).
After initial platelet activation, platelet dense granules release pro-aggregatory
substances. One of these substances is adenosine diphosphate (ADP). ADP interacts with the
family of purinergic G protein-coupled receptors on the platelet surface such as P2Y1, P2Y12
and P2X1 receptors, eventually leading to platelet aggregation. The activation of P2Y1 and
P2X1 receptors initiate an influx of calcium into the platelet, causing shape change and weak
reversible platelet aggregation. On the other hand, once ADP binds onto P2Y12 receptors, it
activates a cascade of events leading to integrin αIIbβ3 receptor activation. This receptor is
important for strong and irreversible platelet aggregation. Thienopyridines, including ticlopidine
(Ticlid), clopidogrel (Plavix), and prasugrel (Effient), were generated to irreversibly block the
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P2Y12 receptor. Thienopyridines in combination with aspirin is the standard of care in
management of acute ischemic stroke (64, 68-70).
One of the most common pathways of platelet activation is the activation of the platelet
glycoprotein IIb/IIIa receptor, also known as the platelet integrin αIIbβ3 receptor. The platelet
integrin αIIbβ3 receptor serves as a platelet surface receptor for fibrinogen. Aggregating platelets
stick together by the crosslinking of receptors by the bivalent fibrinogen molecule. Despite the
dual antiplatelet treatment of aspirin and thienopyridine, platelets can still be activated through
stimuli that are insensitive to these drugs such as thrombin, resulting in activation of integrin
αIIbβ3 receptors. Thus, a class of drugs that block the integrin αIIbβ3 receptor was developed.
Abciximab is a chimeric antibody that binds with high affinity to the integrin αIIbβ3 receptors and
inactivates them. Tirofiban and eptifibatide are small molecules that competitively bind to the
integrin αIIbβ3 receptors. These three agents for intravenous use have been shown to be effective
in preventing heart attack and ischemic stroke (64, 71-73). The efficiency of aspirin,
thienopyridines, and integrin αIIbβ3 receptor blockers in preventing strokes and heart attacks
suggest that antiplatelet therapy could be a potential tool in precluding arterial blood clotting.

Normal platelet physiology:
In circulation, resting platelets have a discoid shape that is maintained by a ring-shaped
bundle of microtubules at the platelet periphery, known as a circumferential microtubule band.
The circumferential microtubule band is also important in encasing the cytoplasm of a platelet.
In addition, platelets contain two types of granules named α-granules and dense granules. Upon
platelet activation, α-granules and dense granules secrete contents that are required for creating a
firm plug to seal the blood vessel damage. The α-granule is the most abundant organelle in
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platelets and plays a crucial role in hemostasis, wound healing, and inflammation. They contain a
plethora of proteins that comprise the bulk of the platelet secretome. For example, hemostatic
factors (von Willerbrand factor (vWF), the adhesion molecule P-selectin, coagulation factor V,
thrombospondin, fibrinogen), angiogenic factors (angiogenin, vascular endothelial growth
factor), antiangiogenic factors (angiostatin, platelet factor-4), growth factors (platelet-derived
growth factor, and tumor growth factor beta), proteases (matrix metalloproteinase-2, matrix
metalloproteinase-9), necrotic factors (tumor necrosis factor alpha, tumor necrosis factor beta)
and other cytokines are all found in α-granules (74-76). Dense granules are smaller than αgranules, fewer in number, and predominantly contain small molecules including magnesium,
calcium, adenosine diphosphate (ADP), adenosine triphosphate (ATP), serotonin, and histamine.
The true function of a dense granule is not clearly defined. However, the secretion of dense
granules always occurs along with platelet activation. Studies have shown that dense granule
deficiency causes prolonged bleeding time (77-79). The platelet interior also contains the open
canalicular system, which is an internal membrane found inside platelets. The open canalicular
system serves as a pathway for the transport of substances into the platelet and as a conduit for
discharge of secretory products during platelet release reactions. Also, the open canalicular
system helps increase the platelet surface area that is available for interaction with its outside
environment and serves as a membrane reservoir of platelet plasma membrane that can be
evaginated onto the platelet surface during interaction with surfaces (80-83). Additionally,
mitochondria found in platelets have demonstrated an influence in a variety of purposes such as
metabolism, activation, energy production, regulation of cell processes, and viability (84, 85).
Platelet structures and their functions are shown in Figure 4.
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Upon contact with the extracellular matrix through endothelial damage or exposure to
soluble agonists, platelet activation stimulates the rapid reorganization of the cytoskeleton
resulting in the transformation of platelets from discoid to fully spread cells. Generally, there are
two steps in platelet shape change. In the first step, the discoid cells undergo extensive
cytoskeletal rearrangement including the disassembly of the circumferential microtubule band,
resulting in an intermediate spherical shape or a rounded ball. In the second step, actin
polymerization causes the membranes of the cells to protrude, causing the creation of
pseudopodia extensions (86-88). The extent of platelet shape change and the extension of the
pseudopodia depend on the platelet activation pathway. When platelets are exposed to an
activating surface, they will flatten and spread over that surface to greatly increase their contact
area. In the body, this would allow for increased coverage of the site of vessel damage as well as
providing more space for adhesion to occur (89, 90). Once platelets are activated, they release
their granules to the extracellular environment, leading to several events. The granule contents
play an important role in recruiting additional platelets to the site of injury where they bind to the
adherent platelets and form aggregates, activating other platelets, promoting the blood coagulant
cascade, and stimulating the wound healing process (91-93).

The common platelet activation pathways:
Mechanisms that control platelet activation require intracellular signal transduction
initiated by platelet receptors for adhesion proteins and soluble agonists. These common
adhesion proteins are collagen and vWF, and both are found in the vascular wall upon blood
vessel injury. Other soluble agonists include thrombin, ADP and TXA-2. These are released
from the sites of blood vessel injury, inflammation, or from other platelets during platelet
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activation. These agonists and adhesive molecules activate platelets by binding to their
respective receptors on platelet membranes, most of which are G-protein-coupled receptors
(GPCR), leading to the activation of platelet adhesion receptors, mainly integrin αIIbβ3 receptor.
The integrin αIIbβ3 receptor then mediates platelet aggregation.
Platelet activation via GPCRs involves three major G-protein mediated signaling
pathways that are triggered by the activation of the G proteins Gαi, Gαq, and Gα12/13 (94, 95).
Gαi functions by inhibiting adenylyl cyclase, preventing the accumulation of cAMP; thereby
inducing platelet activation and aggregation (94, 96). Gαq activation stimulates the activity of
phospholipase C-β, which catalyzes the release of diacylglycerol and inositol (1,4,5)triphosphate from membrane phosphatidylinositol 4,5 bisphosphate. Diacylglycerol and inositol
(1,4,5)-triphosphate in turn activate protein kinase C and stimulate the release of calcium from
the dense granules into the cytoplasm. Elevation in cytosolic calcium concentration is essential
for platelet activation (94, 97, 98). Activation of the Gα12/13 subunit in platelets initiates activation
of the small GTPase RhoA. RhoA and Rho kinase activation trigger phosphorylation of myosin
light chain kinases, which regulate the reorganization of the actin cytoskeleton associated with
platelet shape change (94, 99).
Collagen is the most thrombotic component of the subendothelium. Upon vascular
damage, collagen is exposed to circulating platelets where it can serve as a substrate for platelet
adhesion and also can induce platelet activation. Two receptors involved in the platelet response
to collagen are integrin α2β1 and glycoprotein VI. Integrin α2β1 functions to adhere platelets to
collagen and allows platelets to interact with the lower affinity receptor glycoprotein VI, which
is mainly responsible for platelet activation. Platelet activation in response to collagen is
mediated by the binding of collagen to the platelet receptor glycoprotein VI. As a result of
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ligation and clustering of glycoprotein VI, tyrosine phosphorylation occurs at the associated
transmembrane protein and Fc receptor γ-chain within its immunoreceptor tyrosine-based
activation motif. This promotes an association between the Fc receptor γ-chain and the tyrosine
kinase Syk. Subsequent activation of Syk leads to the phosphorylation of phospholipase Cγ2,
which leads to an increase in cytoplasmic calcium levels. An increase in intracellular calcium is
associated with morphologic change, the presentation of procoagulant surfaces, and the secretion
of platelet granule contents, resulting in platelet activation and aggregation (100-105). The
interaction of collagen and platelets is crucial and may be considered to be the initial event in
hemostasis and thrombosis (106).
Simultaneous activation of the coagulation system results in the generation of thrombin.
Thrombin is a serine protease, the terminal enzyme of the hemostatic system, and the most
potent agonist for platelet activation in vivo. During thrombus formation, thrombin converts
fibrinogen to fibrin (Figure 2), activates factor XIII (cross links fibrin in the clot), and activates
factors XI, VIII, and V (generates more thrombin). Also, thrombin serves as a major activator of
platelets by binding and cleaving protease activator receptors (PARs). The PAR family is a
subfamily of related G protein coupled receptors that are activated by proteolytic mechanisms.
Specific cleavage of the amino terminal sequence that unmasks a new N-terminal sequence that
functions as a tethered ligand, binding to a conserved region on the extracellular loop 2 domain
of the PAR, and resulting in a series of cellular signaling events (107-111). In humans, PAR1 is
the primary thrombin receptor on platelets. Since PAR1 contains a hirudin-like domain, which
has a high affinity thrombin binding site, it recruits thrombin via its exosite I. This interaction
enables thrombin to bind specifically and efficiently to activate PAR1 (107, 108). Thrombin also
cleaves and activates PAR4, which is considered a secondary thrombin receptor. In contrast with
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PAR1, PAR4 lacks a hirudin-like domain, and a higher concentration of thrombin is required to
activate PAR4 and initiate intracellular signaling events (107, 108). Mice lack a PAR1
homologue; therefore, mouse PAR4 is utilized as their primary thrombin receptor. Thrombincleaved PAR1 or thrombin-cleaved PAR4 leads to the activation of Gα12/13 and Gαq and in turn
induces Rho and Ca2+ signaling (108). Some studies have also shown PAR1 can bind to Gαi and
cause the inhibition of adenylyl cyclase (112-113). When studying platelets, it is often desirable
to activate PAR receptors to promote full platelet activation while avoiding surface proteolysis
and fibrin formation caused by the proteolytic activities of thrombin. Thus, one can alternatively
utilize synthetic peptides of the sequences corresponding to the tethered ligand portion of the
receptor to activate PAR receptors. The human PAR1 peptide SFLLRN-NH2 and the murine
PAR4 peptide AYPGKF-NH2 can be used as agonists to activate platelets (114-115). In our in
vitro system, thrombin will be mainly used to stimulate clot formation.
Although ADP itself does not typically cause the initial platelet activation event as
collagen or thrombin does, ADP is essential in promoting the secondary platelet response (91).
Following platelet activation, platelet degranulation releases ADP into the platelets’ surrounding
environment. ADP activates platelets by interacting with the G protein-coupled receptors P2Y1
and P2Y12. The P2Y1 receptor couples to Gαq. It is now established that activation of the P2Y1
receptor coupling with Gαq leads to the activation of phospholipase C-β, a subsequent increase in
cytosolic calcium, and the activation of protein kinase C. However, the P2Y1 receptor only
causes a transient increase in the concentration of intracellular ionized calcium that is released
from dense granules, which again initiates platelet aggregation and is responsible for platelet
shape change. P2Y12 receptors couple to Gαi. The activation of the P2Y12 receptor and subsequent
coupling with Gαi leads to the inhibition of adenylyl cyclase and the activation of
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phosphoinositide 3-kinase and causes the amplification of calcium levels. Thus, P2Y12 activation
results in amplification and stabilization of the aggregation response (116-120).
TXA-2 is not only produced and released by stimulated platelets; many studies have
shown that TXA-2 is also released by a variety of other cells such as macrophages,
neutrophils, and endothelial cells (121). TXA-2 is a chemically unstable lipid mediator involved
in several pathophysiologic processes including primary hemostasis, atherothrombosis,
inflammation, and cancer. In human platelets, the production of TXA-2 occurs via a sequential
process that begins with arachidonic acid (AA). AA is incorporated in the phospholipid
membrane of the body’s cells. During coagulation, phospholipase A2 enzyme cleaves and frees
AA from the phospholipid membrane. Then, the cyclooxygenase isoenzymes COX-1 and COX2 catalyze AA into the formation of proinflammatory TXA-2, antithrombotic prostacyclin, and
other prostaglandins. TXA-2 has prothrombotic properties, as it stimulates the activation of new
platelets as well as platelet aggregation. This is achieved when it binds and activates its G
protein-coupled receptor. As a result, Gαq and Gαi pathways are activated causing an increase in
the free cytosolic calcium and drop in cAMP production. These events consequently induce
platelet-shape change, degranulation and conformational change of integrin αIIbβ3 receptors on
the platelet surface (122-125).
Each platelet activation pathway utilizes its own unique receptors and signal transduction
mechanisms, which explains why various types of antiplatelet drugs were created to prevent
platelet activation. For example, acetylsalicylic acid and non-steroidal anti-inflammatory drugs
inhibit the COX-enzyme in the thromboxane pathway; vorapaxar is a competitive PAR-1
antagonist, and thienopyridines are selective ADP receptor inhibitors.
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Calcium is an essential component of coagulation and platelet activation. Platelet
activation can be inhibited in vitro by the use of calcium chelating agents such as
ethylenediaminetetraacetic acid (EDTA) and sodium citrate. Both are commonly used as
anticoagulants for the collection of blood samples. EDTA strongly and irreversibly chelates
calcium and other divalent metal ions present in the blood, thus halting blood clotting. Sodium
citrate acts similarly but not as strongly as EDTA. Sodium citrate anticoagulation can be readily
reversed by the addition of calcium, which is required before platelets can become competent for
activation again.

Fibrinogen and integrin αIIbβ3 receptor interaction - a potentially powerful strategy to
specifically target activated platelets:
All of these platelet-signaling events converge on the final common pathway of platelet
activation, which is the functional upregulation of integrin adhesion receptors. The activation of
the integrin αIIbβ3 receptor or glycoprotein IIb/IIIa is most important. On the surface of platelets,
the most abundant receptor is integrin αIIbβ3. There are about 80,000 copies per unstimulated
platelet (126, 127). Integrin αIIbβ3 plays a particularly crucial role in thrombus formation by
promoting platelet aggregation. Integrin αIIbβ3 function depends on two different signal
transduction pathways: inside-out and outside-in signaling. The inside-out signaling pathway is
initiated by the binding of one or more agonists to their platelet membrane receptors such as
thrombin, collagen, ADP, or TXA-2. Receptor-mediated signaling events lead to the conversion
of the integrin αIIbβ3 receptors from low affinity to high affinity conformation, thus making the
αIIbβ3 receptors ready to bind to their ligand, which is fibrinogen. Once activated, the αIIbβ3
receptor is capable of binding fibrinogen at a single receptor binding site, leaving the second
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binding site on the bivalent fibrinogen molecule free to bind onto an additional αIIbβ3 receptor
either on the same platelet or on an adjacent activated platelet (128-130). This crosslinking of
two receptors by bound fibrinogen allows platelet-platelet interaction and leads to platelet
aggregation (Figure 5) (131). After αIIbβ3 binds fibrinogen and crosslinks adjacent receptors,
integrin αIIbβ3 is then capable of reverse signal transmission inside the cell, called outside-in
signaling (130, 132). Under integrin outside-in signaling, the ligand-occupied receptors interact
with the actin cytoskeleton, causing the integrin with bound ligand to centralize on the plane of
the platelet membrane moving along the underlying actin cytoskeleton. The final location of the
migrated cross-linked receptors is dependent on the platelets’ activation morphology (Figure 6).
In surface-activated platelets, the integrin with bound ligand will centralize on the platelet
surface from its periphery to the vicinity of the platelet granulomere; whereas, in suspensionactivated platelets, ligand-occupied receptors will localize at the platelet-platelet junctions where
platelets have become cross-linked together or will migrate into the open canalicular system of
the platelet (133-136). Moreover, outside-in signaling through platelet integrin αIIbβ3 activation
facilitates the clot retraction process that results in the fibrin clot gradually being pulled in on
itself, shrinking to a smaller volume clot and extruding excess fluid. This draws the edges of
damaged tissue together and forms a mechanically stable clot (137-139).
Fibrinogen is the primary ligand of the integrin αIIbβ3 receptor. Fibrinogen is a soluble
glycoprotein complex that is synthesized by the liver and circulates in human blood at 3mg/mL.
Fibrinogen is a dimer where each monomer consists of two chains of each α, β and γ held
together by disulfide bonds. The N-terminal of all six chains come together to form the center of
the molecule known as the E-domain, from which the monomers extend in opposite directions as
coiled-coils followed by C-terminal globular D-domains (140-142). Respectively, the structure
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of fibrinogen is presented as three linearly arranged domains, D-coil-E-coil-D. Fibrinogen plays
important roles in both the blood coagulation cascade and platelet aggregate formation. During
blood clot formation, the generation of thrombin triggers the conversion of soluble fibrinogen to
insoluble fibrin. Thrombin cleaves the N-terminal fragments of the α and β chains within the Edomain of fibrinogen; this releases fibrinopeptides A and B, respectively, and produces
fibrin. The release of fibrinopeptides A and B results in the exposure of four binding sites on the
E-domain, each of which can interact with a D-domain from different fibrin molecules to form
fibrin polymers that consist of lattice networks of fibrin that in turn form long, branching, and
flexible fibers (142-144). Fibrin strands gather together to make a mesh that traps platelets,
RBCs, and several different proteins and cells to form a clot. In addition, thrombin
proteolytically converts the plasma protransglutaminase factor XIII (FXIII) to activated FXIII
(FXIIIa) which cross-links fibrin molecules via the γ chain between D-domains to ensure
stabilization and resistance to degradation of the fibrin clot (145, 146). Fibrinogen has a
significant role in platelet response to injury. Fibrinogen binding to its platelet receptor requires
platelet activation, which allows for platelet-platelet interaction and platelet aggregation. Platelet
aggregation involves the binding of the platelet integrin αIIbβ3 receptor to the C-terminal Ddomain of fibrinogen, a vital step in normal arterial bleeding response (147).
Since the binding of fibrinogen to its receptor is essential for platelet function, fibrinogen
binding to its receptor on activated platelets has been extensively studied and characterized. The
discovery that Glanzmann’s thrombasthenia, an autosomal recessive bleeding disorder, is caused
by deficient or dysfunctional integrin αIIbβ3, has led to a significant effort to develop
antithrombotic agents that target and block the platelet fibrinogen receptors (148). Abciximab,
(ReoProÒ), is the Fab fragment of a human-murine chimeric monoclonal antibody that binds and
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blocks the integrin αIIbβ3 on human platelets, and thus inhibits platelet aggregation. Abciximab
has been shown to be effective in preventing restenosis during percutaneous coronary
interventions and in myocardial infarctions (149). However, abciximab showed no significant
benefit in the treatment of ischemic stroke (150). This is largely because abciximab has been
associated with a significant increase in symptomatic intracranial hemorrhaging. Furthermore,
patients treated with abciximab for myocardial infarction were at a higher risk of
thrombocytopenia. The risk of thrombocytopenia was especially elevated in patients receiving
abciximab re-administration (151, 152). The lack of specificity of abciximab for activated
platelets limits its utility as a therapeutic for ischemic stroke. However, exploiting the interaction
between fibrinogen and integrin αIIbβ3 remains a potential strategy if it were possible to
specifically target activated platelets in occlusive thrombi.
Integrin αIIbβ3 receptors can bind fibrinogen via the recognition peptide sequence ArgGly-Asp (RGD) found on the α chain (153-156), although the primary interaction occurs through
the C-terminal peptide of the γ chain. Thus, integrin αIIbβ3 on platelets has been targeted by using
the binding of short synthetic RGD peptide sequences to inhibit aggregation of human platelets.
However, using fibrinogen to target αIIbβ3 receptors on platelets may be superior to RGD
peptides. Fibrinogen binding to its platelet integrin αIIbβ3 receptor requires agonist activation on
platelets, which creates a method to distinguish between quiescent circulating platelets and
activated platelets, whereas the binding of short synthetic RGD peptides does not (157).
Additionally, fibrinogen targeting activated platelets would be superior to αIIbβ3-directed
antibodies such as abciximab, which is only moderately selective for activated αIIbβ3 and has a
systemic effect on all platelets. Many studies have successfully used fibrinogen conjugated-gold
nanoparticles to demonstrate the interaction between fibrinogen and integrin αIIbβ3 receptors

21

using electron microscopy (80, 90, 158-164). These studies suggest that using fibrinogenconjugated nanoparticles could be used to select activated platelets. Thus, we propose that we
could use the full fibrinogen molecule to specifically target activated platelets in an occlusive
clot and utilize this as a potential treatment for ischemic stroke.

Nanoparticle-based induced cell death:
While tPA based treatments of ischemic stroke target lysis of the fibrin within blood
clots, we propose that specifically targeting activated platelets in an occlusive clot may provide a
better treatment for ischemic stroke patients. Nanoparticles represent an active area of research
and show great promise in biological applications (165). For example, in passive targeting,
nanoparticles have been successfully developed for cancer therapy by taking advantage of unique
tumor tissue biology. Tumors have high vascular density, increased vascular permeability, and
impaired lymphatic drainage. These physiologic characteristics contribute to the formation of
solid tumors and inflamed tissue. Together, these features of a tumor enhance nanoparticle
accumulation in tumor tissue (166, 167). In fact, nanoparticles can be engineered to better target
a particular tissue type cell by optimizing their physiochemical characteristics such as
nanoparticle composition, size, shape, and surface properties (168). Active targeting involves the
use of a targeting ligand for the enhanced delivery of nanoparticles to specific sites. Typical
ligands include small molecules, peptides, antibodies and nucleic acids that have been
conjugated to the nanoparticle surface via non-covalent or covalent methods (169). Ligandconjugated nanoparticles facilitate active targeting of nanoparticles to receptors that are present
on target cells, causing cell internalization, or specific uptake through receptor-mediated
endocytosis (170, 171). Active targeting can allow for very specific targeting of a cell type, or
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even selecting between activated and inactivated cells of the same type. Thus, active targeting
using nanoparticles may have benefits in reducing systematic toxicities and other adverse effects.
These targeting methods have been focused mainly on the development of anticancer
treatments; however, the concept can be applied to various cell types of interest if they express
unique targetable features. Furthermore, the use of these therapies would require specific
targeting of cells, but could also require nanoparticle properties that cause effects, such as
damage to the cells of interest. Nanoparticle-based treatments could induce cell death either by
cytotoxic agents or be capable of inducing cell death directly. If we can combine specific cell
targeting with a method of causing cell death, then nanoparticle-induced side effects such as
toxicity or disruption will be largely restricted to the targeted cells or a specific tissue site. For
instance, doxorubicin is one of the best known and most widely used anticancer chemotherapy
drug. The therapy-limiting factor for this drug is toxicity caused cardiomyopathy, which may
produce congestive heart failure and death (172, 173). To avoid this complication, doxorubicin is
encapsulated in a closed liposome as a carrier to reduce the systematic toxicity of the drug.
Encompassing the drug in a liposome also allows a method for targeting cancer cells via ligand
binding to functional folate receptors (174, 175). Other nanoparticle-based systems can lead to
cellular destruction, such as death-induced gene therapy (apoptosis-induced gene therapy and
toxin-induced gene therapy) (176, 177), or physical damage caused by hyperthermia (178).

Magnetically induced hyperthermia as alternative therapy for ischemic stroke:
Since nanoparticles can be engineered and modified with distinct compositions, size,
shapes, functionalities, and surface chemistries, they can display unique physical and chemical
properties and represent an increasing area of interest in the development of nanodevices. These
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have the potential to be used in a wide range of applications that range from energy production to
industrial production processes to biological applications. Considering the other properties
including electric, optical, magnetic, and thermal attributes, nanoparticles could be used in
variety of biological applications. Some of them are liposomes, albumin-bound, gold, and
magnetic iron oxide.
Liposomes are the first nanoparticle platform. Liposomes are spherical vesicles that
contain a phospholipid bilayer structure or membrane that spontaneously encloses an internal
aqueous solution. The structure of the membrane can vary significantly, making it possible to
create a vast number of different liposomes. In fact, liposomes can mimic biological cells;
thereby, liposomes are highly biocompatible for drug delivery systems (165, 179-182). However,
liposome drug development to larger-scale production and to the clinic are still restricted due to
their instability, polydispersity, toxicity at repeated administration, and capability of inducing
immune responses.
Albumin is a component of the human blood, so as an endogenous protein it shows no
immunogenicity, ensuring that albumin-based nanoparticles have good biocompatibility.
Albumin-bound nanoparticles use the endogenous albumin pathways to carry hydrophobic
molecules in the bloodstream. As a result, albumin-based nanoparticles have been successfully
adapted as drug delivery vehicles. Albumin-bound paclitaxel (Abraxane) is a highly successful
treatment for metastatic breast cancer (165, 179, 183, 184).
Magnetic iron oxide nanoparticles have been studied extensively and are among the most
widely used nanoparticles in many biomedical applications such as drug delivery, therapeutic
treatment, contrast agents for MRI imaging, and in vitro diagnostics (185). Nanometer-sized
particles are known to be superparamagnetic as a result of their small size. Superparamagnetic
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nanoparticles only become magnetized when placed within a magnetic field and return to a nonmagnetized state after an external magnetic field is removed. Therefore, the superparamagnetic
property may be safe for use in biological system applications by giving the nanoparticles an
on/off switch. Despite their great potential, using magnetic nanoparticles in biological systems
poses challenges with respect to their electrical conductivity, optical properties, chemical
stability, biocompatibility, and bioaffinity (186, 187). Gold nanoparticles have chemical
inertness, surface properties, electronic structures, and optical properties that have made them
appropriate for a number of clinical applications (188). Therefore, coating magnetic
nanoparticles with gold could overcome some of the limitations of magnetic nanoparticles.
Nanoparticles consisting of a gold coating with magnetic iron oxide (magnetite, Fe3O4) cores
have been developed (186, 187, 189). The gold coating protects the magnetic iron oxide core
from oxidation, ionization, and external pH. Additionally, the gold coating provides a surface
that is capable of enhancing the conjugation with proteins (187, 189). Gold-coated magnetite
nanoparticles have been used to target cultured human prostate and murine breast cancer cells
through antibody-surface antigen interactions and then cause cell death after magnetic field
exposure (189-192).
The synthesis of gold-coated magnetite nanoparticles involves two key processes: the
iron core synthesis and the subsequent gold coating. Iron oxide magnetic nanoparticles can be
synthesized by methods of thermal decomposition, aqueous alkaline, or microemulsion. Among
these methodologies, magnetite synthesized by the aqueous alkaline method has been most
frequently used due to its producing nanoparticles with strong magnetic behavior and because it
allows for control nanoparticle size. In aqueous alkaline precipitation, dissolved iron salts are
oxidized by a strong base which results in the precipitation of iron oxide from the solution to
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form simple nanoparticles. The resultant nanoparticles are hydrophilic, and they tend to
aggregate to reduce the surface energy caused by their large surface-area-to-volume ratio. Thus,
using anionic surfactants, such as tetramethylammonium hydroxide (TMAOH), as dispersing
agents impacts the negative charge on the nanoparticle surface and keeps them in a colloidal
state (193-196). Since nanoparticles are synthesized in water, their surface is most compatible
with an aqueous environment; therefore, their reaction by-products are relatively non-toxic.
However, the presence of surfactant-stabilized iron oxide nanoparticles is toxic and unstable at
physiologic salt and pH conditions (193,197-199). Stabilization can be further achieved by
coating the surface with metal (197, 198, 200, 201) or proteins (197, 202-204) to protect the iron
oxide nanoparticles from agglomerating under physiologic conditions and to provide a means to
keep the nanoparticles stable within a biological system. The attachment of gold atoms onto
magnetite cores can be achieved by using reducing agents such as hydrazine, sodium citrate, and
sodium borohydride. In these procedures, the gold shell is prepared by mixing nanoparticles with
a gold chloride aqueous solution, followed by the introduction of reducing agents. The addition
of these agents reduces gold chloride to produce gold atoms that assemble on the magnetite core
(205-207).
Hence, gold-coated magnetite nanoparticles are not simple molecules by themselves; they
consist of a surface layer, shell layer, and a core. The surface layer can be functionalized with a
variety of small molecules, proteins, metal ions, surfactants, and polymers. Also, the surface
modifications do not impair the magnetic properties of the nanoparticles. In our study, the
fibrinogen molecule is used as the surface layer to specifically target the integrin αIIbβ3 receptor
on an activated platelet. The shell is chemically different material from the core. The gold shell
improves stability of the iron oxide at physiological conditions and provides a surface for
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conjugation with proteins, which in this case is fibrinogen. The core is magnetite and essentially
the central portion of the nanoparticles and causes the heating effect when exposed to a magnetic
field.
Hyperthermia refers to heat treatment that is delivered specifically to a lesion site to
destroy unwanted tissues. As early as 1866, fever-like conditions were proposed as a significant
therapeutic for cancer treatment. Tumors have increased susceptibility to elevated temperature
compared to healthy tissue due to their increased rate of cell cycling, increased hypoxia, poor
fluid exchange, and increased acidity (208). Therefore, hyperthermia has been commonly used in
treating cancer. The biggest limitation of hyperthermia is the potential to damage normal
surrounding tissue. Concentrating hyperthermia treatment more specifically at the target site by
delivering small magnetic particles to the tumor would provide a therapeutic advantage. For
example, as early as 1957 sub-micron sized magnetite particles were used to target metastases
and induce hyperthermia by injection into the lymphatic system, followed by exposure to an
oscillating magnetic field (OMF) (209). Treatment was refined by decreasing the diameter of
particles to ~10 nm or smaller to minimize the damage to normal surrounding tissue (210-213).
Although these treatments were successful in killing tumor cells such as prostate and mammary
carcinoma, their application was limited to large solid tumors only. In these treatments, the
nanoparticles were physically placed near the tumors rather than specifically targeted to the
cancerous cells. When an external magnetic field was applied to heat the particles, the heat
generated by the nanoparticles caused hyperthermic cell death. In this approach, creating the
desired effect depends on bulk heating. Therefore, many surrounding normal cells were heated
and killed along with cancerous cells. Methods to overcome the limitations of non-specific
hyperthermia treatment have been pursued. For example, encasing magnetic particles in a
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positively charged liposphere improves the particles’ adsorption and accumulation properties. In
fact, having a positive surface charge increases the affinity for rat glioma cells up to 10-fold as
compared to neutral uncharged magnetoliposome (214). In other studies, conjugation of
antibodies for cell-specific surface markers to the nanoparticles (215, 216) have been employed
and primarily used for magnetic resonance imaging (MRI) studies. As mentioned above,
antibody-conjugated gold-coated magnetite nanoparticles have successfully labeled prostate and
breast cancer cells. When these labeled cancer cells were exposed to an oscillating magnetic
field, they were successfully disrupted. Thus, gold-coated magnetite nanoparticles could be able
to target and destroy specifically any type of cell that can be labeled using protein and antibodies
as long as nanoparticles reach the cell surface or final target destination in sufficient amounts to
convey hyperthermia damage. Therefore, it is possible to use magnetically induced hyperthermia
as a treatment for ischemic stroke.
For our applications, fibrinogen-conjugated gold-coated magnetite nanoparticles can be
injected into circulation and specifically target integrin αIIbβ3 receptors on activated platelets in
an occlusive clot. When exposed to an external OMF, the resultant hyperthermia causes damages
only at the area of interest. This treatment is preferred because it is non-invasive, and potentially
highly localized with relatively minimal risk of adverse effects.
Applying the existing technology of hyperthermic anti-cancer techniques to anti-platelet
therapy has the potential to benefit both fields. This novel approach to treating ischemic stroke
by using fibrinogen-conjugated gold-coated magnetite nanoparticles to specifically target
integrin αIIbβ3 on activated platelets followed by exposure to an OMF could be used as a
replacement for, or in combination with, other ischemic stroke therapies including tPA.
Additionally, the development of this novel anti-platelet therapy for ischemic stroke and

28

determining and optimizing the treatment conditions will be useful not only for targeting
platelets, but also other pathologic cell types such as cancer.

Central hypothesis:
Our overall hypothesis is that fibrinogen-conjugated, gold-coated magnetite nanoparticles
can specifically target activated platelets within occlusive thrombi, leading to disruption with an
oscillating magnetic field. In the whole blood system, we propose that fibrinogen-conjugated
nanoparticles will bind selectively onto activated platelets within a blood clot, potentially
associate with the fibrin network, and not interact with RBCs. Since arterial clots consist mainly
of activated platelets and fibrin, our targeting methods may give us multiple targets. We also
propose that the complexity of fibrin clot structure, due to stimulation with varying doses of the
agonist thrombin, can influence the efficiency of fibrinogen-conjugated, gold-coated
nanoparticle penetration and incorporation into clots. Consequently, it leads to the realization
that optimizing fibrinogen-conjugated, gold-coated magnetite nanoparticle penetration and
concentration within arterial clots is essential in the success of disrupting clots. If we can
improve nanoparticle penetration, concentration, and efficacy, then clots can be dislodged, and
blood flow can be restored. The scope of these aims is to investigate and characterize fibrinogenconjugated gold-coated magnetite nanoparticle targeting of activated platelets in a whole blood
system in vitro. Even though all studies have only been performed in vitro, a strong emphasis
was utilized to predict how the methodology is expected to perform in vivo in anticipation of
future studies using a mouse model of arterial thrombosis and eventually, human therapeutic
trials.
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Figures and Figure Legends:

Plasminogen
Plasmin

tPA

Fibrin

Product of Fibrin
breakdown

Figure 1. Schematic visualization of the molecular interactions regulating physiological
fibrinolysis. On the fibrin surface, tissue plasminogen activator (tPA) converts plasminogen to
the proteolytic enzyme plasmin. Plasmin then cleaves fibrin into smaller pieces.
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Thrombin
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Fibrinogen

Platelet-rich plasma (PRP) Clot
Activated platelet

Fibrin Monomers

Fibrinogen
RBCs
Platelet Aggregate

Fibrin Polymers

Whole blood (WB) clot
Figure 2. A schematic representation of arterial blood clot formation in vitro. Thrombin plays a
central role in thrombus development. Thrombin generated at a site of injury activates resting
platelets, and then activated platelets aggregate via fibrinogen mediated platelet-platelet
interactions. Thrombin also converts fibrinogen into fibrin polymers, which together with
platelet aggregates form fibrin clots. In the presence of red blood cells or other blood plasma
components, whole blood clots are formed.
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Figure 3. Schematic of mechanisms of platelet activation inhibitors- Aspirin, thienopyradine, and
GPIIb/IIIa blockers modified from N. Clapper, 2007 (64). AA, arachidonic acid; ADP, adenosine
diphosphate; COX-1, cyclooxygenase 1; Dense, dense granule; GPIIb/IIIa, glycoprotein IIb/IIIa;
PgG2, prostagladin G2; PgH2, prostagladin H2; TXA-2, thromboxane A2; α, α granule.
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Figure 4. Structural features of a resting platelet and their functions.
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Aggregation of platelets
Integrin αIIbβ3 receptors are bound
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Figure 5. Platelet aggregation modified from Y. Yeghiazarians, 2000 (131). Upon platelet
activation by agonists such as thrombin, ADP, TXA-2, and collagen, inside-out signaling triggers
integrin αIIbβ3 receptors and they become competent to bind to their ligand - fibrinogen.
Fibrinogen mediates platelet-platelet interactions; thereby, forming platelet aggregation.
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Suspension-activated platelets

BEI

SEI

Surface-activated platelet

Figure 6. Labeling of surface-activated and suspension-activated platelets using fibrinogenconjugated gold nanoparticles (FGN-cAu18). In the surface-activated platelet, FGN-cAu18 bind to
the activated platelets tightly and displays the well characterized labeling pattern. The bound
labels for the most part clear the periphery and are primarily centralized inside the platelet
surface membrane, concentrating in the area around the granulomere. In suspension-activated
platelets, some FGN-cAu18 nanoparticles remain on the surface of aggregated platelets, but are
primarily found at platelet-platelet junctions and internalized. White arrows indicate the presence
of FGN-cAu18. Secondary electron images (SEI) are on the top row and backscattered electron
images (BEI) are on the bottom row. Size bars equal 1μm.
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Chapter 2 - Investigating Interaction of Nanoparticles with Clot Components
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Abstract:
Ischemic stroke patients have limited treatment options available. The only FDAapproved drug, tissue plasminogen activator, comes with a significant risk of bleeding
complications. We are investigating an alternative treatment that specifically targets activated
platelets in occlusive clots using fibrinogen-conjugated, gold-coated magnetic nanoparticles
(FGN-cAu-Fe3O4) for hyperthermia. Previous work showed that FGN-cAu-Fe3O4 could
specifically target activated platelets in a purified platelet system (1). In vivo, however, there are
more factors that might potentially impact the binding of nanoparticles such as fibrin, red blood
cells (RBCs), and other cells and proteins present in whole blood to consider. Thus, it is
important to examine the interaction of nanoparticles with plasma components such as platelets,
RBCs, and fibrin to determine the extent of off-target nanoparticle association with clot
components.
We hypothesize that fibrinogen-conjugated nanoparticles specifically interact
with activated platelets, potentially bind onto fibrin, and do not associate with RBCs. To
test the interaction of nanoparticles with clot components, each of fibrinogen, platelet-rich
plasma (PRP), or platelet-poor plasma spiked with RBCs were allowed to form clots using
thrombin. Then, samples were labelled with fibrinogen-conjugated nanoparticles, followed by
either scanning electron microscopy or transmission electron microscopy preparation.
Supernatants, sections, and medial cross-sections were analyzed by scanning electron
microscopy to observe both the topography and interior of the samples. As expected, no
interaction between fibrinogen-conjugated nanoparticles and RBCs was observed. This
suggested that our method is specific and could be safe enough to be used in vivo for treatment of
ischemic stroke. While we proposed targeting activated platelets, the potential for fibrinogen-
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conjugated nanoparticles to associate with the fibrin network was significant. Interestingly, many
labels found were associated with fibrin more often than with activated platelets. These results
suggested that along with activated platelets, fibrinogen-conjugated nanoparticles can interact
strongly at high concentration with fibrin. Fibrin might be a competitor of activated platelets in
binding with nanoparticles; on the other hand, it can also be another potential site-specific target
to treat ischemic stroke. These experiments helped to better understanding these nanoparticle
interactions and educated us about the feasibility of using fibrinogen-conjugated nanoparticles in
vivo to treat ischemic stroke.

Introduction:
Previous studies have shown that fibrinogen-conjugated gold coated-magnetite
nanoparticles could specifically target activated platelets in a purified platelet system. When
labeled aggregates were exposed to an oscillating magnetic field (OMF), the aggregates were
successfully disrupted (1). This suggested that the method could be a means to restore the flow
of blood through an occluded vessel. We have proposed that our method specifically targets the
activated platelets in occlusive clots and leaves quiescent platelets unaffected, which is critical in
developing a stroke therapy with minimal risk of bleeding complications. However, the arterial
clots that cause ischemic stroke not only contain activated platelets but also fibrin, red blood
cells (RBCs), white blood cells (WBCs), and other proteins including coagulation factors. These
components might contribute to potential extensive off-target binding and affect the specificity
of fibrinogen-conjugated nanoparticles in targeting the clots. Therefore, a better understanding of
these nanoparticle interactions will educate us about the feasibility of using fibrinogenconjugated nanoparticles in vivo to treat ischemic stroke.

57

Arterial thrombosis results from clot formation within atherosclerotic arteries. This
happens when fatty or calcium deposits cause artery walls to thicken, leading to a buildup of
plaque in the artery walls. As a result, this plaque can suddenly rupture. This is followed by
platelet aggregation, thrombus formation and vessel occlusion, and potentially heart attack or
ischemic stroke occurs (2, 3). In addition, arterial thrombosis often occurs at places of high shear
flow. Typically, arterial clots are rich in platelets and form at the sides of or around ruptured
atherosclerotic plaques, giving them the appearance of a white clot. In addition to platelets,
arterial thrombi contain fibrin. In fact, many reports have showed that in the coronary and other
large arteries, most of the thrombi detected at atherosclerotic plaque rupture sites consisted of a
mixture of fibrin and platelets, with fibrin being more abundant (4-7). In addition to fibrin and
platelets, arterial thrombi consist of RBCs, cellular microvesicles, and leukocytes. It has been
reported that arterial thrombi contained by volume 43% fibrin, 31% platelets, 17% RBCs, 5%
cellular microvesicles, and 2% leukocytes (7).
The interactions of fibrinogen with platelets via platelet integrin αIIbβ3 (GPIIb/IIIa)
receptors is well-studied. Platelet integrin αIIbβ3 is the most abundant receptor on the platelet
surface. There are about 80,000 receptors per unstimulated platelet (8). Fibrinogen binding to its
platelet receptor requires platelet activation. Upon platelet activation of the integrin by an insideout signal, the integrin changes its conformation from bent to extended, allowing it to bind to its
ligand, fibrinogen. Once fibrinogen has been bound, its ability to crosslink receptors on different
platelets results in aggregation (9-11). Additionally, ligand-occupied receptors undergo integrin
outside-in signaling, allowing the receptor to interact with the actin cytoskeleton, causing the
integrin with its bound ligand to centralize in the plane of the platelet membrane. Clearing
occupied receptors from the peripheral regions of the platelet in an actin-myosin dependent
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manner removes steric hindrance and makes additional unoccupied receptors available for
fibrinogen binding (12-15). Importantly, outside-in signaling by platelet integrin αIIbβ3 plays an
important role in clot retraction, in which a fibrin clot gradually pulls in upon itself, shrinking to
a smaller volume after platelet activation and fibrin deposition are well underway (16, 17).
Previous studies have shown that fibrinogen-conjugated nanoparticles specifically bind
onto surface-activated platelets around the granulomere (18-22). In suspension, most fibrinogen
labels will bind to their platelet receptors, and move along the surface of the platelet to a final
destination in the open canalicular system (15, 23-25). The migration of fibrinogen-conjugated
nanoparticles to the interior of platelet aggregates is desirable for targeting in that it will allow
the treatment to disrupt the entire volume of platelet aggregates or clot rather than only those
platelets exposed on the surface of the clot. Also, the location of fibrinogen-conjugated
nanoparticles at the center of clots is crucial for how nanoparticle-induced hyperthermia will
affect both platelet structure and clot integrity. In our particular experiment, normal platelets in
plasma were allowed to form clots before being exposed to fibrinogen-conjugated nanoparticles.
We were interested in how specifically fibrinogen-conjugated nanoparticles interact with
activated platelets in an existing platelet-rich clot such as would be found in arterial thrombi. The
feasibility of using fibrinogen-conjugated nanoparticles needs to be evaluated under this
simplified condition before we can apply this cell-targeting method in vivo.
Fibrin is the most abundant component of the arterial clot. It accounts for 43% of the total
volume of the arterial clot. Fibrin is fibrous, non-globular protein and it is formed by the
cleavage of fibrinogen by the protease thrombin, which causes it to polymerize. As a result, the
polymerized fibrin traps platelets and RBCs and forms a clot (11, 26-29). In our experiment,
thrombin enzymatic activity is sustained until samples are fixed, so it may convert both plasma
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fibrinogen and fibrinogen-conjugated nanoparticles into fibrin. Because of the ability of fibrin to
polymerize, it is possible for both plasma fibrin and fibrin-conjugated nanoparticles to become
incorporated into the fibrin meshwork of the growing clot. The potential of highly localized
targeting of fibrin could strengthen our power in disrupting a clot.
It has been assumed that RBCs play a largely passive role in thrombosis and hemostasis.
However, now it has become apparent that RBCs have a variety of important functions and exert
substantial impacts on hemostasis and thrombosis (7, 30, 31). Even though RBCs only account
for 17% of arterial clot volume, RBCs still contribute to the bulk, structure, and potential
occlusive behavior of the clot. Therefore, when using fibrinogen-conjugated nanoparticles to
target arterial clots in vivo, we cannot neglect the possibility that RBCs might associate with
fibrinogen-conjugated nanoparticles.
In fact, studies have shown that fibrinogen played an important role in RBC aggregation.
In the 1960s, fibrinogen was identified as a cause of RBC aggregation (32, 33). In addition,
elevating fibrinogen concentration resulted in an increase in RBC sedimentation rate and the
clustering of red blood cells caused thrombosis and similar agglomerates (34-36). Fibrinogeninduced erythrocyte aggregation is considered to be caused by a combination of a nonspecific
binding mechanism of fibrinogen to the erythrocyte membrane and a specific binding between
fibrinogen and the erythrocyte membrane via an erythrocyte’s integrin αIIbβ3 like-receptor and
CD47 (integrin-associated protein) (30, 35, 37- 41).
Although studies showed the fibrinogen-erythrocyte interaction exists, they failed on
further characterizing it. A study using atomic force microscopy reported that the fibrinogenerythrocyte interaction is transient, and this transient interaction cannot lead to stable clot
formation but is only able to increase erythrocyte aggregation (30). Under physiological
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conditions in vivo, the applied shear forces can break clusters into single cells (42). This suggests
that in high shear conditions in an artery, existing fibrinogen-erythrocyte interactions would be
weak. Indeed, duration of the fibrinogen-erythrocyte bond is very short at only 0.04% of the
duration of fibrinogen-platelet binding. Not only that, fibrinogen has low affinity for binding
onto RBCs in comparison to platelets (30). Furthermore, it is possible that the fibrinogenerythrocyte interaction can be lost and masked by the presence of abundant serum albumin.
Albumin is known to have a capacity to bind to lipids, so it may bind to the erythrocyte
phospholipid membrane, coating part of the erythrocyte surface and making the fibrinogen
receptors on erythrocyte membrane less accessible for fibrinogen binding (43, 44). Also, there is
variation in fibrinogen-erythrocyte interactions during cell aging. The fibrinogen-erythrocyte
receptors progressively become non-functional as RBCs age due to the depletion of sialic acids,
which is the principal source of negative charges on RBC membranes (39). In brief, even though
fibrinogen-erythrocyte interactions exist, the strength and amount of the fibrinogen-erythrocyte
interaction is still questionable.
Here, we will examine the interaction of fibrinogen-conjugated nanoparticles and RBCs
that are already entangled by fibrin mesh and incorporated into RBC clots. We anticipated that
fibrinogen-conjugated nanoparticles and RBC interactions would be rare events. Therefore, we
expected to detect minimal number of nanoparticles found inside RBCs or bound onto the RBC
membrane surface. Since our experiment occurred in vitro without any of the flow or shear found
in physiological conditions such as arteries, any interactions between fibrinogen-conjugated
nanoparticles and RBCs observed might be impossible in vivo.
Gold nanoparticles have a robust synthesis due to their ease of performance, high
production yield, and stability (45, 46). Conjugation of proteins to gold nanoparticles is often
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done by non-ionic adsorption, which is rapid, economical, and results in a protein-conjugated
gold nanoparticle with high avidity. Also, most proteins can be conjugated onto gold
nanoparticles by non-ionic adsorption and not lose their functionality (47-49). Additionally, it
has been expected that coating magnetite nanoparticles with gold will still provide a surface for
non-ionic protein adsorption similar to that of colloidal gold. Thus, gold nanoparticles have been
not only commonly used for biological labeling but also are considered a standard model that can
predict the functionalization of magnetic nanoparticles in targeting specific cell types, shown
through their use with fibrinogen, and with antibodies targeting activated platelet and tumor
cells, respectively (50, 51). Since synthesizing fibrinogen-conjugated, gold-coated magnetite
nanoparticles (FGN-cAu-Fe3O4) is not a robust procedure, previous studies and we ourselves (1,
15, 19, 22, 52, 53) have routinely used the more robust fibrinogen-conjugated gold nanoparticle
(FGN-cAu18) model in light and electron microscopy to examine labeling and platelet
physiology.
In this chapter, we will be comparing the interaction of FGN-cAu18 and FGN-cAu-Fe3O4
with clot components to confirm whether or not FGN-cAu18 and FGN-cAu-Fe3O4 share a
common characteristics and functionalization in terms of targeting clots. Then, FGN-cAu18 will
be used as representative model or the control to examine nanoparticle penetration,
concentration, and disruption of clots in the next chapters.
We hypothesize that fibrinogen-conjugated nanoparticles will specifically bind onto
activated platelets, may associate with the fibrin network, and will not interact significantly with
RBCs. The results from these experiments will provide insight into whether using fibrinogenconjugated nanoparticles can be developed into a safe in vivo treatment for ischemic stroke or
not.
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Materials and Methods:
Synthesis of colloidal gold nanoparticles (cAu18):
Glassware used for gold synthesis was washed with 7X detergent (MP Biomedicals,
Solon, OH) and rinsed extensively with distilled water (ddH2O) and Millipore distilled deionized
water (MDDW). 18nm gold (cAu18) preparation was synthesized as described previously
(20,54). Briefly, 4% gold (III) chloride [HAuCl4 3H2O] (Sigma-Aldrich) was added to 0.2μm
filtered MDDW in a round-bottom flask to a final concentration of 0.01%. Under the fume hood,
a heating mantle was used to boil the reaction flask for 5 minutes. Then, fresh 0.2μm filtered 1%
trisodium citrate dihydrate (Fisher Scientific, Pittsburgh, PA) was added directly into the boiling
reaction mixture to a final concentration of 0.02%. The flask was swirled vigorously and
continuously until the distinct red color was developed. The color changed from yellow to
colorless, then black, blue, purple, and finally red in approximately 5 minutes. The reaction was
then refluxed for 30 minutes. The mixture flask was allowed to cool to room temperature (RT),
and stored at 4ºC. The average size of the cAu18 was read with a UV–visible spectrophotometry
(DU800®, Beckman Coulter Inc) at 522nm.

Conjugation of fibrinogen to 18nm colloidal gold nanoparticles (FGN-cAu18):
Fibrinogen was conjugated to cAu18 by non-ionic protein adsorption (15,19). An
adsorption isotherm was performed to determine the optimal protein concentration to stabilize
the colloidal gold. The minimum amount of fibrinogen required to prevent flocculation was
8μg/ml of the gold solution. Also, previous work showed that the optimum adsorption of
fibrinogen onto gold nanoparticles occurs at or slightly basic to the isoelectric point of the
protein, which was pH 6.5. First, the cAu18 was warmed to RT before the gold solution was
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adjusted to pH 6.5 with 0.2N K2CO3 as measured by using a gel-filled electrode (Accumet®,
Fisher Scientific). If the desired pH went too high, more 18nm colloidal gold solution was added.
Next, human fibrinogen (plasminogen, von Willebrand factor and fibronectin depleted, Enzyme
Research Laboratories, South Bend, IN) at twice the stabilizing concentration (16μg/ml) was
incubated with the cAu18 for 5 minutes. Then, fresh 1% polyethylene glycol (PEG) (average MW
20,000, Sigma-Aldrich) was added to the reaction mixture at a final concentration of 0.004% as a
stabilizing agent. The fibrinogen-conjugated cAu18 (FGN-cAu18) nanoparticles were
concentrated and excess protein was removed by centrifugation at 16,000 x g for 10 minutes.
The supernatant was aspirated and the soft pellet was resuspended in Tyrode’s buffer containing
0.1% bovine serum albumin (BSA) (15mM HEPES, pH 7.4, 3.3mM Na2HPO4, 138mM NaCl,
2.7mM KCl, 5.5mM glucose, 1mM MgCl2, 1mg/mL BSA) at one-tenth the original nanoparticle
volume. To roughly assess the cAu18 concentration of the preparation, the optical density was
read at 522nm (OD522) by using a UV–visible spectrophotometry. OD522 was adjusted between
0.2 and 1.0 for use in labeling experiments.

Synthesis of colloidal magnetite nanoparticles (cFe3O4):
Magnetite nanoparticles (cFe3O4) were synthesized by an aqueous alkaline
coprecipitation method (55) with some modifications. Briefly, to remove all oxygen from the
water, MDDW was heated to near boiling with a microwave before degassing the water under
vacuum for a minimum of 1 hour with stirring at 60rpm and applied heat at 215°C. Degassed
water was transferred into a 3-angle neck flask in the fume hood, with a stirring apparatus run by
a variable-speed power drill in one port and an oxygen-free argon source introduced through
another. Under argon, 5mL of a solution of 0.64M anhydrous FeCl3 and 0.32M anhydrous
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FeCl2 (Sigma-Aldrich, St Louis, MO) in 0.4M HCl was added dropwise through the third port to
50mL of 1.5M NaOH in degassed water at 32°C-38°C with stirring. The colloid was allowed to
precipitate, then was washed three times by centrifugation at 5000 x g for one minute and
resuspended in degassed water. A last wash in 0.1M tetramethylammonium hydroxide
(TMAOH) (Alfa Aesar, Ward Hill, MA) was processed in the same manner. Magnetite
nanoparticles were size fractionated by centrifuging at 7000 x g for 5 minutes in 0.1M TMAOH.
The suspended cFe3O4 particles were aged for exactly three days at 4°C before use in the gold
coating procedure.

Preparation of gold-coated magnetite nanoparticles (cAu-Fe3O4):
After the cFe3O4 were aged for three days at 4°C in 0.1M TMAOH under argon
atmosphere, gold growth on cFe3O4 was performed as previously reported (56). Under argon,
cFe3O4 sol was diluted 100-fold in 0.00275% hydrazine hydrate (Sigma-Aldrich) in a total
volume of 100mL using degassed water. Then, the total of 120μL of 4% aqueous HAuCl4×3H2O
was added dropwise in 4 aliquots while mixing vigorously, resulting in a final concentration of
0.12mM Au3+. The cAu-Fe3O4 were assessed by a UV–visible spectrophotometry and visually
by the color of the resultant colloid. Blue sols were discarded, and successful products were red
in color and stored under argon at RT. Successful colloid preparations were used within one
week for labelling experiments.

Conjugation of fibrinogen to gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4):
Fibrinogen was conjugated to cAu-Fe3O4 by non-ionic protein adsorption as described
previously (15), with some modification. First, pH of the cAu-Fe3O4 was adjusted by adding 1M
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4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Acros, Fisher Scientific), pH 6.5,
to a final concentration of 10mM. Then, cAu-Fe3O4 was incubated with fibrinogen at a final
concentration of 16μg/mL for 5 minutes at RT. Next, 1% PEG was added to a final concentration
of 0.004% to stabilize the nanoparticles. FGN-cAu-Fe3O4 nanoparticles were centrifuged to
separate them from excess protein at 16,000 x g for 10 minutes. The supernatant was discarded,
and the pellet was resuspended in Tyrode’s buffer with 0.1% BSA. To roughly assess the
concentration of FGN-cAu-Fe3O4 in the sol, the optical density was read at 522nm (OD522) using
a UV–visible spectrophotometry. OD522 was adjusted between 0.2 and 1.0 for use in labeling
experiments.

Isolation of human platelets:
Whole blood (WB) was withdrawn from healthy donors in accordance with the
University of Wisconsin-Milwaukee Institutional Review Board. WB was drawn by
venipuncture of healthy donors currently not taking anticoagulant or antiplatelet drugs. Venous
blood was anticoagulated with 3.8% sodium citrate. Then, the anticoagulated blood was
centrifuged at 100 x g for 15 minutes at RT. The platelet-rich plasma (PRP) layer, was carefully
transferred to polypropylene tubes. Relatively small amounts of PRP were left in the collection
tubes to ensure no contamination by any WBCs and RBCs occurred. Then, the remainder was
spun at 300 x g for 15 minutes to obtain platelet-poor plasma (PPP). During centrifugation, the
PRP was applied to a 25mm x 90mm column of Sepharose CL-2B (Sigma-Aldrich, St. Louis,
MO) that was equilibrated with Tyrode’s buffer with 0.1% BSA to obtain gel-filtered platelets
(GFPs). GFP count was adjusted to 150,000 cells per μL by diluting in autologous PPP (Figure
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7). The isolated platelets were used within 2 hours of blood draw to ensure normal platelet
functions were preserved.

Isolation of human red blood cells (RBCs):
The same procedure found above in the isolation of human platelets, through the
obtaining of PPP step, was used. Briefly, WB was obtained from a healthy donor, citrated, and
centrifuged at 100 x g for 15 minutes at RT. The supernatant was fully removed, including a
small volume of RBCs to ensure complete removal of the buffy coat containing WBCs and a few
platelets. The supernatant was centrifuged again at 300 x g for 15 minutes at RT to produce PPP.
The packed RBCs were diluted with autologous PPP to bring the suspension back to its original
volume of citrated WB (Figure 8).

Fibrin(ogen) and fibrinogen-conjugated nanoparticle interaction:
Human fibrinogen stock was diluted to 3mg/mL in 5mM NaCl. It was then supplemented
with 2mM CaCl2 and clotted with 1nM of human thrombin (Haematologic Technologies Inc.,
Essex Junction, VT) for 10 minutes at 37°C in a microcentrifuge tube. Then, FGN-cAu18 or
FGN-cAu-Fe3O4 was added to a final nanoparticle-associated fibrinogen concentration of
96μg/mL. The clots were soaked in the labels for 15 minutes. Clot and supernatant were
collected and prepared by scanning electron microscopy (SEM) and transmission electron
microscopy (TEM) procedures.
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Platelet and fibrinogen-conjugated nanoparticle interaction:
The procedure of examining the interaction of plasma proteins, platelets, and fibrinogenconjugated nanoparticles was followed as for fibrin(ogen). First, 150,000 platelets per μL were
supplemented with 2mM CaCl2. Then, thrombin was added a final concentration of 1nM to
stimulate the formation of the clot. After 10 minutes at 37°C, the sample was incubated with
either FGN-cAu18 or FGN-cAu-Fe3O4 at a final nanoparticle-associated fibrinogen concentration
of 96μg/mL for 15 minutes at 37°C. Again, supernatant and clots were obtained and processed
by SEM and TEM procedures.

Red blood cell and fibrinogen-conjugated nanoparticle interaction:
The RBCs were processed as for fibrin and platelets. Briefly, CaCl2 and thrombin were
added into RBCs in PPP at the final concentrations of 2mM and 1nM, respectively, to stimulate
RBC clot formation for 10 minutes at 37°C. The sample was labeled with FGN-cAu18 or FGNcAu-Fe3O4, to a final nanoparticle-associated fibrinogen concentration of 96μg/mL, for 15
minutes at 37°C. Then, both supernatant and clot were collected, followed by SEM and TEM
preparation.

Scanning electron microscopy (SEM) standard preparation for supernatant samples:
SEM preparation was followed as described previously (1) with some modifications.
Supernatants were diluted 1:20 in 1% glutaraldehyde (Ted Pella, Inc.) in 0.1M HEPES, pH 7.4
and fixed for 30 minutes at RT. After 30 minutes primary fixation, samples were collected on
Whatman® NucleporeTM Track-Etched Membranes with 13mm diameter and 0.4μm pore size
using 5cc syringes attached to 13mm MilliporeSigmaTM SwinnexTM filter holders. Then, the
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membranes were washed 3 times with 0.1M HEPES, pH 7.4, for 10-15 minutes and followed by
post-fixation with 0.05% OsO4 (Ted Pella, Inc.) in HEPES for 30 minutes at RT. The membranes
were washed with distilled deionized water before transfer into a critical point dry holder and
processed by dehydration in a graded ethanol series for 10-15 minutes incrementally beginning
with 25%, then 50%, 70%, 80%, 85%, 90%, 95%, twice with 100%, and once with 100% ethanol
over type 3A molecular sieves (Grace Davison, Columbia, MD). The samples were dried in a
Balzer CPD 020 unit, using sieve-dried 100% ethanol as the intermediate fluid and liquid carbon
dioxide (CO2) as the transitional fluid. After critical point drying, samples were affixed to 13mm
Cambridge stubs by carbon conductive double-sided adhesive tabs (Lift-N-Press ™, Ted Pella,
Inc.). Conductive isopropanol-based graphite paint (Pelco®, Ted Pella, Inc.) was applied around
the edges of the stubs and allowed fully to dry before the samples were coated with carbon in an
Edwards E306A thermal evaporation coating system. Analysis was performed on a Hitachi S4800 FE-SEM scanning electron microscope using 2-3kV accelerating voltage for secondary
electron (SE) imaging and 15kV accelerating voltage for backscattered electron (BE) imaging.

Scanning electron microscopy (SEM) standard preparation for clots:
SEM preparation of clots was similar to supernatant SEM preparation with a few
modifications. The clots were fixed in 1% glutaraldehyde in 0.1M HEPES for 2 hours at RT,
followed by fresh 1% glutaraldehyde with 1% tannic acid in 0.1M HEPES, pH of 7.4, overnight
at 4°C. Clots were washed 3 times with 0.1M HEPES, pH 7.4, for 10-15 minutes followed by
post-fixation with 0.05% OsO4 for 2 hours at RT. The clots were then washed with distilled
deionized water before being transferred into the critical point drier holder and dehydrated in a
graded ethanol series for an hour at each increment (25%, 50%, 70%, 80%, 85%, 90%, 95%,
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twice with 100%, and once with 100% EtOH stored over type 3A molecular sieves). The clots
were dried by the above procedure in a Balzer CPD 020 unit. The clots were mounted onto
13mm Cambridge stubs with 2 Ton® clear medium cure water-resistant adhesive epoxy
(Devcon®). The epoxy was cured overnight, and the clots were secured onto the stubs. Clots
were then fractured in half using new stainless-steel GEM® razor blades. The samples were
coated using the Edwards E306A thermal evaporation coating system, with carbon fiber as the
source. The samples were examined with a Hitachi S-4800 FESEM. The backscattered images
were taken at 15kV accelerating voltage between 200X and 2000X magnification. The 200X
magnification images were montaged using Adobe® Photoshop® CC version 14.1.2 x 32 to
generate 2D images of entire clot sections.

Transmission electron microscopy standard preparation for clots or supernatants:
After primary fixation in 1% glutaraldehyde with 1% tannic acid in 0.1M HEPES pH 7.4,
supernatants were centrifuged at 16,000 x g to pellet fibrin strands, platelets, or the RBCs that
were not incorporated into clots. Then, the supernatants were discarded. A drop of molten 2%
agar (Difco®, Bacto® Agar, Detroit, Michigan, USA) in 0.1M HEPES pH 7.4 was added into
each pellet, mixed well, and allowed to solidify. These pellets were prepared for TEM in parallel
with the fixed clots. Pellets and clots were washed 3 times with 0.1M HEPES, pH 7.4, for 10-15
minutes, followed by post-fixation with 0.05% OsO4 in 0.1M HEPES, pH 7.4, at RT for 2 hours.
The samples were then washed using distilled deionized water 3 times for 10-15 minutes each
before staining with 1% uranyl acetate for 2 hours. Samples were dehydrated in a graded ethanol
series for at least 1 hour at each increment (25%, 50%, 70%, 80%, 85%, 90%, 95%, and two
times 100%), followed by two changes of propylene oxide (Electron Microscopy Sciences®) for
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one hour each. The samples were infiltrated and embedded in low viscosity Quetol-Spurr’s resin
(Electron Microscopy Sciences®) (57). The samples were cured for 72 hours at 60°C. Semi-thin
(~30-50μm) sections were cut using an RMC MT-7000 ultramicrotome. The sections were
picked up on 12mm diameter round glass coverslips (Fisherbrand®, Fisher Scientific) and
affixed onto 13mm Cambridge stubs using conductive carbon tapes (Ted Pella, Inc.).
Conductive isopropanol-based graphite paint was applied around the edges of the stubs and
allowed to fully dry before the samples were coated with carbon using an Edwards E306A
compact thermal evaporation coating system. Sections were examined between 5kV and 7kV
accelerating voltage in ExB backscattered mode using a Hitachi S-4800 FE-SEM.

Results:
Previous work has shown fibrinogen conjugated-gold nanoparticles, including both FGNcAu18 and FGN-cAu-Fe3O4, associating specifically with activated platelets in a purified platelet
system. However, PRP and WB systems appear more complex not only in structural organization
but also in cell components. Besides activated platelets, PRP and WB clots contain an additional
large amount of fibrin(ogen) and fibrin(ogen) plus RBCs, respectively (Figure 9,10). This might
affect the specificity of fibrinogen-conjugated nanoparticle targeting, and the ability of the
nanoparticles to interact with activated platelets. Thus, examining the interaction of fibrinogenconjugated nanoparticles with other clot components, such as fibrin(ogen) and RBCs, allowed us
to characterize the specificity of their binding to clot components and determine the extent of
their off-target nanoparticle associations.

71

To examine the potential interactions between fibrinogen-conjugated nanoparticles and
fibrin, plasma platelets, or RBCs, these experiments were done three times with three different
donors of platelets and RBCs. Commercial purified human fibrinogen was used.

Fibrin(ogen) and fibrinogen-conjugated nanoparticle interaction:
Fibrin clots were formed by stimulating 3mg/mL fibrinogen with 1nM thrombin,
followed by labelling with FGN-cAu18 or FGN-cAu-Fe3O4. The clots formed were relatively
small in size and pink colored after the labeling step. Many small pink fibrin strands remained
suspended in the supernatant. Pink color indicated that FGN-cAu18 or FGN-cAu-Fe3O4 interacted
strongly with the fibrin(ogen). Since both fibrin clots and supernatant visually looked pink, we
concluded that FGN-cAu18 or FGN-cAu-Fe3O4 was present in the fibrin clots and associated with
suspended fibrin(ogen) strands. As expected, secondary electron images (SEI) of the suspended
fibrin strands remaining after clot formation were observed as long fibers. Also, many FGNcAu18 nanoparticles were bound onto fibrin strands. Under backscattered electron imaging (BEI),
the signal from FGN-cAu18 was strongly detected and appeared brightly throughout the samples
(Figure 11). In findings consistent with the observations of remaining supernatant from FGNcAu18 labeled fibrin clots, samples of remaining supernatant from fibrin clots labeled with FGNcAu-Fe3O4 nanoparticles also showed a strong interaction between fibrin and FGN-cAu-Fe3O4
nanoparticles. Again, FGN-cAu-Fe3O4 nanoparticles were found throughout the fibrin network
(Figure 12). The only minor difference between FGN-cAu18 nanoparticles and FGN-cAu-Fe3O4
nanoparticles was that FGN-cAu-Fe3O4 nanoparticles appeared less bright in comparison to
FGN-cAu18 nanoparticles when using BEI images. This is due to the lower atomic number of
magnetite as compared to gold-79.
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Observation of fixed medial sections of fibrin clots labeled with either FGN-cAu18 or
FGN-cAu-Fe3O4 nanoparticles showed that both types of nanoparticles were able to penetrate
successfully from the outside of the clot to its interior. Furthermore, high nanoparticle
concentrations were found both inside and outside the fibrin clots (Figure 13, 14).
Observation from cross-sections of FGN-cAu18 and FGN-cAu-Fe3O4 labeled fibrin clots
and the remaining supernatant allowed us to clearly visualize the association between the
nanoparticles and fibrin strands (Figure 15, 16). Many fibrinogen-conjugated nanoparticles were
found clustered together and bound to fibrin strands. They were also found between fibrin
strands, and at the junctions between fibrin strands. Moreover, significantly high concentrations
of fibrinogen-conjugated nanoparticles were found not only in the fibrin clot but also throughout
the supernatant remaining over the clot.
These experiments showed that FGN-cAu18 and FGN-cAu-Fe3O4 share similar
characteristics when they interact with fibrin. First, both types of fibrinogen-conjugated
nanoparticles interacted strongly with fibrin strands. Secondly, it appeared that fibrinogenconjugated nanoparticles had the ability to penetrate deep into the interior of fibrin clots. Lastly,
significantly high concentrations of fibrinogen-conjugated nanoparticles were found at the
periphery and interior of fibrin clots.

Platelet, plasma fibrinogen, and fibrinogen-conjugated nanoparticle interaction:
When GFPs in autologous PPP were stimulated with 1nM thrombin, the activated
platelets and fibrin interacted with each other to form GFP clots. Also, some small platelet
aggregates formed that did not associate with GFP clots, instead remaining suspended in the
plasma. After thrombin treatment, samples were labelled with FGN-cAu18 or FGN-cAu-Fe3O4.
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Platelet aggregates looked pink when collected on the Nuclepore membrane, whereas GFP clots
appeared wrapped around by pink webbing. Upon SEM analysis, the platelet aggregates, even
though they were not included into the clot, were still heavily labeled with FGN-cAu18 or FGNcAu-Fe3O4 (Figure 17, 19). This accounted for the pink color observed on the Nuclepore filter
membrane when the platelet aggregates were collected. Likewise, SEM analysis of GFP clots
showed the fibrinogen-conjugated nanoparticles bound to the clot periphery (Figure 21, 22),
accounting for the pink webbing observed wrapped around the clot.
As we expected, we observed similar results with platelet aggregates labeled with FGNcAu18 or FGN-cAu-Fe3O4. From SEI images, labels were observed at the surface of the activated
platelets, and at platelet-platelet junctions. Additionally, bright signals were detected from
nanoparticles inside the activated platelets, as seen in the BEI images (Figure 17, 19). Notably,
cross-section images showed that FGN-cAu18 and FGN-cAu-Fe3O4 localized in the center of
activated platelets at remarkably high concentrations compared to the nanoparticle concentration
found at the periphery of platelet aggregates (Figure 18, 20).
The montage assembled of medial GFP clot sections labelled with FGN-cAu18 and FGNcAu-Fe3O4 nanoparticles showed similar results. It appeared that nanoparticles were able to
penetrate deep inside of the GFP clots, although a higher concentration of nanoparticles was
found near the periphery. While lower nanoparticle concentration was observed at the interior of
the clots, the labels were scattered throughout the entirety of clot and many small nanoparticle
clutters were observed (Figure 21, 22). In comparison with the fibrin clot labeled with
fibrinogen-conjugated nanoparticles, higher amounts of nanoparticles were incorporated into the
fibrin clot than into the GFP clot.
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Cross-section images of GFP clots showed that both FGN-cAu18 and FGN-cAu-Fe3O4
were able to penetrate deep into the interior of GFP clots. Nanoparticles slightly interacted with
activated platelets within the GFP clots, as cross-section images of the clots reveal (Figure 23,
24). However, nanoparticle concentration within GFP clots was relatively low compared to
nanoparticle concentration found within fibrin clots.
In brief, these results provided several important insights relating to platelet and
nanoparticle interaction. First, FGN-cAu18 and FGN-cAu-Fe3O4 interacted with platelets
similarly. Second, nanoparticles specifically interacted with activated platelets. Third,
nanoparticles had an ability to penetrate both platelet clots and platelet aggregates. Fourth, there
were higher concentrations of nanoparticles interacting with platelets in aggregates not
associated with clots (in the supernatant over the clot) than with activated platelets found inside
of platelet clots.

RBCs and fibrinogen-conjugated nanoparticles interaction:
When RBCs suspended in PPP were stimulated with 1nM thrombin, clots and
supernatants formed and were labelled with either FGN-cAu18 or FGN-cAu-Fe3O4. Results from
the samples collected did not differ between FGN-cAu18 and FGN-cAu-Fe3O4 labels.
From the supernatant, we found either a very minimal number of or no nanoparticles
associated with RBCs. Some nanoparticles were found on the surface of the RBCs, but they did
not specifically bind to RBCs. Instead, FGN-cAu18 strongly interacted with the fibrin strands
present (Figure 25, 26).
RBC clots visually appeared to be the largest clots among RBC, GFP, and fibrin clots.
RBC clots mainly contained RBCs wrapped around with fibrin strands (Figure 27, 28). Low
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nanoparticle concentration was found both at the periphery and interior of the RBC clots. It
appeared that nanoparticles were limited to the outside edge of RBC clots and were unable to
penetrate deep into the interior of the clot. Therefore, minimal amounts of the label were found at
the center of RBC clots. Even though a few nanoparticles were present in RBC clots, those
nanoparticles interacted with fibrin strands rather than RBCs.
Cross-sections of RBC clots labeled with FGN-cAu18 and FGN-Fe3O4 showed that labels
specifically associated with fibrin strands and not RBCs. Also, nanoparticles were able to
penetrate into RBC clots. Moreover, nanoparticles were scattered throughout the RBC clots at
low concentrations and only incorporated with the fibrin network. Again, no nanoparticles were
found at the site of RBCs (Figure 29, 30).
Cross-sections of RBCs remaining in the supernatant labeled with either FGN-cAu18 or
FGN-Fe3O4 showed no nanoparticles in supernatant samples. There was absolutely no interaction
between nanoparticles and RBCs in the supernatant since no nanoparticles bound onto RBCs and
no nanoparticles localized inside RBCs (Figure 29,30).
Overall, FGN-cAu18 and FGN-cAu-Fe3O4 bound specifically to fibrin and not RBCs.
FGN-cAu18 and FGN-cAu-Fe3O4 had the ability to penetrate into RBC clots via their interaction
with fibrin strands. Although FGN-cAu18 and FGN-cAu-Fe3O4 were found within RBC clots,
there were very limited amounts of label occurring in both the periphery and interior of RBC
clots.

Discussion:
Previous studies have shown fibrinogen-conjugated nanoparticles specifically target the
activated platelets in a purified platelet system (1). However, PRP and WB systems are more
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complex in terms of both protein and cell components, and are more representative of the
physiological system. Thus, examining the specificity and the potential extent of off-target
fibrinogen-conjugated nanoparticle association with clot components such as fibrin, platelets and
RBCs in plasma provided meaningful information about the feasibility of using fibrinogenconjugated nanoparticles to treat ischemic stroke in vivo. First, the interaction between
fibrinogen-conjugated nanoparticles and activated platelets in plasma, even after clotting
occurred, was confirmed. Fibrinogen-conjugated nanoparticles were able to penetrate the
platelet-rich GFP clots, where they specifically bound onto activated platelets, were found at
platelet-platelet junctions, and were primarily localized in the interior of the activated platelets.
Second, fibrinogen-conjugated nanoparticles strongly interacted with fibrin. A significantly high
FGN-cAu18 or FGN-cAu-Fe3O4 concentration was observed both in fibrin clots and fibrin strands
taken from the supernatant over clots. Additionally, the association of FGN-cAu18 or FGN-cAuFe3O4 with fibrin strands outweighed their association with activated platelets and RBCs. Thus,
in vivo fibrin can compete with activated platelets as label targets. However, if binding were
highly localized, fibrin could serve as a very attractive additional target of fibrinogen-conjugated
nanoparticles. Since arterial clots contain both fibrin and activated platelets as their main
components, having an extra target could be an advantage of this method over tPA in treating
ischemic stroke. Third, RBCs displayed no interaction with fibrinogen-conjugated nanoparticles.
When RBC clots or their supernatants were labeled with either FGN-cAu18 or FGN-cAu-Fe3O4,
there was no binding or penetrating of the labels into RBC samples. This suggests that using
FGN-conjugated nanoparticles for cell targeting is specific enough that it may be safe enough for
in vivo use. Fourth, FGN-cAu18 and FGN-cAu-Fe3O4 behaved similarly in terms of interacting
with clot components. FGN-cAu18 is a robust synthesis; whereas, FGN-cAu-Fe3O4 is a more
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variable procedure. Thus, these results confirm that FGN-cAu18 can be a representative model
for FGN-cAu-Fe3O4 in term of studying the penetration of nanoparticles into clots.

Fibrinogen-conjugated nanoparticles target activated platelets:
When platelets were activated by thrombin and then labeled with fibrinogen-conjugated
nanoparticles, the nanoparticles bound to the activated platelets tightly and display a well
characterized labeling pattern. In the supernatant samples, labeling occurred on the surface of
aggregated platelets, at platelet-platelet junctions, and inside platelets. High amounts of label
accumulated especially at the center of activated platelets within the open canalicular system.
These events can be explained by the regulation of integrin αIIbβ3 in platelets (8,58). Upon
platelet activation due to the stimulation of soluble agonist-thrombin, the inside-out signal results
in the activation of integrin αIIbβ3 with high affinity, allowing it to bind to its ligand fibrinogen.
Once fibrinogen has bound, its ability to crosslink receptors on different platelets results in
aggregation (8-11,59). Additionally, ligand-occupied receptors undergo integrin outside-in
signaling for the receptor to interact with the actin cytoskeleton, causing integrin with bound
ligand to centralize on the platelet membrane plane and move along the underlying actin
cytoskeleton (12-15). As a result, fibrinogen-conjugated nanoparticles were observed most
significantly at the center of platelet aggregates rather than at the periphery. Furthermore, we
expected that fibrinogen-conjugated nanoparticles would have the ability to penetrate and
effectively incorporate into existing platelet clots. However, as we observed, labeling was
somewhat scattered throughout the cross-section of the clot. This result could be due to a few
reasons. First, labeling time with FGN-cAu18 or FGN-cAu-Fe3O4 for both clots and supernatant
were only 15 minutes. Second, platelet-rich clots were relatively bigger in size and volume in
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comparison to platelet aggregates. Thus, 15 minutes of labeling might only be sufficient for
nanoparticles to migrate into moderately sized platelet aggregates, but not large platelet-rich
clots. Therefore, in order to experience a higher concentration of nanoparticles inside of plateletrich GFP clots, longer labeling time might be required. In the present study, we focused on
examining the interaction between fibrinogen-conjugated nanoparticles and various components
of clots, not optimizing label conditions. We feel that using 15 minutes of incubation with the
label was sufficient to address these interactions between platelets. Here, we confirmed that
fibrinogen-conjugated nanoparticles specifically interacted with platelet aggregates and had the
ability to penetrate into platelet-rich clots.

Fibrinogen-conjugated nanoparticles do not associate with RBCs:
Throughout all RBC samples labeled with either FGN-cAu18 or FGN-cAu-Fe3O4, the
presence of nanoparticles either inside of RBC clots or in supernatants appeared insignificant and
virtually undetectable. Also, no nanoparticles were found in the interior of the RBCs. Although a
few labels were found, the labels tended to associate with fibrin strands rather than RBCs.
The lack of fibrinogen-conjugated nanoparticle interaction with RBCs could be due to
several factors. First, the fibrinogen-conjugated nanoparticles might have a low affinity for
binding onto the RBC membrane via an integrin αIIbβ3 like receptor. In fact, it has been reported
that the interaction between fibrinogen and an unknown receptor on the RBC membrane has a
lower affinity for binding compared to the platelet receptor (30). This could have influenced how
well the fibrinogen-conjugated nanoparticles bound to RBCs. Second, the fibrinogen-erythrocyte
interaction is transient. As a result, disruption of the interaction between fibrinogen and RBCs
could be expected. It has shown that even though there is a specific fibrinogen-erythrocyte
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interaction, the fibrinogen-erythrocyte bond is only 0.04% the lifetime of fibrinogen-platelet
binding (30,39). That may explain why the binding of fibrinogen-conjugated nanoparticles onto
RBCs seemed a rare event. Third, fewer receptors for fibrinogen exist on the RBCs surface (31),
together with interference from the fibrin network that wrapped around the outside of clotted
RBCs, could mask fibrinogen from binding to its erythrocyte receptor. As a result, the chance of
fibrinogen-conjugated nanoparticles associating with RBCs trapped inside of the clot was
limited. Therefore, we observed the label associating mostly with fibrin instead of RBCs.
Fourth, a previous study showed that a decrease in fibrinogen-erythrocyte interaction occurred
because of RBC aging (39). Knowing that, newer RBCs might bind more to fibrinogen. This is
likely to be only a minor factor in explaining low fibrinogen-conjugated nanoparticle-erythrocyte
interaction occurring in our experiments, as we used fresh blood samples that are expected to
have a normal distribution of ages of RBCs. If we combine all the factors listed above, we can
reasonably conclude that fibrinogen-conjugated nanoparticles do not interact, or have only very
minimal interaction, with RBCs.

Fibrinogen-conjugated nanoparticles strongly associate with fibrin(ogen):
We observed a significant association of fibrinogen-conjugated nanoparticles with both
fibrin clots and fibrin strands in the clot supernatants. The results matched our expectations. The
mechanism of fibrin(ogen)-fibrin interaction is well defined. Thrombin cleaves fibrinopeptides
from the fibrinogen molecule to create fibrin monomers. The cleavage of fibrinopeptides allows
“knob-hole” interaction between fibrin monomers, causing the fibrin monomers to polymerize
and form protofibrils which aggregate laterally to make fibers. Branching, both longitudinal and
lateral growth of fibers, leads to a three-dimensional gel network or formation of a fibrin clot
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(10,28,60,61). Using that knowledge could help to explain our experiments’ results. When
thrombin was introduced to stimulate the formation of the fibrin clot, plasma fibrinogen was
converted into fibrin. Similarly, fibrinogen-conjugated nanoparticles might be converted to
fibrin-conjugated nanoparticles. Because of the ability of the interaction to form fibrin networks
via polymerization of monomers and fibers, the interaction of plasma fibrin and fibrinconjugated nanoparticles might also occur. Therefore, we observed the presence of labels
throughout fibrin clots and supernatant at significant concentrations. Additionally, since in this
experiment we formed the clot with one component, plasma fibrin, the fibrin clot was smaller in
volume and less complex in structural components and organization. Thus, it could have allowed
for maximal interaction of fibrinogen-conjugated nanoparticles and fibrin, causing nanoparticles
to penetrate into fibrin clots or associate with fibrin strands in the supernatant. The results of
fibrinogen-conjugated nanoparticles and fibrin interactions suggested when using fibrinogenconjugated nanoparticles to target clots in vivo, the association of fibrinogen-conjugated
nanoparticles with fibrin is unavoidable.

Expected in vivo application:
These results suggest that fibrinogen-conjugated nanoparticles can interact strongly with
activated platelets in an existing clot. Thus, targeting platelets for magnetically-induced
hyperthermia as a treatment for ischemic stroke could be a viable option. However, these results
also revealed that fibrinogen-conjugated nanoparticles strongly interact with fibrin strands. Thus,
fibrin seems to be a competitor of activated platelets for binding with fibrinogen-conjugated
nanoparticles. While we originally proposed specifically targeting activated platelets in occlusive
thrombi, having an additional target in fibrin might strengthen our power to disrupt clots. If
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binding of the fibrinogen-conjugated nanoparticles was limited to the area of the occlusion, fibrin
could be another potential site-specific target to treat ischemic stroke. Because arterial clots are
mainly composed of fibrin and activated platelets (4-7, 62, 63), fibrinogen-conjugated
nanoparticles could bind to both protein and cellular components, strengthening our targeting
strategy. Since nanoparticle binding to fibrin is dependent on clot formation, this could work
synergistically with activated platelet binding as a treatment for ischemic stroke. Additionally,
these results demonstrated that there was no interaction between fibrinogen-conjugated
nanoparticles and RBCs. RBCs contribute to the bulk and the occlusive potential of a clot.
Hence, our method could have a minimal amount of extended off-targeting and provide a safe
treatment for ischemic stroke when performed in vivo.
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Figure 7. Schematic flow chart of isolation of human platelets. Whole blood (WB) was drawn
from a healthy donor and anticoagulated with 3.8% sodium citrate. Citrated blood was
centrifuged at 100 x g for 15 minutes to obtain platelet-rich plasma (PRP). To isolate purified
platelets (gel-filtered platelets, GFPs), PRP was applied to a Sepharose CL-2B column. GFPs
were adjusted to 150,000 platelets per μL by dilution in platelet-poor plasma (PPP), which was
collected by centrifuging the sample remaining after PRP was collected at 300 x g for 15
minutes.
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Figure 8. Schematic flow chart of isolation of human red blood cells. Citrated blood was
centrifuged twice: first at 100 x g for 15 minutes, then at 300 x g for 15 minutes to remove all
PRP, WBCs, and PPP from packed RBCs. Then, packed RBCs were resuspended in PPP back to
the original volume of citrated blood in the first step.
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Figure 9. TEM micrographs of PRP clot cross sections. Many fibrin strands and activated
platelets were present throughout PRP clots. White and black arrows indicate fibrin and platelets,
respectively. Scale bars equal 1μm.
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R
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W
Figure 10. SEM micrographs of WB clot cross sections. Few WBCs and activated platelets were
observed in the WB clots. Many RBCs were trapped by fibrin strands. White and black arrows
indicate fibrin and platelets respectively. R and W indicate RBCs and WBCs, respectively. Size
bars equal 5μm.
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SEI

BEI

Figure 11. SEM micrographs of the supernatant remaining over a fibrin clot labelled with FGNcAu18 nanoparticles. FGN-cAu18 nanoparticles strongly interacted with fibrin(ogen) strands. Low
magnification images appear on the top row and high magnification of the areas indicated in the
boxes are shown in the bottom row. Secondary electron images (SEI) are the left column and
backscattered electron images (BEI) form the right column. White arrows indicate the presence
of FGN-cAu18. Size bars equal 1μm.
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SEI

BEI

Figure 12. SEM micrographs of the supernatant remaining over a fibrin clot labelled with FGNcAu-Fe3O4 nanoparticles. In SEI, long fibrin strands connected together to form a fibrin network,
and many FGN-cAu-Fe3O4 nanoparticles bound to fibrin strands, giving a bumpy appearance.
Under BEI, FGN-cAu-Fe3O4 nanoparticles resolved as small bright spots found throughout the
sample. High numbers of FGN-cAu-Fe3O4 nanoparticles associated with fibrin strands. Low
magnification images are on the top row and high magnification of the areas indicated in the
boxes are in bottom row. White arrows indicate the presence of FGN-cAu18-Fe3O4. Size bars
equal 1μm.
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0.2mm

Figure 13. Montage of medial fibrin clot section labeled with FGN-cAu18. FGN-cAu18
nanoparticles penetrated throughout the fibrin clot from the periphery to the interior. White
boxes indicate the areas shown at higher magnification. White arrows indicated representative
FGN-cAu18 nanoparticles. White size bars equal 10μm.
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0.5mm

Figure 14. Montage of medial fibrin clot section labeled with FGN-cAu-Fe3O4 nanoparticles.
FGN-cAu-Fe3O4 nanoparticles appear as very bright spots in SEM images. FGN-cAu-Fe3O4
nanoparticles were found not only at the periphery but also at the interior of the fibrin clot. Also,
high concentrations of FGN-cAu-Fe3O4 nanoparticles accumulated throughout the fibrin clot.
White boxes indicate the areas shown at higher magnification. White arrows indicate
representative FGN-cAu-Fe3O4 nanoparticles. White size bars equal 50μm.
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Supernatant

Clot

Figure 15. Cross-section of fibrin clot and the supernatant remaining over a fibrin clot labelled
with FGN-cAu18 nanoparticles. FGN-cAu18 nanoparticles interacted with fibrin at the junctions
between fibrin strands. FGN-cAu18 nanoparticles penetrated into the fibrin network. High
concentrations of FGN-cAu18 nanoparticles localized both in the fibrin clot and remaining
supernatant samples. White arrows indicate the FGN-cAu18 nanoparticles. White boxes indicate
the area of higher magnification found on the bottom row. Scale bars equal 1μm.
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Supernatant

Clot

Figure 16. Cross-section of fibrin clot and the supernatant remaining over a fibrin clot labeled
with FGN-cAu-Fe3O4 nanoparticles. FGN-cAu-Fe3O4 nanoparticles bound onto fibrin strands
and were present throughout the supernatant and clot. Additionally, FGN-cAu-Fe3O4
nanoparticles were found at high concentrations in both the supernatant and deep inside the fibrin
clot. White arrows indicate FGN-cAu-Fe3O4 nanoparticles. White boxes indicate the area of
higher magnification found on the bottom row. Scale bars equal 1μm.
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SEI

BEI

Figure 17. SEM micrographs of suspended GFP labeled with FGN-cAu18. Labels were found at
the surface, at area of platelet-platelet interaction, and inside activated platelets. White arrows
indicate FGN-cAu18. SEI on the left displayed topography of the platelet aggregates and BEI on
the right shows the localization of the FGN-cAu18. Size bars equal 1μm.
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Figure 18. SEM micrographs of cross sections of platelet aggregate labeled with FGN-cAu18.
FGN-cAu18 accumulated mostly in the center of the activated platelets. Comparatively few
nanoparticles were found at the periphery of platelets or at platelet-platelet junctions. White
arrows indicate FGN-cAu18. Scale bars equal 1μm.
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SEI

BEI

Figure 19. SEM micrographs of suspended GFP labeled with FGN-cAu-Fe3O4. Labels were
found at the surface, at area of platelet-platelet interaction, and inside activated platelets. White
arrows indicate FGN-cAu-Fe3O4. SEI on the left shows the topography of platelet aggregates and
BEI on the right shows the localization of the FGN-cAu18-Fe3O4. Size bars equal 1μm.
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Figure 20. SEM micrographs of cross sections of platelet aggregates labeled with FGN-cAuFe3O4. FGN-cAu-Fe3O4 accumulated most in the center of activated platelets. Comparatively
few nanoparticles were found on the periphery of platelets or at platelet-platelet junctions. White
arrows indicate FGN-cAu-Fe3O4. Scale bars equal 1μm.
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0.5mm
Figure 21. Montage of medial platelet clot section labeled with FGN-cAu18 nanoparticles. FGNcAu18 nanoparticles appear as bright spots in the SEM images. FGN-cAu18 nanoparticles were
found not only at the periphery but also inside of platelet clots. However, as observed by moving
from the outside to the inside of the platelet clot, nanoparticles concentration became reduced.
White boxes indicate the areas shown at higher magnification. White arrows indicate
representative FGN-cAu18 nanoparticles. White size bars equal 10μm.
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0.5mm

Figure 22. Montage of medial platelet clot section labeled with FGN-cAu-Fe3O4 nanoparticles.
FGN-cAu-Fe3O4 nanoparticles appear as bright spots in the SEM images. FGN-cAu-Fe3O4
nanoparticles were found not only at the periphery but also inside platelet clots. Clusters of
nanoparticles were scattered throughout the platelet clot. White boxes indicate areas shown at
higher magnification. White arrows indicated representative FGN-cAu-Fe3O4 nanoparticles.
White size bars equal 10μm.
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Figure 23. Cross-section of GFP clot labeled with FGN-cAu18 nanoparticles. FGN-cAu18
nanoparticles were found inside the GFP clot. FGN-cAu18 nanoparticles were scattered
throughout the cross-section, primarily associated with fibrin strands. White arrow indicates
FGN-cAu18 nanoparticles. Scale bar equals 1μm.
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Figure 24. Cross-section of a GFP clot labeled with FGN-cAu-Fe3O4 nanoparticles. FGN-cAuFe3O4 nanoparticles were found inside the GFP clot. FGN-cAu-Fe3O4 nanoparticles were
scattered throughout the cross-section, primarily associated with fibrin strands. White arrow
indicates the FGN-cAu-Fe3O4 nanoparticles. Scale bar equals 1μm.
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Figure 25. SEM micrographs of supernatant remaining over RBC clot labeled with FGN-cAu18
nanoparticles. There was no noticeable interaction between RBCs and FGN-cAu18 observed. A
few nanoparticles were found on the surface of the RBCs; however, they appeared randomly and
rarely. Additionally, most nanoparticles found in the sample were associated with fibrin strands.
Secondary electron images (SEI) are on the left and backscattered electron images (BEI) taken of
the same area are on the right. White arrows indicate the presence of FGN-cAu18. Size bars
equals 2μm.
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Figure 26. SEM micrographs of the supernatant remaining over RBC clot labeled with FGNcAu-Fe3O4 nanoparticles. There was no specific interaction between RBCs and FGN-cAu-Fe3O4
observed. Few nanoparticles were found at the surface of the RBCs. Nanoparticle presence was
random and rare. Additionally, most nanoparticles found in the sample were associated with
fibrin strands. Secondary electron images (SEI) are on left and backscattered electron images
(BEI) of the same area are on the right. White arrows indicate the presence of FGN-cAu-Fe3O4.
Size bars equal 2μm.
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Figure 27. Montage of medial RBC clot section labeled with FGN-cAu18 nanoparticles. RBC
clots appeared larger in size and more tightly packed with many RBCs wrapped by fibrin strands.
Nanoparticles were found most at the periphery and associated with fibrin strands rather than
RBCs. Also, moving from outside to inside of the RBC clot, the nanoparticle concentration
decreased significantly, with no nanoparticles being found in the center of the RBC clot. White
boxes indicate the areas shown at higher magnification. White arrows indicate representative
FGN-cAu18 nanoparticles. White size bars equal 50μm unless indicated otherwise.
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Figure 28. Montage of medial RBC clot section labeled with FGN-cAu-Fe3O4 nanoparticles.
RBC clots were larger in size and tightly packed with many RBCs were wrapped by fibrin
strands. Most labeling was found at the periphery, with no labels being found at the center of the
RBC clot. Nanoparticles strongly interacted with fibrin, not RBCs. No labeling was observed on
the RBCs. White boxes indicate areas shown at higher magnification. White arrows indicate
representative FGN-cAu-Fe3O4 nanoparticles. White size bars equal 50μm.
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Figure 29. Cross-section of a RBC clot and the supernatant remaining over a RBC clot labeled
with FGN-cAu18 nanoparticles. FGN-cAu18 nanoparticles were able to penetrate into the RBC
clot. The bound nanoparticles associated mainly with fibrin but not RBCs. There were no
nanoparticle interactions with RBCs in either clots or supernatant. White arrows indicate the
FGN-cAu18 nanoparticles. Scale bars equal 2μm.
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Clot

Supernatant

Figure 30. Cross-section of a RBC clot and the supernatant remaining over a RBC clot labeled
with FGN-cAu-Fe3O4 nanoparticles. The bound nanoparticles associated only with fibrin strands
and not RBCs. There were no nanoparticles found associated with the RBCs in either clots or
supernatant. White arrows indicate the FGN-cAu-Fe3O4 nanoparticles. Scale bars equal 5μm.
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Chapter 3- Describing Clot Structure and Nanoparticle Penetration at a Physiologic
Range of Thrombin Doses
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Abstract:
We are investigating an alternative therapy for ischemic stroke that targets activated
platelets rather than fibrin in occlusive clots using fibrinogen-conjugated magnetic nanoparticles
and exposure to an oscillating magnetic field (OMF). This requires specific nanoparticle-receptor
interactions on activated platelets in the clot. Previous studies have demonstrated the specific
targeting of fibrinogen-conjugated, gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4) to
activated platelets in a purified platelet system. When followed by exposure to an oscillating
magnetic field, the activated platelets in aggregates were disrupted. Platelet-rich plasma (PRP)
and whole blood (WB) systems are more complex in terms of both the protein and cell
components, but are also more representative of the physiological system. Developing FGNcAu-Fe3O4 into an effective therapy will depend on how efficiently the nanoparticles penetrate
into clots and their resulting final concentration inside clots. We have used the robust model of
fibrinogen-conjugated gold nanoparticles (FGN-cAu18) to examine the effect the 3-dimensional
network of fibrin and blood cell components found in PRP and WB clots has on nanoparticle
penetration. We hypothesized that different fibrin architecture resulting from clotting at
different physiological thrombin concentrations determines the extent of nanoparticle
penetration into clots. PRP and WB were clotted in vitro using low and high doses of thrombin,
followed by soaking in FGN-cAu18. Sections and medial cross-sections were analyzed by
scanning electron microscopy to observe both the topography and interior of the clots. Frozen
cross-sections were treated with silver enhancement and analyzed by light microscopy to
quantify the depth of nanoparticle penetration observed in different donors.
From our experiments, we have found the following: First, the arrangement of cells
through the clots differed between the systems. In PRP, fibrin and platelets were distributed
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throughout the clot. In WB clots, a meshwork of fibrin and platelet aggregates was observed on
the clot surface, and the interior consisted of closely packed, compressed polyhedral erythrocytes
with very little fibrin present. Second, the dose of thrombin available during clotting
significantly influenced the density of clot structure. High thrombin doses produced a dense
network of small diameter fibrin filaments, and low doses produced a more open network of
large diameter fibers. Third, the extent of nanoparticle penetration was inversely related to the
density of the fibrin network and the number of activated platelets and erythrocytes. Fourth,
while variation between donors was observed, its effect on nanoparticle penetration was largely
overcome at high thrombin concentrations where there was a dense clot structure and an overall
lower degree of nanoparticle penetration. These results provide important insight into the
development of a nanoparticle-based therapeutic agent for treating ischemic stroke.

Introduction:
Previous studies have demonstrated the successful development and use of fibrinogenconjugated, gold-coated magnetite nanoparticles to target activated platelets in a purified platelet
system and the use of an OMF as a means to disrupt the activated platelet aggregates (1).
However, an in vivo blood clot will also have a fibrin network, red blood cells (RBCs), and white
blood cells (WBCs). Previous chapters discussed the interaction of nanoparticles with blood clot
components including fibrin, activated platelets, and RBCs. We demonstrated that conjugated
nanoparticles have the ability to bind to fibrin strands and activated platelets, but not RBCs. To
build on these studies and support our overall hypothesis, this chapter will demonstrate proof of
principle that labels can be incorporated into thrombi in the presence of plasma fibrin(ogen) and
RBCs. It will allow us to observe the location and quantify the degree of penetration of the labels
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into PRP and WB clots. We used both PRP and WB systems to address this instead of using only
the WB system. We will start with the less complex PRP model, which will educate us about
what problems we may encounter in the WB system and help us solve them efficiently.
Additionally, efficient nanoparticle penetration into the clot interior depends on how the fibrin
and blood cell components interact to form a 3-dimensional clot structure. This structure is
dependent on the thrombin doses used. Therefore, determining the range of responses observed
in our donor pool allows us to design in vitro experiments that have physiologic relevance to in
vivo systems.
Upon vascular damage, tissue factor (TF) expressed on the subendothelial cells is
exposed to blood. TF binds and serves as a cofactor for circulating factor VIIa (FVIIa), a serine
protease, thereby significantly increasing its enzymatic activity. The TF and FVIIa complex
catalyzes the conversion of the zymogen factors VII, IX, and X into activate serine proteases
FVIIa, FIXa and FXa. TF-mediated generation of FXa is referred to as the extrinsic pathway of
coagulation (2-4). FXa can also be generated via the intrinsic pathway. The intrinsic pathway
begins with the formation of the primary complex on collagen by high molecular weight
kininogen, prekallikrein, and factor XII. This causes the conversion of prekallikrein and factor
XII into kallikrein and FXIIa, respectively. The activated FXIIa then turns factor XI into FXIa.
Factor XIa activates factor IX, which with its co-factor FVIIIa, forms the tenase complex. This
activates factor X into FXa (2,5,6). Like FVIIa and FIXa, FXa associates with a cofactor, FVa,
thus forming the prothrombinase complex. The prothrombinase complex catalyzes conversion of
the zymogen prothrombin (factor II) into thrombin (FIIa) (the common pathway) (2,3,7,8). Then,
thrombin acts as a procoagulant by stimulating platelet activation via their protease activated
receptors (PARs). It also catalyzes the cleavage of fibrinogen to insoluble fibrin monomers
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which spontaneously polymerize to form fibrin strands that will attach to activated platelets and
trap RBCs to form clots. Thrombin further supports coagulation by activating factor XIII to the
transglutaminases FXIIIa that crosslink fibrin strands at lysine residues to strengthen and
stabilize the blood clot and stop bleeding (9,10).
The formation of the clot depends on the availability of thrombin. In normal circulation,
the range of thrombin in plasma is approximately 5.5 mIU/mL (0.055nM) or less. When
coagulation is activated, the local thrombin concentration in plasma is likely to be between 6.6
mIU/mL to 10 IU/mL (0.066nM-100nM). Anything above 10 IU/ml, or 100nM, is considered an
unrealistically high concentration of thrombin (11-14). The capacity of thrombin generation from
circulating prothrombin is considered to represent an individual’s ability to respond to tissue
injury and prevent bleeding. However, directly and accurately measuring the in vivo thrombin
concentration in plasma is very difficult for several reasons. First, thrombin has a very short halflife in plasma due to high concentration of its naturally occurring direct inhibitors such as
antithrombin and other circulating protease inhibitors (14,15). Second, measuring thrombin
concentration in the presence of plasma fibrinogen is challenging because thrombin rapidly
interacts with fibrinogen to form insoluble fibrin strands, which in turn binds to and entraps
active thrombin locally at the site of the clot (16). Third, thrombin generated in plasma following
in vitro stimulation will vary between donors. Therefore, we will use the knowledge of
physiologically relevant thrombin doses to investigate the impact of its concentration on clot
structure and the penetration of nanoparticles. We examined the impact of thrombin doses
between 0nM and 10nM.
The thrombin concentration present at the time of clotting dictates the fibrin clot
structure. Low concentration (<1nM, <0.1 U/mL) of thrombin generates turbid, permeable, and
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unstable fibrin clots that are composed of thick, loosely-woven fibrin strands. Higher thrombin
concentration produces non-turbid, less permeable, and comparatively stable fibrin clots
composed of thin, tightly-packed fibrin strands (17-22). In fact, many studies have shown that
more dense and stable clots are associated with thrombosis; whereas, loosely-woven, unstable
clots are related to bleeding disorders (23-30). Most previous studies have examined thrombin
effects on fibrin structure in purified systems that consisted of only thrombin and purified
fibrinogen. In vivo, many components beside fibrin participate in thrombus formation, including
activated platelets, WBCs, and RBCs. In fact, fibrin can interact with and wrap around platelet
aggregates to create a net that traps more platelets and other blood cells. Therefore, clot
formation in vivo will be more complex. To more completely understand the role of thrombin in
clot formation, PRP and WB systems should be taken into consideration. Therefore, to build our
understanding of the role of blood clot architecture in thrombosis and how it might impact the
development of a nanoparticle-based therapeutic agent for treating ischemic stroke, we used
fibrin morphology to describe PRP and WB clot architecture produced over a range of
physiologically relevant thrombin doses. We expected that at low thrombin concentrations, both
PRP and WB clots would be loosely packed into less dense and more porous networks; whereas,
higher thrombin doses would cause PRP and WB clots to be tightly pack into denser and less
porous networks.
The differentiation of fibrin clot structures also contributes to the varying degrees of clot
stability, including resistance to fibrinolysis and anticoagulants. In fact, using increasing
thrombin concentrations produced fibrin clots composed of thinner, highly branched fibers that
were less porous, less permeable, and more rigid; thereby, these clots were less susceptible to
dissolution by fibrinolytic proteins. When fibrinogen was clotted with low thrombin
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concentrations, a thicker fiber matrix was associated with a more permeable, more porous, and
less rigid clot structure. Thus, these clots were less resistant to fibrinolysis (31,32).
The differences in architecture of PRP and WB clots that might occur at various thrombin
concentrations might influence the degree of penetration of nanoparticles as well. The porous
network of clots formed at low thrombin concentrations might be more susceptible to fibrinogen
conjugated-nanoparticle penetration; whereas, tightly packed clot networks that resulted from
higher thrombin doses might limit the access of nanoparticles into the interior of clots. Moreover,
in the absence of RBCs, the PRP clot offers much better ability to investigate the fibrin
architecture. However, including the RBCs is critical to evaluating the in vivo environment.
Thus, using both PRP and WB clots to examine the efficiency of nanoparticle penetration will
address whether our nanoparticle-based targeting of arterial clots in ischemic strokes is viable for
clinical trials.
Investigating the nanoparticle penetration in both PRP and WB clots from different
donors is also necessary. These experiments will allow us to evaluate the variation of
nanoparticle penetration not only between PRP and WB systems, but also between donors. To
some extent, different donors might respond differently to the same thrombin doses. It is also
possible that donor clot structures might be distinct from one another, and the degree of
nanoparticle penetration into clots might vary accordingly. Hence, we examined this potential
phenomenon with the expectation that at the certain range of thrombin concentrations where
clotting occurs, most donor responses will behave similarly in regard to nanoparticle penetration
into clots.
As we discussed in previous chapters, fibrinogen-conjugated gold nanoparticles (FGNcAu18) and fibrinogen-conjugated gold-coated magnetite (FGN-cAu-Fe3O4) share a common
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characteristic and functionalization in targeting of clots. In addition, FGN-cAu18 synthesis is a
more robust procedure compared to FGN-Au-Fe3O4 synthesis. Therefore, FGN-cAu18 will be
solely used for investigating nanoparticle penetration in this chapter.
The overall hypothesis of this chapter is that the different fibrin structures resulting from
clotting at different thrombin doses will determine the penetration depth of fibrinogenconjugated nanoparticles into the clots. Testing this hypothesis will provide us vitally important
answers for the following questions: First, does thrombin concentration influence PRP and WB
clot formation in vitro? Second, can nanoparticles be incorporated into thrombi in the presence
of plasma fibrin(ogen)? Third, what efficiency of nanoparticle penetration into blood clots can
we expect? Lastly, does variation of nanoparticle penetration exist between donors?

Materials and Methods:
PRP and WB sample preparation:
Fresh blood samples were collected from normal adult donors and processed to produce
PRP and WB as described in Chapter 2.

Determine the range of responses to physiologically relevant thrombin doses in PRP:
PRP was adjusted to 150,000 cells per µL by diluting in PPP. The experiments were
performed in a round bottom, 96-well microtiter plate (Thermo Scientific TM, NuncTM). First,
30µL of 5X CaCl2 and thrombin (Haematologic Technologies), prepared in Tyrode’s buffer
(15mM HEPES, pH 7.4, 3.3mM Na2HPO4, 138mM NaCl, 2.7mM KCl, 5.5mM glucose, 1mM
MgCl2, 0.1% BSA) with 0.1% bovine serum albumin (BSA), was mixed to produce solutions
with a final concentration of 5mM CaCl2 and concentrations of 0nM, 0.5nM, 1nM, 5nM, and
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10nM of thrombin in a final volume of 100µL. Solutions were added into wells on one row of
the plate and incubated at 37°C for 3 minutes. Next, 80µL of PRP at 150,000 cells per µL was
pipetted into a different row of the 96-well plate and incubated at 37°C for 1 minute. Clotting
was initiated by using a multi-channel micropipettor to deliver and mix 20µL of the 5X CaCl2
and thrombin solution with the 80µL PRP. The clotting reactions were allowed to run for 12-15
minutes at 37°C, with shaking every 5 seconds on a microtiter plate reader (Versa Max,
Molecular Devices). Readings at 405nm were recorded as kinetic plots and analyzed using
SoftMax Pro software. Clotting time was determined as the time to maximum velocity (Vmax) of
the change in turbidity, using 5 data points and approximating the midpoint of the curve to
calculate Vmax (33). The extent of clotting was measured as the volume of supernatant (in µL)
remaining over the solid clot.

Determine the range of responses to physiologically relevant thrombin doses in WB:
A fibrometer (BBLâ, FibroSystemâ) was used to determine clotting time of WB at the
various doses of thrombin. The fibrometer system employed is the same as is often used for
routine coagulation tests. To measure clotting times, a series of 3X CaCl2 and thrombin mixtures
were prepared in Tyrode’s buffer with 0.1%BSA to deliver a final concentration of 5mM CaCl2,
with concentrations of 0nM, 0.5nM, 1nM, 5nM, 10nM thrombin. These solutions were
incubated with 200µL of WB on a fibrometer at 37°C. First, the 3X CaCl2 and thrombin
solutions were warmed to 37°C for 3 minutes. In a polypropylene cup beneath the fibrometer
probes, 200 µL of WB was incubated at 37°C for 1 minute. Then, 100µL 3X CaCl2 and thrombin
were added to WB and the timer bar was simultaneously pressed, dropping the probe into the cup
and starting the timer. When a strand of fibrin was picked up by the probe, the circuit was closed,
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and the timer was stopped. The total time elapsed from delivery of the thrombin to the first fibrin
formation was reported as the clotting time (in seconds).

Examine the architecture of clot structure at different thrombin concentrations:
PRP and WB were allowed to form clots in 96 well plates at various (0nM, 1nM, 0.5nM,
5nM and 10nM) thrombin concentrations as described above and followed by SEM and TEM
preparation. SEM and TEM preparation to analyze both surface and interior structures of PRP
and WB clots were performed as described in Chapter 2.

Analysis of porosity of PRP and WB clots using colloidal carbon, light microscopy and ImageJ:
PRP and WB clots were allowed to form in the microtiter plate reader at different
thrombin concentrations (1nM and 10nM). The clots were then fixed in 1% glutaraldehyde in 0.1
HEPES, pH 7.4 for 30 minutes at RT. The clots were placed in Higgins India black ink that had
been diluted 1:5 and soaked overnight at RT. After removal from ink, the clots were washed 3X
with 0.1M HEPES. Each clot was then embedded in OCT compound (Triangle Biomedical
Science, Inc) and frozen on dry ice. The sections were cut between 7μm and 10μm thick and
taken from the center of the clot. They were collected onto with poly-L-lysine coated slides.
Each clot was examined and then imaged under a Nikon Eclipse 50i and using PixelLink
Megapixel Firewire camera. All photos of each clot were used to reconstruct an image of the
entire clot in Adobe® Photoshop® CC. Once the reconstructed images were aligned, they were
analyzed in ImageJ. In ImageJ, clot section images were converted to 32-bit grayscale for
thresholding. The threshold of the grayscale image was adjusted until only the areas where the
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ink had penetrated could be read. The program then calculated the proportion of black area to
white area, and was reported as the percent area of the blood clot that was penetrated by ink.

Evaluate the degree of nanoparticle penetration into PRP and WB clots using SEM technique:
FGN-cAu18 was prepared as described in Chapter 2. PRP and WB clots were allowed to
form in the microtiter plate reader at different thrombin concentrations (1nM and 10nM). Then,
they were incubated with FGN-cAu18 for 15-20 minutes at 37°C and underwent SEM preparation
through mounting onto stubs. The clots were fractured and coated with carbon. The
backscattered images were taken at 15kV or 30kV accelerating voltage at low magnification
(200X magnification) or high magnification (1000X-2000X magnification). Entire twodimensional pictures of clot cross sections were reconstructed and assembled with Adobe®
Photoshop® CC version 14.1.2 x 32 using images taken at 200X magnification.

Quantifying the penetration of nanoparticles into PRP and WB clots by using silver enhancement
(SE) and light microscopy:
The clotting was performed in the microtiter plate reader as described above. Briefly,
PRP and WB were clotted with 0nM, 1nM, 5nM and 10nM thrombin solutions before being
labeled with FGN-cAu18 for 15 minutes followed by fixation in 1% glutaraldehyde in 0.1M
HEPES pH 7.4 for 30 minutes at RT. Then, the clots were washed with 0.1M HEPES pH before
being embedded in OCT compound and frozen with dry ice. Frozen clots were sectioned on a
cryostat (Leica CM 1900) between -18˚C and 20˚C, and the thickness of each section was about
7μm to 10μm thick. They were then picked up on poly-L-lysine coated slides and fixed with 1%
glutaraldehyde for 5-10 minutes at RT. Sections were washed and rehydrated with Millipore
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double deionized water (MDDW) before being treated with silver enhancement (SE) solution
(Sigma-Aldrich). SE solution was prepared freshly by mixing solution A (silver salt) and
solution B (initiator) in a 1:1 ratio according to the manufacture’s direction. The SE solution was
immediately applied to the slides that contained clots labeled with fibrinogen conjugated-gold
nanoparticles and allowed to incubate in the dark for 3 to 5 minutes. During this period, the SE
solution enlarged the gold colloid label by precipitation of metallic silver to give a high contrast
signal visible under light microscopy. After 3-5 minutes, the sections were washed thoroughly
with MDDW, fixed with 2.5% of sodium thiosulfate for 2-3 minutes, and then rinsed thoroughly
with MDDW. Cover glasses were mounted using VectaMount® permanent media (Vector
Laboratory) before being analyzed on a Nikon® TE2000U light microscope under the 4x, 10x,
and 20x Plan Apo objectives. Images were captured on PixeLink Megapixel Firewire camera. An
entire two-dimensional picture of a clot cross-section was reconstructed using Adobe®
Photoshop® CC version 14.1.2 x 32 to assemble images that were taken with either 4x or 10x
objectives. To measure the degree of nanoparticle penetration, diameters were measured at the
widest dimension of the clot. Penetration of FGN-cAu18 was measured as the distance of the
deepest silver deposition (determined at 20x) from the nearest edge of the clot. Percent
penetration was calculated as the penetration distance divided by the diameter.

Results:
Previous studies have demonstrated the successful development of fibrinogenconjugated, gold-coated magnetite nanoparticles as a means to target and disrupt activated
platelet aggregates in a purified platelet system by exposure to an OMF. However, in a blood clot
system, there will be a fibrin network, RBCs, and WBCs in addition to platelets. Hence, building
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upon the isolated platelet system, we examined the architecture of PRP and WB clots over a
range of physiologically relevant thrombin doses and characterized the range of responses in a
normal donor pool. The penetration of nanoparticles into PRP and WB clots will be analyzed
through these results, thus confirming whether the nanoparticles can incorporate into thrombi.

Determine the range of normal donor responses to physiologically relevant thrombin doses in
PRP:
There were differences between donors that were observed from the PRP clotting curves
(Figure 31). For example, the qualities unique to the individuals included baseline OD (due to
the lipids in plasma), maximum OD (clot structure), the time to Vmax, and rate of responses. Even
though different donors have different clotting profiles, they still shared common clotting
characteristics. First, recalcified PRP did not clot in the absence of thrombin in the microtiter
plate assay. Second, PRP clotted between a 0.5nM and 10nM range for all donors. Third,
increasing thrombin concentration decreased clotting time. It was observed that clotting time
distinguished between low and high doses (Table 1 and Figure 32). Clotting time variation was
reduced significantly at higher doses of thrombin (5nM-10nM) (Figure 32). Fourth, the size of
the clot increased as the thrombin concentration increased, which was indicated as less
supernatant remaining after clotting (Table 2 and Figure 33).

Determine the range of normal donor responses to physiologically relevant thrombin doses in
WB:
The microtiter plate reader was also used to study WB clot formation at various thrombin
concentrations in parallel with PRP. From our experiment, we observed that even in the absence

125

of thrombin, recalcified WB clotted. Overall, data from Table 3 and Figure 34 showed that WB
clots were larger than PRP clots. Interestingly, various thrombin doses did not strongly influence
the size of WB clots. In other words, once WB samples were sufficiently stimulated to clot, the
size of WB clots stayed relatively constant between different thrombin concentrations. Minor
donor to donor variation was observed in the size of the WB clot among thrombin doses.
The fibrometer method is more often used to study WB clotting rather than the microtiter plate
assay. In the presence of a normal RBC count, measurements of visible light transmitted through
wells of a microtiter plate cannot be made. The fibrometer measures clot formation by
mechanical detection of the clot using a moving probe. Platelet-poor plasma (PPP) was used as a
standard control for the fibrometer technique. Clotting time curves from PPP, PRP and WB all
showed greater variation between donors at low thrombin doses (0.5nM, 1nM) than at higher
doses (5nM, 10nM), where it was essentially eliminated. As the clotting system became more
complex, the clotting times decreased (Table 4, Table 5, and Figure 35).

Examine the architecture of PRP clots at different thrombin concentrations:
The above data demonstrate that the normal range of thrombin responses show very
similar results at 0.5nM and 1nM. Another cluster of similar results is found at 5nM and 10nM.
We therefore defined thrombin doses as “low” at 1nM, and “high” at 10nM, and used these doses
in our studies of clot ultrastructure.
When PRP clots were formed at low thrombin concentration, many spaces and pores
were observed from the surface of the clots. Also, fibrin strands were loosely packed with low
numbers of activated platelets. Observations of the interior of PRP clots were consistent with
surface views. Clots contained many spaces, with few activated platelets associated with thick,
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long, woven fibrin strands. Thus, low thrombin concentration PRP clots were very porous and
might be permeable (Figure 36).
In contrast, PRP clots formed in high thrombin concentrations had surfaces that were
tightly packed with many activated platelets and fibrin. No pores or spaces were found on the
surface of the clots. The interior of PRP clots at high thrombin concentrations appeared with a lot
of thin, chunky fibrin that interacted with many activated platelets to form highly dense networks
with small spaces and pores. PRP clots at high thrombin concentrations were less porous and
permeable (Figure 37).
Even though there were some slight differences in the number of activated platelets,
fibrin diameter, and the number of pores found in the images from different donors, the overall
results stayed consistent. Low thrombin concentration PRP clots appeared extremely porous,
whereas high thrombin concentration PRP clots were less porous.

Examine the architecture of WB clots at different thrombin concentrations:
At low thrombin concentration, the surfaces of WB clots consisted of biconcave RBCs
that were wrapped loosely with fibrin strands. Also, very few activated platelets were found at
the exterior of WB clots. Since fibrin wrapped around the RBCs very loosely, there were many
open pores that could be seen from the surface views. Inside the clot, biconcave RBCs and fibrin
were present throughout. There were still spaces or pores inside WB clots (Figure 38).
At high thrombin concentration, the surface of WB clots contained many RBCs, activated
platelets, and fibrin fibers. These components of the WB clot interacted with each other forming
a very tight and significantly dense network. There, no such pores or holes could be seen from
the surface. Interestingly, from the interior view provided by cross-sectioning, biconcave RBCs
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changed their shape into polyhedrons. They seemed to be contracted and squeezed into the core
of the clots and arranged side by side next to each other in a way that allowed no space between
them. Fibrin and activated platelets were found inside the WB clot; however, the majority of
these were accumulated at the clot periphery. High thrombin concentrations formed clots that
tended to be impermeable and nonporous (Figure 39).
Three different donors shared very similar results of WB clot structures that formed at
different thrombin concentrations. Low thrombin concentration produced open network clots
containing biconcave RBCs, fibrin strands, and few activated platelets. In contrast, high
thrombin concentration generated WB clots with high numbers of activated platelets, dense
fibrin networks at the surface, and polyhedral RBCs in the clot core.

Analysis of the porosity of clots at different thrombin concentrations:
Since low thrombin concentration tended to form PRP clots with porous networks, we
expected that these same clots would allow colloidal materials to migrate easily into the clot
interior and appear throughout the clot network. Our results testing PRP clots formed at low
thrombin concentrations with colloidal carbon met our expectation. The low thrombin
concentration PRP clots appeared very dark due to the abundant presence of colloidal carbon.
The black color present throughout the frozen cross-sections of the clots indicated that colloidal
carbon was able to penetrate from the periphery inwards to the clot interior (Figure 40B).
Without colloidal carbon, our control PRP clot looked white or transparent (Figure 40A and C).
With high thrombin concentration formed PRP clots, the colloidal carbon accumulated
predominantly at the clot periphery. Few dark spots could be observed inside the clot. However,
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the entirety of the clot did not look much different as compared to the control, with the exception
of the periphery where the colloidal carbon accumulated (Figure 40D).
The WB clots looked red or pink in color. When a WB clot was stimulated with 1nM
thrombin and soaked overnight with colloidal carbon, the carbon dye was able to penetrate into
the clot through the pores and open spaces. We observed that most of the dye was present outside
of the frozen cross-sections. Moving toward the center of the frozen cross-sections, dye
concentration was significantly decreased, as was indicated by the lessening appearance of black
color inside the clot. In addition, there was no colloidal carbon found at the center of the clot
(Figure 41B). The size of WB clots formed at higher thrombin concentrations was larger in
comparison to the size of clots formed at low thrombin concentrations. Also, the frozen crosssections revealed a highly dense network. This was indicated by the intact samples and less
tearing apart when sectioning. Moreover, the colloidal carbon was limited in its distance of
migration into WB clots formed at high thrombin concentration. Colloidal carbon resided only at
the periphery of the WB clot and none of it was able to move into the interior of the WB clot
(Figure 41D). In the WB clot control samples, no colloidal carbon was observed, and the samples
looked pink and red in color (Figure 41A and C).
Quantitative data of the percent area of the PRP clots penetrated by colloidal carbon was
measured by the threshold function of ImageJ. Results from three different donors showed that
low thrombin concentration formed clots had a higher percentage of area positive for colloidal
carbon compared to high thrombin concentration formed clots, which had a lower percent of area
containing colloidal carbon. For PRP clots, the average was 12% colloidal carbon for 1nM
thrombin and 8.78% colloidal carbon for 10nM thrombin. For WB clots, there was an average of
3.57% and 1.55% of colloidal carbon areas for 1nM and 10nM thrombin, respectively. Also, as
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the systems became more complex, the percent of area containing colloidal carbon decreased.
Here, we observed that the percent of colloidal carbon positive areas in PRP clots was higher
when compared with WB clots. Additionally, more donor to donor variation in the percent of
area containing colloidal carbon areas in PRP clots was observed than in WB clots (Table 6,
Figure 42).

Describe the penetration of nanoparticles into clots at different thrombin concentrations:
Since the three donors shared very similar characteristics in the penetration of colloidal
materials into clots at different thrombin concentrations, Donor 1 samples were chosen as
representative of the general observations relating to the degree of nanoparticle penetration.
When low thrombin concentration PRP clots were labeled with FGN-cAu18, the labeling
was found throughout PRP clots. It was easy to find and observe the nanoparticles using SEM
analysis. High nanoparticle concentration was found at the outside edge of the clot. Moving into
the middle of the sample, the nanoparticle concentration slightly decreased. Nanoparticles were
able to migrate all through the clot to a final localization at the center (Figure 43). In high
thrombin concentration PRP clots, nanoparticles were again found both at the clot periphery and
interior. However, it was harder to recognize nanoparticles in the interior of the clot using the
SEM since they occurred in low concentrations (Figure 44).
In WB clots formed at low and high thrombin concentration, the majority of
nanoparticles were localized to the peripheral area of the clots. In low thrombin concentration
WB clots, few nanoparticles were able to migrate into the clot interior, resulting in a limited
depth of penetration and internal concentration of FGN-cAu18 (Figure 45). In terms of high
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thrombin concentration WB clots, it was extremely rare to find any nanoparticles at the center of
the clots, thus nanoparticle penetration was restricted to the clot periphery (Figure 46).
There were several general observations from data that were collected from three
different donors. First, nanoparticle concentration was always higher at the periphery for both
PRP and WB clots. Second, the number of nanoparticles was reduced as we looked further into
the interior of the clot. Third, more nanoparticles were able to penetrate into PRP clots and less
nanoparticles were able to penetrate into WB clots. The SEM results from three donors were
consistent in terms of overall depth of nanoparticle penetration and concentration (Figure 47-50).

Quantify nanoparticle penetration into PRP and WB clots using silver enhancement:
Since we only roughly estimated the nanoparticle penetration by using SEM, here we sought
to quantify the degree of nanoparticle penetration from various donors using silver enhancement
(SE) and light microscopy.

1. SE and light microscopy as a quick screening method for nanoparticle penetration:
In FGN-cAu18 labeled PRP clot cross-sections, without the treatment of SE the periphery of
the clot looked pink and the interior of the clot looked white or transparent. With the use of SE,
the borders of the clots appeared to be darker or black instead of pink, and some dark spots were
scattered throughout the clot. The black areas indicated the presence of metallic silver deposited
at the site of the FGN-cAu18 labeling. In the control samples, which lacked the labeling of FGNcAu18, with SE treatment, a few minor artifacts were observed; however, in comparison with the
absence of SE treatment, there were no significant differences between these samples (Figure
51). In regard to the WB clot samples, SE improved the contrast between the red color of the WB
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and the pink color of gold nanoparticles; thus, SE provided a better visualization of the
difference between WB and gold nanoparticles within the sample. In the presence of SE, gold
nanoparticles appeared black in color instead of the pink that was commonly observed in the
samples without the treatment of SE. Again, in the control without gold and with or without SE,
the sample was pink in color (Figure 51). Using the SE and light microscopy method usually
allowed us to obtain data within the same day of the experiment. As a result, data analysis could
be done the day following the experiment.

2. SE and light microscopy in studying clot network structure and nanoparticle penetration:
PRP and WB clots were formed at different thrombin concentrations (0.5nM, 1nM, 5nM, and
10nM) to observe the fibrin network density. Also, these PRP and WB clots were labeled with
FGN-cAu18 to quantify the degree of nanoparticle penetration into clots at different thrombin
concentrations.
In PRP, low thrombin concentration (0.5nM and 1nM) clots had smaller diameters, more
pores, and open spaces inside; whereas, high thrombin concentration (5nM and 10nM) clots had
larger diameters and contained less internal spaces, fewer pores, and a denser fibrin network
within the clots. Also, it was observed that nanoparticles were found both outside and inside of
clots formed at low thrombin concentrations; in contrast, the nanoparticles were limited to the
edge of clots formed with high thrombin concentrations. These were reflected by the calculations
of percent nanoparticle penetration into clots. By using the deepest distance of the nanoparticle
penetration divided for the largest diameter of the clot, we calculated the percent of nanoparticle
penetration into 0.5nM, 1nM, 5nM, and 10nM PRP clots of example donor 5 were 35%, 23%,
8.3% and 4% respectively (Figure 52).
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In WB, both low and high thrombin concentration clots were tightly packed with RBCs in
addition to the fibrin network. Not many spaces nor pores were found within the WB clots. The
nanoparticle penetration was mostly limited to the periphery of the WB clot. It was slightly
deeper when the WB clot was formed with low thrombin concentration. Using Donor 5 as an
example, there were about 22% and 18% of nanoparticle penetration for 0.5nM and 1nM
thrombin clots, respectively. The nanoparticle penetration was reduced to 14% and 11% for 5nM
and 10nM thrombin clots (Figure 53).

3. Quantify the nanoparticle penetration using silver enhancement and light microscopy:
The diameter of the clots increased as the thrombin concentration increased for all six donors
in both PRP and WB clots. Also, WB clots appeared bigger in size compared to PRP clots. For
PRP, the average of diameter of clots from six donors was 1.68mm, 1.86mm, 2.1mm, and
2.45mm for concentrations of 0.5nM, 1nM, 5nM and 10nM thrombin, respectively. In WB clots,
average diameters were 2.39mm, 3.09mm, 3.03mm, and 3.56mm for concentrations of 0.5nM,
1nM, 5nM, and 10nM thrombin, respectively. We also observed that both the distance of
maximum nanoparticle penetration and percent of nanoparticle penetration were inversely related
to thrombin doses. In other words, as thrombin concentration increased, there was a decrease in
the depth of nanoparticle penetration. The average of distance of migration from the six donors’
PRP clots at different thrombin concentrations were 0.45mm, 0.39mm, 0.27mm, and 0.22mm for
0.5nM, 1nM, 5nM, and 10nM of thrombin, respectively. For WB clots, the average distance of
nanoparticle migration was 0.43mm, 0.49mm, 0.297mm, and 0.3mm formed using 0.5nM, 1nM,
5nM and 10nM of thrombin, respectively. For the percent of nanoparticle penetration, the
averages were 18.1%, 15.8%, 9.58%, and 8.11% for 0.5nM, 1nM, 5nM, and 10nM thrombin
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formed PRP clots; whereas, the averages were 26.17%, 19.61%, 12.58%, and 9.57% for the
percent of nanoparticle penetration in WB clots formed at 0.5nM, 1nM, 5nM, and 10nM,
respectively (Tables 7 and 8).
The graph of thrombin concentration versus percent of nanoparticle penetration was created
based on the data from Tables 7 and 8. In PRP clots, there was a higher degree of donor to donor
variation in percent of nanoparticle penetration. The variation in percent of nanoparticle
penetration was reduced at higher thrombin concentration. In WB clots, donor to donor variation
in percent of nanoparticle penetration decreased. Also, the percent of nanoparticle penetration
between low and high thrombin concentration-formed clots was only slightly different. In
addition, WB clots showed lower percent of nanoparticle penetration than PRP clots (Figure 54).

Discussion:
The use of fibrinogen-conjugated gold nanoparticles to target PRP and WB clots in vitro
was evaluated with an emphasis on describing the architecture of PRP and WB clots over a range
of physiologically relevant thrombin doses including characterization of the range of responses
in different donors and investigation of the penetration of nanoparticles into the clots. First, the
normal range of normal donor responses to physiologically relevant thrombin doses was
determined between 0nM and 10nM thrombin for our blood clotting system. We also further
categorized them into two distinct groups. Low doses of thrombin were indicated at 1nM or
below and high doses of thrombin were between 5nM and 10nM. Low doses of thrombin were
similar in their characteristics of longer clotting time, lower maximum OD, and variation in
clotting between donors. High doses of thrombin showed extremely shorter clotting time, higher
maximum OD, and greater consistency in clotting between donors. With these results, we
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learned to expect that low thrombin concentrations would enhance differences between donors
and high thrombin concentrations would reduce such variations. Second, the availability of
thrombin at the time of clotting strongly influences the architecture of PRP and WB clots. High
thrombin concentration produced less porous, highly compact and stable clots; whereas, low
thrombin concentration generated loose, more porous, and unstable clots. The stability of a clot
affects how easily the clot can be dissolved or disrupted in vivo. Hence, high thrombin
concentration clots will be well protected from fibrinolysis and nanoparticle penetration. In
contrast, clots formed at low thrombin concentrations will be permeable and highly susceptible
to fibrinolysis and nanoparticle penetration. Third, nanoparticle penetration was highly impacted
by the density and organization of blood clot components. The depth of nanoparticle penetration
was limited to the periphery of the clot when it contained a denser fibrin network and more
activated platelets and RBCs. In vivo, thrombi are expected to be even more complex and
closely packed with proteins and blood cell components. Thus, it is reasonable to expect that in
vivo (1) no, or only a few, nanoparticles could migrate into the interior of the clots and (2) the
depth of nanoparticle penetration could be limited to the clot edge. These observations proved
that nanoparticles can be incorporated into preexisting clots such as those that form occlusions.
However, in order to improve the efficiency of nanoparticle penetration and concentration, we
may need to optimize the labeling procedures. Also, multiple applications of nanoparticles may
provide better outcomes. Fourth, there was variation in the percent of nanoparticle penetration
between different donors. However, we observed that at higher thrombin concentrations in the
WB clot system, the variation between donors was almost eliminated. At a high thrombin dose
(10nM), variation between different donors was minimal. This means that the potential
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therapeutic effect of nanoparticles used to target an occlusive clot in vivo could be consistent
between patients.

Determine the range of normal donor responses to physiologically relevant thrombin doses:
Different labs prefer different doses of thrombin as the routine stimulus of in vitro clot
formation. Thus, depending on the purposes of a given experiment, particular thrombin
concentrations can be used. Thrombin is a potent coagulant produced by the cleavage of
prothrombin by factor Xa. Thrombin is then actively involved in clot formation and is not
directly measurable as a circulating protein. Rather, prothrombin time assays are used to measure
the time it takes for a clot to form. Therefore, determining the exact thrombin concentration is
still very challenging. Many studies use large ranges of thrombin concentrations to observe its
impact on fibrin clot structures in vitro, some between 0.0055nM and hundreds of nM. Some
fibrinogen assays even used thrombin concentrations above hundreds of nM that cannot be found
in normal plasma (34-38). Our experiments are interested in looking at donor responses to
physiologically relevant thrombin doses. Hence, concentrations between 0nM and 10nM
thrombin were investigated.
In PRP, clotting curve profiles from different donors were unique. Clotting curves may
vary by day, or even hour, with the same donor. This could be due to many factors such as diet,
time of blood draw, daily stress, and amount of available proteins, lipids, and other blood
components in circulation. The microtiter plate reader experiments were able to demonstrate that
0.5nM and 1nM of thrombin doses shared similar clotting characteristics including longer
clotting time and lower maximum OD405. Also, 0.5nM and 1nM thrombin clots appeared smaller
in size. In comparison, clots formed with 5nM and 10nM thrombin had shorter clotting times and
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were larger. Subsequent analysis showed that clots that produced higher maximum OD405 values
has dense fibrin networks. At 5nM and 10nM thrombin, the clotting times and maximum OD405
values were consistent, with minimal variation between donors.
Our study using the fibrometer method resulted in similar findings. More variation in
clotting time versus log thrombin concentration at 0.5nM and 1nM was observed, compared to
the variation in clotting time versus log thrombin concentration at 5nM and 10nM. As the system
became more complex, the clotting time was reduced significantly. WB had the shortest clotting
time compared to PPP and PRP.
Together, we concluded that 0.5nM and 1nM could be grouped and considered as low
thrombin doses, while 5nM and 10nM could be considered as high thrombin doses. Since 0.5nM
appeared more inconsistent in clot formation, 1nM thrombin was preferred as an experimental
low dose. Thus, 1nM and 10nM were chosen to represent low and high thrombin doses in the
study of clot structure and its effects on nanoparticles throughout this chapter. Moreover,
concentrations above 100nM thrombin were not considered for our study because they are not
representative physiologically and might not occur in vivo. It is possible that different clotting
characteristics between donors such as clot density, and clotting times might be completely
overcome at overdoses of thrombin. Therefore, we might not be able to investigate the effects of
thrombin doses in clot formation.

Examine the architecture of clots at different thrombin concentrations:
Most previous studies have examined fibrin clot formation in the absence of cells or else
in purified platelet systems (1,17,36,39). Here, our study reveals additional information on how
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fibrin, activated platelets and RBCs associate with each other to form clots under physiologic
thrombin concentrations.
In PRP, low thrombin concentration resulted in fibrin and a few platelets loosely packed
into a porous network. High thrombin concentration allowed clots to form with fibrin and many
activated platelets tightly packed together into a dense network. At low thrombin concentration,
WB clots consisted mostly of fibrin loosely wrapped around biconcave RBCs, with a few
activated platelets throughout the clot. At high thrombin concentration, WB clots consisted of
highly branched fibrin with many activated platelets at the surface, while polyhedral RBCs
resided compactly at the core. Due to the differences in blood components between PRP and
WB, the clots’ structure and organization of blood components were different. In PRP, fibrin and
activated platelets interacted with each other and appeared throughout clot. Since PRP is a less
complex system, the clot tended to be smaller in size with more open spaces. In WB, especially
at high thrombin concentration, fibrin and activated platelets organized at the periphery of the
clots and RBCs were squeezed into the interior. In general, WB formed larger clots that were
highly compacted and less porous. These experiments used blood obtained from three different
donors. The results obtained were consistent between donors.
These results suggested that clots formed at low thrombin concentrations might be more
permeable and less protected from fibrinolysis compared to clots formed at high thrombin
concentrations. Also, WB clots would be more of a challenge for both fibrinolysis and
penetration by nanoparticles compared to PRP clots. We expect thrombi found in vivo would
have similar characteristics to the experimental clot formed with the combination of high
thrombin concentration and WB complexity.
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Analysis of clot porosity at different thrombin concentrations:
A perfusion chamber is commonly used to determine the porosity of the clot in vitro (4042). The flow, shear, and pressure can be adjusted to mimic physiologic conditions found in vivo.
Then, the volume can be collected to report the porosity, permeability, and diffusivity of the
clots. Setting up the flow through to be like in vivo conditions requires the assembling of a
perfusion apparatus, and optimizing and motoring the rate of flow, shear and pressure. Here, our
experiments utilized a rough measurement of clot porosity with a simple system. We soaked the
clots in colloidal carbon, visualized the porosity of clots with light microscopy, and quantified
the porosity of clots with ImageJ. Although our model is static, our goal was to evaluate the
different porosity of clots formed at different thrombin concentrations, so we did not expect that
introducing flow and shear would be necessary to address the question. Also, the presence of
shear and flow could have made the system more complicated and difficult to evaluate.
Observations of the architecture of clots formed at different thrombin concentrations
were made. Clots formed at low thrombin concentrations appeared porous and hollow inside;
whereas, clots were less porous and not hollow when formed at high thrombin concentrations. In
addition, the more complex in components the clots were, represented by WB clots in our
experiments, the less pores and internal spaces were found inside of the clots. Our results
regarding the porosity of clots at different thrombin concentrations supported these observations.
The PRP clots formed at low thrombin concentrations had more pores, and thus colloidal carbon
was able to occupy a greater percentage of the clot area. WB clots formed at high thrombin
concentrations had results at the opposite end of the spectrum compared to the PRP clots formed
at low thrombin concentrations. We found less area occupied by colloidal carbon inside of these
clots. That means WB clots formed with high thrombin concentrations had less porosity. The
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porosity of the clots can be used to predict the stability of clots in fibrinolysis (31, 32) and we
expect it will also predict the efficiency of using nanoparticles to label the clots. With more open
network and pores, these clots allow for proteins, or our labels, to be able to penetrate and
interact with their targets inside of blood clots. The access of the labels or proteins could have
limited entry to the clot interior if the clots were solid and less hollow and porous.
In vivo, we expect that the thrombi would result from local thrombin concentration in the
range of our high dose or even above (17, 43) and would be likely to resist fibrinolysis and
nanoparticle penetration. These clots would appear less porous and hollow in the interior of the
clots. Thus, these results imply that using nanoparticles to target the activated platelets in the
clots would mainly occur at the clot surface.

Describe the penetration of nanoparticles into clots at different thrombin concentrations:
The degree of nanoparticle penetration into clots depended on both the thrombin
concentration available at the time of clotting and the complexity of blood clot components.
Different fibrin organizations resulted from clotting with different thrombin doses, which in turn
determined penetration depth of fibrinogen-conjugated nanoparticles into the clots. The
penetration of nanoparticles was inversely related to thrombin concentration. High thrombin
doses produced a dense network of small diameter fibrin filaments. This phenomenon prevented
nanoparticle penetration. Low doses produced a more open network of large diameter fibers;
thereby, allowing nanoparticles to migrate deep into the interior of the clots. The extent of
nanoparticle penetration was also inversely related to the density of the fibrin network and the
number of activated platelets and erythrocytes. Nanoparticle penetration was found at both the
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periphery and interior of PRP clots; whereas, nanoparticle migration was limited to the outer
edge of WB clots.
WB clots at high thrombin concentration were impermeable; thereby, they resisted
nanoparticle penetration. Previously, we demonstrated that high thrombin concentration WB
clots contain many activated platelets at the periphery, and fewer in the interior of the clots. We
propose using fibrinogen-conjugated nanoparticles to target only the activated platelets in the
occlusive clots. Hence, FGN-cAu18 still interacted with many activated platelets on the clots’
surface even though the clots might have been tightly packed without spaces and pores
internally. Also, it is possible that there was an extremely low number of nanoparticles that were
able to penetrate deep into the clots due to fewer activated platelets and high resistance to
penetration. The success of our magnetic nanoparticle-induced hyperthermia to disrupt occlusive
clots requires both depth of nanoparticle penetration and concentration. Therefore, in order to
bring nanoparticles into the interior of clots, we might need multiple rounds of labeling and
subsequent exposure to the OMF. This would, step by step, slowly destroy activated platelets
from the clot periphery to the interior. Eventually, clots would become small in size and no
longer able to block blood flow. In terms of polyhedral RBCs at the clot center, we anticipate
that they will bounce back into biconcave-shaped individuals and flow away in circulation.
The shear stress observed within the circulatory system is an important factor in the
complex and dynamic human in vivo environment that might strongly impact the effectiveness of
nanoparticle penetration and delivery. First, shear stress can change the interaction between cells
and nanoparticles (44, 45). Thus, it is possible that a reduction in the binding strength between
nanoparticles and activated platelets could occur if there are increasing shear forces experienced
by the nanoparticles. Second, the flow can influence the distribution of nanoparticles in the
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plasma by preventing gravitational settling (45, 46). Third, shear stresses found in vivo could
induce changes in the morphology of clots including the thickness of fibrin, the tightness of clot
structures, and the presence of additional blood components (47- 49). These changes could
decrease the efficiency of nanoparticle penetration into clots.
Human bodies are a highly complex system and possess a dynamic environment that will
represent a challenge for nanoparticle delivery and penetration. By evaluating nanoparticle
penetration in classic stasis in vitro, these conditions might be oversimplified and lead to an
overall low predictability towards their behavior clinically. If possible, shear stress should be
taken into account in the continued study of nanoparticle penetration into occlusive clots. These
findings will have important implications in the development of nanoparticle delivery strategies
for disrupting clot formation and enhancing clot dissolution.

Quantify nanoparticle penetration into clots using silver enhancement:
The screening method utilizing silver enhancement and light microscopy was used to
quantify the nanoparticle penetration into clots from donors in our pool. Silver enhancement with
light microscopy has advantages over SEM. It is less time consuming in sample preparation;
thereby, shortening the time of analysis. Also, silver enhancement is considered less expensive in
terms of reagents and equipment. Moreover, SEM requires extensive training. However, there
are some limitations in using silver enhancement to observe nanoparticles in clots. First,
unspecific binding of metallic silver onto samples can cause artifacts if the samples were
exposed too long with silver enhancement or the samples were not washed thoroughly before the
application of silver enhancement reagents. Second, since nanoparticles are below the resolution
limit of compound light microscopy, single nanoparticles might be undetectable. However, silver
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enhancement is very good for detecting small clusters of nanoparticles, and our method of
disrupting clots depends on high nanoparticle concentration residing inside of the clots. It is still
valid to utilize silver enhancement to assist our analysis.
In both PRP and WB systems, different donors showed different percentages of
nanoparticle penetration. The differences appeared more varied at lower thrombin doses (0.5nM
and 1nM). As thrombin concentration increased, a reduction in nanoparticle penetration was
observed. At high thrombin concentrations (10nM), the differences in nanoparticle penetration
between donors was significantly diminished. In addition, WB clots had lower percent
nanoparticle penetration and less donor variation compared to PRP clots. Taken together, this
data suggests that at thrombin concentrations similar to those in thrombi formation, nanoparticle
penetration might occur to the same degree in different individuals, and the potential therapeutic
effect could be consistent between patients.

Expected in vivo application:
These results provided several important insights into how the architecture of PRP and
WB clots over a range of physiologically relevant thrombin doses influences nanoparticle
penetration. The complex structure of PRP and WB clots is challenging for nanoparticle
penetration due to the presence of fibrin and RBCs. However, our results suggested that
fibrinogen-conjugated nanoparticles are able to penetrate into clots even in the more challenging
WB clot system. Since the WB clot is the best representation of the physiologic clot found in
vivo, it can serve as a platform to predict the efficiency of nanoparticle penetration into occlusive
clots in vivo. In addition, in terms of the pathological conditions of ischemic stroke, we expect
that local thrombin concentration will be at the high end of the physiological range, or elevated
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above it. As a result, occlusive clots will contain a high-density fibrin network associated with
many activated platelets on the exterior, wrapped around a core of RBCs. These factors can
cause clots to become protected from fibrinolysis and penetration of externally applied
nanoparticles. In order to overcome the limits of nanoparticle penetration into WB clots, we
might need to optimize the labeling concentration, time of incubation, or even use multiple
nanoparticle applications to improve both nanoparticle concentration and penetration inside of
clots in vivo.
Furthermore, we experienced that at high thrombin concentrations in a WB system,
variation of nanoparticle penetration was significantly reduced between donors. This means that
at thrombin concentrations like those that may be found at the thrombus causing an ischemic
stroke, variability could be minimized. So in vivo or even clinically, we expect that the potential
therapeutic effect would be consistent between individuals.
In vivo, the presence of shear stress in blood flow is another aspect that should be taken
into account since we did not address this in our static in vitro experiments. The contribution of
flow and shear would potentially add layers of complexity and dynamics to our system, but it
would provide a better model of in vivo conditions. It is possible that flow and shear could
influence clot structure and the efficacy of nanoparticle penetration. This could produce
considerable challenges and lead us to modify our conclusions of how efficient a nanoparticlebased therapeutic for treating ischemic stroke can be.
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Figures and Figure Legends:

Figure 31
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Figure 31. PRP clotting curves from different donors using various thrombin concentrations.
These experiments were done using three different normal donors, each tested on three different
days. Green, orange, black, blue and red lines represent 0nM, 0.5nM, 1nM, 5nM and 10nM
respectively. In the absence of thrombin, no significant clotting is observed in any donors. 0.5nM
to 10nM thrombin concentration can be considered as a physiologically relevant clotting range in
vitro. In general, little difference is observed between 0.5nM and 1nM, but the responses are
qualitatively different from those seen with 5nM and 10nM. Similarly, little difference is seen
between 5nM and 10nM. Therefore, 0.5nM and 1nM can be considered to represent a “low”
thrombin dose, and 5nM and 10nM can be considered to represent a “high” thrombin dose. For
low thrombin concentration clotting curves, the overall maximum OD405 value was lower than
the overall maximum OD405 value of high thrombin concentration clotting curves. Also, the rate
of response with high thrombin doses was faster, indicated by shorter lag times and steeper
slopes.
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[Thrombin]
0.5nM
1nM
5nM
10nM
[Thrombin]
0.5nM
1nM
5nM
10nM
[Thrombin]
0.5nM
1nM
5nM
10nM

Donor 1 - Time to Vmax (seconds)
Exp #1
Exp #2
1025
212
1183
245
58
53
48
56
Donor 2 - Time to Vmax (seconds)
Exp #1
Exp #2
911
405
521
214
40
46
42
27
Donor 3 - Time to Vmax (seconds)
Exp #1
Exp #2
560
289
166
208
32
20
23
26

Exp #3
900
849
33
37
Exp #3
295
157
27
22
Exp #3
449
291
48
26

Table 1. Clotting time data obtained from PRP clotting curves measured in microtiter plate
reader experiments. Clotting times vary at lower thrombin concentrations (0.5nM-1nM). Higher
thrombin doses reduce variation in clotting times.
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Figure 32. Time to Vmax in response to different doses of thrombin. Increasing thrombin
concentration decreased clotting time. Day to day variation for a single donor was as great as
donor to donor variation at low doses of thrombin. Clotting time variation was eliminated at
higher doses of thrombin. The graph was created from the data shown in Table 1. The time to
Vmax was averaged for each donor at each concentration. Error bars represent standard deviation.
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[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM

Donor 1- PRP Supernatant (µL)
Exp #1
Exp #2
99
100
75
84
70
74
65
70
58
69
Donor 2- PRP Supernatant (µL)
Exp #1
Exp #2
90
100
80
84
68
74
54
69
51
67
Donor 3- PRP Supernatant (µL)
Exp #1
Exp #2
100
99
75
81
75
74
76
70
76
67

Exp #3
91
79
75
75
40
Exp #3
94
71
67
62
58
Exp #3
80
71
51
37
31

Table 2. Volume of supernatant remaining after PRP clot formation. Data correspond to the
experiments report in Table 1 and Figure 32. Increasing the thrombin concentration reduced the
volume of plasma remaining after clotting, indicating a greater percentage of clotting occurred.
That is, a lower volume of residual plasma indicated larger clot sizes. Total starting volume used
was 100µL.
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Remaning supernatant after clotting (µL)
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[Thrombin]
Figure 33. The volume of supernatant remaining after PRP clots formed at different thrombin
concentrations. This graph was generated from data shown in Table 2. Increasing thrombin
concentration generally decreased the residual plasma after PRP clotting, indicating larger clots.
Error bars represent standard deviation.
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[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM

Donor 1- WB Supernatant (µL)
Exp #1
Exp #2
46
45
40
38
45
41
46
42
44
38
Donor 2- WB Supernatant (µL)
Exp #1
Exp #2
45
53
46
59
45
54
46
54
40
53
Donor 3- WB Supernatant (µL)
Exp #1
Exp #2
54
52
56
60
54
61
54
52
44
50

Exp #3
46
36
42
37
38
Exp #3
63
47
51
50
49
Exp #3
48
59
54
51
54

Table 3. Volume of supernatant remaining after WB clots formed, obtained from samples clotted
in the microtiter plate reader in parallel with PRP samples. Data are from the same three normal
donors tested on the same three days. As thrombin concentration increased, the amount of
residual supernatant changed only slightly, but much less than was observed in the PRP system.
Clot sizes among thrombin doses was relatively consistent, including in the absence of thrombin.
Clots were larger than the corresponding PRP clots at every thrombin concentration. Total
starting volume used in the experiment was 100µL.
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Remaining supernatant after clotting (µL)
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Figure 34. The volume of supernatant remaining after WB clots formed at different thrombin
concentrations, obtained from the microtiter plate reader experiments. This graph was
constructed from data in Table 3. When thrombin concentration increased, the amount of
remaining supernatant left over slightly changed. The variation in clot size seemed consistent
among thrombin doses. Less volume indicated bigger clot size. The total volume used in starting
experiment was 100µL. Error bars represent standard deviation.
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Donor 1
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
Donor 2
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM
Donor 3
[Thrombin]
0nM
0.5nM
1nM
5nM
10nM

PPP
no clot
277.4
120.4
21.9
12.9
PPP
no clot
231.4
170.5
21
18.9
PPP
no clot
315.5
208.9
35.3
17.3

Exp #1
PRP
332.7
250.8
97.9
20.9
12.9
Exp #1
PRP
686.9
350.5
120.3
19.9
18.9
Exp #1
PRP
222.4
163.9
121.9
26.4
14.9

WB
195.9
96.4
73.9
19.9
2.7
WB
122.5
119.4
50
17
10
WB
171.9
86.9
73.3
18.4
4.3

Clotting Time (seconds)
Exp #2
PPP
PRP
WB
no clot
240
216.4
219
189.9 100.9
187.9
115
59.4
22
20.4
18.9
16
11.4
11.5
Exp #2
PPP
PRP
WB
no clot 371.7 273.5
228
183.4 264.4
179
135.4 108.9
29.4
29
22
25.9
19.4
14.4
Exp #2
PPP
PRP
WB
no clot 180.4 179.4
217.4 167.5 153.4
209.9 110.9 101.3
34.9
27.5
21.4
21.5
21
12.9

PPP
no clot
197.9
191.4
20.9
18.4
PPP
no clot
237.4
231.4
31.4
21
PPP
no clot
227.4
200.9
30.1
19.9

Exp #3
PRP
234
159
97
21
18
Exp #3
PRP
222.4
163.9
101.9
26.4
14.9
Exp #3
PRP
332.1
167.5
101.9
19.9
18.9

WB
106.9
98.5
67.2
18.9
10.6
WB
195.9
96.4
73.9
19.9
11.7
WB
97.4
96
74.9
18.9
9.7

Table 4. The clotting time data obtained from the fibrometer experiments. The table shows the
clotting time (in seconds) for platelet poor-plasma (PPP), platelet rich-plasma (PRP), and whole
blood (WB) that were collected from three different donors tested on each of three different days.
In general, PPP had the longest clotting time and WB had the shortest clotting time. In addition,
thrombin concentration strongly influenced the clotting time. 0nM, 0.5nM, and 1nM thrombin
had prolonged clotting time; whereas, 5nM and 10nM had significantly reduced clotting time.
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PPP
[Thrombin]
0.5nM
1nM
5nM
10nM
PRP
[Thrombin]
0.5nM
1nM
5nM
10nM
WB
[Thrombin]
0.5nM
1nM
5nM
10nM

Mean Clotting Time (seconds)
Donor 1
Donor 2
Donor 3
231.4
232.3
253.4
166.6
193.6
206.6
21.6
27.3
33.4
15.8
21.9
19.6
Mean Clotting Time (seconds)
Donor 1
Donor 2
Donor 3
199.9
232.6
166.3
103.3
119.2
111.6
20.8
25.1
24.6
14.1
17.7
18.3
Mean Clotting Time (seconds)
Donor 1
Donor 2
Donor 3
98.6
160.1
112.1
66.8
77.6
83.2
19.2
19.6
19.6
8.3
12.0
9.0

Log [Thrombin]
-0.3
0.0
0.7
1.0
Log [Thrombin]
-0.3
0.0
0.7
1.0
Log [Thrombin]
-0.3
0.0
0.7
1.0

Table 5. The average clotting time of PPP, PRP, and WB calculated from Table 4. These
averaged data were used to graph the clotting time versus log thrombin concentration shown in
Figure 35.
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Figure 35. Platelet poor-plasma (PPP), platelet rich-plasma (PRP), and whole blood (WB)
clotting time versus log thrombin concentration obtained from a fibrometer. Each curve
represents the average of three different experiments from Table 4. Clotting time curves show
that when thrombin concentration increased, clotting time decreased. As thrombin doses
increased (5nM-10nM), clotting time variation was eliminated. Error bars represent standard
deviation.
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Figure 36. PRP clot structures formed at low thrombin doses from three different donors.
Overall, PRP clot surfaces from three different donors share similar characteristics. At low doses
of thrombin (1nM), thick, long, woven fibrin strands were loosely associated with some activated
platelets. The surfaces of clots were open with many pores. Within the clots, there were empty
spaces. These clots appear more permeable. Surface images are secondary electron images and
interior images are backscattered images. White and black arrows indicate activated platelets and
fibrin, respectively. Size bars equal 1μm.
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Figure 37. PRP clot structures formed at high thrombin doses from three different donors. At
high doses of thrombin (10nM), externally many activated platelets bind to fibrin strands
forming a tightly dense network without many pores. Thinner and shorter fibrin strands
cooperated with activated platelets creating the compact architecture inside of the clot. The clots
appear less permeable. Surface images are secondary electron images and interior images are
backscattered images. White and black arrows indicate activated platelets and fibrin,
respectively. Size bars equal 1μm.
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Figure 38. WB clot structures formed at low thrombin doses from three different donors. At low
thrombin concentration, the surface of the WB clot consisted of loose fibrin strands that wrapped
around biconcave RBCs, with a very limited number of activated platelets found. Inside the
clots, biconcave RBCs associated with fibrin strands and the clots contained many spaces.
Surface images are secondary electron images and interior images are backscattered images.
White arrows and black arrows indicate activated platelet and fibrin, respectively, and R
indicates RBCs. Size bars equal 2μm.
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Figure 39. WB clot structures formed at high thrombin doses from three different donors. At
high thrombin concentration, fibrin strands, activated platelets, and RBCs formed a dense
network. No pores were found at the surface of the clot. Inside the clot, the RBCs changed their
shape from regular biconcave to polyhedral shape and orientated into the core of the clot as
activated platelets and fibrin were arranged at the periphery. Surface images are secondary
electron images and interior images are backscattered images. White arrows and black arrows
indicate activated platelets and fibrin, respectively. R indicates RBCs. Size bars equal 2μm.
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Figure 40. Visualization of colloidal carbon penetration into PRP clots formed at low (A, B) and
high (C, D) thrombin concentrations. Boxed areas in the upper images are shown below at higher
magnification. At low thrombin concentration, ink migrated throughout the clot and the clot
looked darker compared to the control without ink. At high thrombin concentrations, the ink
appeared only at the border of the clot. This indicated that high thrombin concentration clots had
a less porous network compared to low thrombin concentration clots. Black arrows indicate
colloidal carbon.

160

A

(-) ink

B

C

(+) ink

0.5mm

0.5mm

50µm

50µm

D

(-) ink

(+) ink

0.5mm

0.5mm

50µm

50µm

Figure 41. Visualization of colloidal carbon penetration into WB clots formed at low (A, B) and
high (C, D) thrombin concentrations. Boxed areas in the upper images are shown below at higher
magnification. Ink was able to permeate into the low thrombin clot but was mostly limited to the
periphery. Ink was restricted to the rim of the clot at high thrombin concentrations. These results
suggested that low thrombin concentration WB clots might contain more pores while high
thrombin concentration WB clots might have less pores. Black arrows indicate colloidal carbon
accumulation.
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The percent of area of the blood clot that was penetrated by ink
PRP
WB
[Thrombin]
1nM
10nM
1nM
10nM
Donor 1
12.60%
10.60%
3.80%
2%
Donor 2
10.21%
7.04%
3.77%
1.60%
Donor 3
13.20%
8.70%
3.14%
1.06%
Table 6. The percent area of the PRP and WB clots penetrated by colloidal carbon measured by
the threshold function of the ImageJ program. In general, PRP clots had a higher percentage of
area permeated by ink in comparison with WB clots. Low thrombin concentration clots had a
higher percent of area permeated by ink. There were slight differences in percent ink areas
between donors in WB clots; whereas, more variation occurred among donors in PRP clots.
These results suggested that PRP clots formed with low thrombin concentration might be more
porous than WB clots formed at high thrombin concentration.
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Figure 42. Comparison of area penetrated by colloidal carbon ink in clots formed from plateletrich plasma (PRP) and whole blood (WB). Both PRP and WB clots were created with 1nM or
10nM of thrombin followed by soaking overnight in ink. The graph was generated by the
average from three donors of the percent of area of the PRP and WB clots penetrated by colloidal
carbon measured by the threshold function of the ImageJ program (Table 6). Error bars represent
standard deviation.
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Figure 43. SEM montage of a medial cross-section of a PRP clot from Donor 1 formed at low
thrombin concentration (1nM). Examples of sites where FGN-cAu18 were found inside clots are
indicated by boxes, with high magnification micrographs of those areas shown. Nanoparticles
appeared throughout PRP clots formed at low thrombin concentration. Higher nanoparticle
concentration was found at the periphery, with decreasing nanoparticle concentration found as
observations moved toward the interior of the clot. The percent of nanoparticle penetration was
about 40%. White arrows indicate FGN-cAu18. White size bars equal 50μm.
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Figure 44. SEM montage of a medial cross-section of a PRP clot from Donor 1 formed at high
thrombin concentration (10nM). Examples of sites where FGN-cAu18 were found inside clots are
indicated by boxes, with high magnification micrographs of those areas shown. Nanoparticles
were found both at the periphery and interior of clot, with slightly less concentration at the
interior. The percent of nanoparticle penetration was 17%. White arrows indicate FGN-cAu18.
White size bars equal 50μm.
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Figure 45
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Figure 45. SEM montage of a medial cross-section of a WB clot from Donor 1 formed at low
thrombin concentration (1nM). Examples of sites where FGN-cAu18 were found inside clots are
indicated by boxes, with high magnification micrographs of those areas shown. Nanoparticles
were mostly found on the outside, and few nanoparticles were able to migrate into the interior,
limiting both concentration and depth of penetration of FGN-cAu18. The percent of nanoparticle
penetration was 18%. White arrows indicate FGN-cAu18. White size bars equal 30μm.
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Figure 46. SEM montage of a medial cross-section of a WB clot from Donor 1 formed at high
thrombin concentration (10nM). Examples of sites where FGN-cAu18 were found inside clots are
indicated by boxes, with high magnification micrographs of those areas shown. At high thrombin
doses, nanoparticles were found only at the edge of the clot. No nanoparticles appeared in the
center of the clot. The percent of nanoparticle penetration was 14%. White arrows indicate FGNcAu18. White size bars equal 30μm.
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Figure 47. Representative images showing the penetration of FGN-cAu18 into PRP clots from
three different donors formed at low thrombin concentration (1nM). Medial cross-sections were
examined; images from the edge and the area where the deepest nanoparticle penetration was
detected are shown. Labeling was found throughout the clot. Near the periphery, a higher
concentration of the nanoparticles was observed while lower concentrations of nanoparticles
were found near the center of the clot. White arrows indicate FGN-cAu18. Size bars equal 5μm.
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Figure 48. Representative images showing the penetration of FGN-cAu18 into PRP clots from
three different donors at high thrombin concentration (10nM). Medial cross-sections were
examined; images from the edge and the area where the deepest nanoparticle penetration was
detected are shown. The labeling was found both at the periphery and interior of the clot. Near
the periphery, a higher concentration of nanoparticles was observed and a lower concentration of
nanoparticles was found near the center of the clot. Compared with the low thrombin
concentration of thrombin formed PRP clot, the accumulation of nanoparticles was reduced both
inside and outside due to the tightly dense structures of associated fibrin and activated platelets.
White arrows indicate FGN-cAu18. Size bars equal 5μm.
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Figure 49. Representative images showing the penetration of nanoparticles into WB clots from
three different donors formed at low thrombin concentration (1nM). Medial cross-sections were
examined; images from the edge and the area where the deepest nanoparticle penetration was
detected are shown. Most of the label was detected near the periphery. Some label migrated to
the interior, but this was very limited in both concentration and depth. The FGN-cAu18
nanoparticles are indicated by white arrows. Size bars equal 5μm.
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Figure 50. Representative images showing the penetration of nanoparticles into WB clots from
three different donors formed at high thrombin concentration (10nM). Medial cross-sections
were examined; images from the edge and the area where the deepest nanoparticle penetration
was detected are shown. The labelling was mostly found at the periphery and at very low
concentrations. There was little chance in finding nanoparticles residing in the center of the clots.
Due to the high dose of thrombin, resulting in the organization of RBCs coordinated with fibrin
and activated platelets into dense networks, limited penetration of nanoparticles occurred. FGNcAu18 nanoparticles indicated in white arrows. Size bars equal 5μm.
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Figure 51. Light microscopy images with and without silver enhancement (SE) of FGN-cAu18 in
labeled PRP and WB clots. In the presence of SE, FGN-cAu18 appeared darker in both PRP and
WB clot sections. There were a few artifacts of SE deposition in the sections. However, clusters
of FGN-cAu18 always looked significantly darker. Thus, for the purposes of quick screening, SE
can still be utilized to study nanoparticle penetration into clots. White arrows indicate FGNcAu18. Size bars equal 10μm.
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10nM

Figure 52. Reconstruction of the frozen sections of PRP clots formed at different thrombin
concentrations (0.5nM, 1nM, 5nM and 10nM) labeled with FGN-cAu18 and treated with SE.
High magnification images as examples of areas containing nanoparticles are from regions
indicated by boxes. Low thrombin concentration clot sections (0.5nM and 1nM) were smaller in
size with a less dense fibrin network. As a result, nanoparticle penetration was deeper. High
thrombin concentration clot sections were larger with a high-density fibrin network; therefore,
nanoparticles accumulated primarily at the edge of the clots. The percentage of penetration was
calculated using the deepest distance of nanoparticle migration into the clot divided by the
diameter of the clot. Percentage of nanoparticle penetration into these PRP clots was
approximately 35%, 23%, 8.3%, and 4% for 0.5nM, 1nM, 5nM, and 10nM thrombin
concentrations, respectively. White arrows indicate FGN-cAu18. White size bars equal 50μm.
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Figure 53. Reconstruction of frozen cross-sections of WB clots formed at different thrombin
concentrations (0.5nM, 1nM, 5nM and 10nM) and treated with SE. High magnification images
as examples of areas containing nanoparticles are from regions indicated by boxes. When WB
clots were formed at 0.5 and 1nM thrombin concentrations, nanoparticles were found at both the
periphery and interior of WB clots, with the latter having a low number of nanoparticles.
Nanoparticles were limited in both distance of migration and concentration when WB clots were
formed at 5nm and 10nM thrombin. The percentage of nanoparticle penetration was 22%, 18%,
14%, and 11% for 0.5nM, 1nM, 5nM, and 10nM thrombin concentrations, respectively. White
arrows indicate FGN-cAu18. White size bars equal 50μm.
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Donor 1

Donor 2

Donor3

Donor 4

Donor 5

Donor 6

[Thrombin]
(nM)
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10

Diameter
(mm)
1
1
2
2
2
2
1.5
2
2
2
2.2
2.5
1
1.5
1.5
2
1.8
1.9
3
4
2.25
2.78
2.38
2.2

Distance
migration (mm)
0.2
0.2
0.18
0.14
0.34
0.26
0.14
0.16
0.4
0.3
0.24
0.16
0.26
0.16
0.18
0.2
0.63
0.44
0.25
0.16
0.88
1
0.63
0.5

%
Penetration
20
20
9
7
17
13
9.3
8
20
15
10.9
6.4
26
10.7
12
10
35
23
8.3
4
39
36
26
22

Table 7. Measurements of clot diameters, deepest distance of nanoparticle penetration, and
percentages of nanoparticle penetration of PRP clots formed at various thrombin concentrations
from 6 donors using the quick screening method (silver enhancement incorporated with light
microscopy). Even though there were donor-donor variations, all donors shared a similar trend.
As the thrombin dose stimulating clot formation was increased, clot diameter increased, and
nanoparticle penetration decreased. Thus, the percentage of penetration was reduced with
increasing thrombin concentration.
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Donor 1

Donor 2

Donor3

Donor 4

Donor 5

Donor 6

[Thrombin]
(nM)

Diameter
(mm)

Distance
migration (mm)

%
Penetration

0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10
0.5
1
5
10

2
2
3
3
1.38
4.5
3
3
3
3
3
3.5
3
3
2.5
3
3.57
3.67
4.17
4.9
1.36
2.38
2.5
3.96

0.34
0.44
0.26
0.2
0.28
0.62
0.23
0.22
0.56
0.48
0.2
0.14
0.34
0.32
0.18
0.26
0.78
0.67
0.58
0.56
0.28
0.34
0.33
0.45

17
22
8.7
6.7
20
13.8
7.7
7.3
18.7
16
6.7
4
11.3
10.7
7.2
8.7
22
18
14
11
19.8
14.3
13.2
11

Table 8. Measurements of clot diameters, deepest distance of nanoparticle migration, and
percentages of nanoparticles penetration of WB clots formed at various thrombin doses from 6
different donors using the SE screening method. Clot size increased as thrombin concentration
increased. The nanoparticle penetration and percentage of nanoparticle penetration were
inversely related to thrombin concentration.
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8
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8

10
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0

2

4
6
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Figure 54. Quantification of nanoparticle penetration in platelet rich-plasma (PRP) and whole
blood (WB) clots using silver enhancement. Donor to donor variation was seen in percentage of
nanoparticle penetration in both PRP and WB systems. Between the two systems, PRP had
higher variation and WB had lower nanoparticle penetration. The variation in nanoparticle
penetration between donors was largely overcome at high thrombin concentrations. Each line
represents data from one donor. The graphs were generated by using data shown in Table 8.
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Chapter 4 - Optimizing the Penetration of Nanoparticles and Disrupting Labeled Clots
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Abstract:
Ischemic stroke patients have limited treatment options available. The only FDAapproved drug comes with a significant risk of bleeding. We are investigating an alternative
treatment that targets activated platelets in occlusive clots using fibrinogen-conjugated goldcoated magnetite nanoparticles (FGN-cAu-Fe3O4) for hyperthermia. The success of disrupting
clots requires both a significant number of nanoparticles localized deep inside occlusive clots
and the efficacy of magnetite nanoparticles. We have found that the penetration and
concentration of the nanoparticles were limited to the outside of clots that formed at high
thrombin concentration, especially in whole blood (WB) clots. Moreover, magnetite nanoparticle
synthesis is not a robust procedure. Heating and killing quality of magnetite nanoparticles is
inconsistent between batches. Hence, we proposed using a phagocytic cell model to test the
magnetite nanoparticle heating and killing efficacy. We hypothesize that increasing label
concentration and incubation time could increase the depth of penetration and
concentration of nanoparticles into clots. Also, using a phagocytic cell model combined with
light microscopy would allow rapid observation of both cell morphology and viability;
therefore, allowing us to predict the efficacy of magnetite nanoparticles. We examined the
impact of label concentration and incubation time on nanoparticle penetration and concentration
by using an in vitro model in which platelet-rich plasma (PRP) and WB were clotted using
different thrombin concentrations followed by labeling with the robust fibrinogen-conjugated
gold nanoparticles (FGN-cAu18) at different concentrations for 15 or 60 minutes. Frozen crosssections were treated with silver enhancement (SE) and analyzed by light microscopy. As
expected, short incubation time and low concentration of FGN-cAu18 result in low label
concentration and penetration inside clots. By increasing FGN-cAu18 concentration and

190

incubation time, penetration and concentration of nanoparticles improves significantly in PRP
clots, but only slightly in WB clots. These results suggest that multiple applications of
nanoparticles may be necessary for the success of a targeted nanoparticle therapy for ischemic
stroke. To test the efficacy of magnetite nanoparticles, the RAW 264.7 murine macrophage cell
line was used. The cells were allowed to ingest magnetite nanoparticles before exposure to an
oscillating magnetic field, followed by analysis using light microscopy and scanning electron
microscopy (SEM). We observed that magnetite nanoparticles had ability to destroy RAW 264.7
cells and would also kill the activated platelets. Therefore, the RAW 264.7 model allowed for a
reasonable prediction of the efficacy of magnetite nanoparticles. Together, these results provided
important information in the development of a nanoparticle-based therapeutic agent for treatment
of ischemic stroke.

Introduction:
Many studies have shown that increasing temperature can disrupt and destroy cells.
Hyperthermia therapy is a type of medical treatment in which body tissue is exposed to
temperature above the physiologic optimum, around 40°C and above (1-4). Most hyperthermia
treatments are primarily focused on attacking tumors. As anti-cancer therapy, hyperthermia
treatment delivers heat directly to the cancer cells to either destroy them or make them more
sensitive to the effects of more conventional treatments, such as enhancing chemotherapy or
radiation. Hyperthermia affects cells and tissues on multiple levels. For example, hyperthermia
results in a profound increase in blood flow, causing vascular occlusion or hemorrhage in tumors
(1). Another pronounced physiological change in tumors is a decrease in tumor pH upon heating.
Cancer cell proliferation is a more vulnerable target under acidic conditions (2-5). Raising
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temperatures cause the cell to release heat shock proteins; thereby, inducing the immune system
to target the cancer cells (6-8). Also, hyperthermia can directly induce DNA damage including
DNA breaks and chromosomal aberrations. Moreover, hyperthermia can disturb multiple DNA
repair pathways via disabling or inhibiting intracellular DNA repair enzymes. Thus,
hyperthermia sensitizes cells to a broad range of DNA-damaging agents, helping it take a more
central role in clinical cancer treatment (9-11). In addition to the above effects, raising the cells’
temperature can cause protein and membrane damage (9,12,13), interfere with the cell cycle
(14,15), impact lipid membrane dynamics and stability (16,17), and cause metabolic imbalance
(18,19).
Hyperthermia can be administered by a variety of methods from relatively simple bulk
heating to quite complex targeted methods including whole-body, regional, and local
hyperthermia. In whole-body hyperthermia, either radiative heat or extracorporeal technologies
are used to raise the temperature of the entire body to at least 41°C. Radiative heating can be
produced by thermal chambers, inductive loops, and hot water blankets to heat up the entire body
superficially. Extracorporeal whole-body hyperthermia works by circulation of extracorporeally
heated blood. The extracted blood is heated by crossing it through a water bath or hot air and
then infused into the main vein. Whole-body hyperthermia is useful in treating metastatic cancer
that has spread widely through the body (20-22). Regional hyperthermia commonly distributes
heat to large areas and is used to treat advanced tumors. In one approach, applicators are
positioned around the surface of an organ or body cavity, and then high energy waves are
produced and directed at the area. These devices release microwave or radiofrequency energy
with a frequency of 350 kHz to 700 kHz to heat the area being treated. Another approach to
regional hyperthermia is perfusion. As with extracorporeal heating, the patient’s blood is isolated
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from the circulation, heated by heating devices, and then pumped back into the desired area.
Typically, anticancer drugs can be pumped in at the same time (20,23-26). Local hyperthermia is
used to treat relatively small tumors. Different types of energy including microwave,
radiofrequency and ultrasound are used to deliver heat. Depending on the tumor location, local
hyperthermia can be performed by different approaches. In external approaches, high energy
waves are aimed at a tumor located near the body’s surface using outside applicators.
Alternatively, a probe can be inserted directly into the tumor. The tip of the probe then releases
the energy to heat the surrounding cancerous tissue (20,24,26-28).
Hyperthermia treatment technology has been approved by the FDA to treat malignant
tumors on either superficial or interstitial parts of the body. However, conventional hyperthermia
methods have several disadvantages. First, hyperthermia treatments require invasive procedures,
special equipment, and skilled treatment teams. Because of that, not all cancer treatment centers
have available hyperthermia treatments. Second, despite the ability of hyperthermia to
synergistically enhance the efficacy of radiotherapy and chemotherapy treatments, the heating
methods are rather crude and do not distinguish between heating of malignant and healthy
tissues. Since the target and the surrounding normal tissues might respond similarly to
hyperthermia, this non-selective tissue heating can cause serious toxic side effects. Hence, the
conventional hyperthermia methods have barriers to their clinical application. Therefore, it is
desirable to improve hyperthermia to target a specific tissue. To do this, most applications
require a method to produced highly localized heating with minimally invasive procedures.
The development of nanomaterials and nanotechnology provide a novel and original
solution to the aforementioned disadvantages. Nanoparticle-based heating methods that use
specific binding of molecules to target a tissue or cell type have been developed (29-35). These
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treatments concentrate on utilizing nanoparticles to convert energy from extrinsic sources into
localized heat, causing hyperthermia solely at the area containing nanoparticles. The most
common external energy sources used for generating heat using nanoparticles are light and an
alternating (or oscillating) magnetic field (36-41).
Photothermal hyperthermia occurs upon generation of surface plasmon resonance in gold
nanoparticles when they absorb light near the infrared range. Then, the surface electrons become
excited and intensively resonant, quickly converting light to heat (34). In order to absorb near
infrared light efficiently, gold nanoparticles can be synthesized into different shapes such as rod
shape (37), hollow spheres (42) and silica-gold core-shell like structures (43). Another way to
enhance the effectiveness of gold nanoparticles in near infrared light absorption is to promote
their agglomeration at the site of interest so that the energy absorption per unit area is increased
(38). Nanoparticles can be functionalized and delivered specifically to the target cells by
different methods including conjugation with proteins or physiologic transportation. Several
studies have shown that photothermal therapies work successfully in vitro, but often have
limitations in vivo due to the attenuation of near infrared light through scattering and absorption
within the tissues, limiting penetration and heating (44-46). Thus, despite promising results in
vitro, there are challenges that must be addressed before this technique can progress to the clinic.
Magnetic hyperthermia utilizes magnetic nanoparticles to transform electromagnetic
energy from an external high frequency field to heat. Magnetite (Fe3O4) and maghemite (γFe2O3) nanoparticles are the most commonly used materials for magnetic hyperthermia and they
are usually referred to as magnetic iron oxide nanoparticles. When exposed to an alternating
magnetic field, these nanoparticles produce heat via two main mechanisms, which are hysteresis
loss and relaxational losses. Hysteresis loss happens when large magnetic iron oxide
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nanoparticles are subjected to the magnetic field; whereas, below 100nm magnetic iron oxide
nanoparticles become superparamagnetic in the presence of the magnetic field and heat is mainly
generated by Néel relaxation and Brownian relaxation (47-50).
There are many advantages of using magnetic iron oxide nanoparticles. First, iron is a
biologically essential component of the human body. The average human adult naturally carries
approximately 3.5-4 grams of iron. These 3-4 grams are distributed throughout the body in
hemoglobin, tissues, muscles, bone marrow, blood proteins, enzymes, ferritin, hemosiderin and
circulating in plasma bound to transferrin (51). Consequently, magnetic iron oxide nanoparticles
have been systemically administrated safely in large quantities in clinical settings unlike other
inorganic nanoparticles (52). In fact, the FDA already approved the application of magnetic iron
oxide nanoparticles as a contrast agent in computed tomography (CT) at high concentration and
magnetic resonance imaging (MRI) at low concentration. This is useful since the magnetic iron
oxide nanoparticle concentration within the tumors can be measured by CT, aiding the estimation
of hyperthermia dosimetry (47,52,53). Moreover, magnetic iron oxide nanoparticles can undergo
surface modification and functionalization. For specific cellular targeting, magnetic iron oxide
nanoparticles can be functionalized with organic molecules or proteins. Iron oxide nanoparticles
can also be coated first with gold and then conjugated with protein (54-60). Not surprisingly,
magnetic iron oxide nanoparticles for magnetic hyperthermia has gained a significant interest as
a potential therapy for cancer treatment among other applications.
Our particular interest is utilizing magnetite nanoparticles to target fibrinogen receptors
on platelets for magnetically-induced hyperthermia to disrupt an occlusive clot causing ischemic
stroke. In the purified platelet system, gel-filtered platelet (GFP) aggregates labeled with
fibrinogen conjugated, gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4) that were exposed

195

to a 500 kHz OMF at 8mT for 30 minutes were successfully disrupted and sustained significant
damage (60). High concentrations of labels were found throughout the aggregates in that system.
In previous chapters we have demonstrated that fibrinogen-conjugated nanoparticles are able to
incorporate into the clots of PRP and WB systems. However, we also noted that the complex
components of PRP and WB challenge the effectiveness of nanoparticle penetration. The depth
of nanoparticle penetration and the total concentration inside of the clot contribute significantly
to the success of clot disruption. Hence, we will evaluate the penetration of label in more
complex PRP and WB clots, as seen previously in GFP aggregates. This will be done under
conditions that approximate in vivo physiology as closely as possible to lay the groundwork for
future animal experiments. The conditions to be investigated include physiologically achievable
label concentration and incubation time. We hypothesize that under optimized conditions the
FGN-conjugated nanoparticles can access the interior of both PRP and WB clots. In these
experiments, FGN-cAu18 will be used to label clots, because penetration of gold nanoparticles is
a more robust, and reproducible procedure than preparation of gold-coated magnetite
nanoparticles. SEM and light microscopy techniques will be used to analyze the data.
Besides the efficiency of nanoparticle penetration into the clot, the efficacy of magnetite
nanoparticles plays an important role in clot disruption. We are using coprecipitation methods to
synthesize the magnetite nanoparticles. The coprecipitation method possesses advantages. It is
simple, ecofriendly, non-toxic in physiological conditions, and the solvent-free process gives
water-soluble and biocompatible superparamagnetic magnetite nanoparticles. The dilemma here
pertains to the quality of the colloids produced from the coprecipitation reaction. Coprecipitation
produce nanoparticles with a broad size distribution (Figure 55). This leads to non-ideal
magnetic behavior compared to the uniform size nanoparticles obtained from other methods of
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synthesis such as the thermal decomposition and electrochemical method (61-63). In fact, within
the same batch of magnetite nanoparticles produced by coprecipitation, several monodisperse
populations of particles coexist and become magnetically inequivalent, leading to a difference in
heat generation when exposed to the OMF. Thus, batch-to-batch variability in the heating
capacity of nanoparticles is a continuing issue. Here, we have used the RAW 264.7 murine
macrophage cell line with light microscopy as a phagocytic cell model to test the heating and
killing properties of Fe3O4 nanoparticles before coating them for targeting experiments.
Relatively rapid scanning with the light microscope allowed us to observe the cells’ morphology
and viability. Here, we hypothesized that using a phagocytic cell model combined with light
microscopy will allow us to predict the efficacy of magnetite nanoparticles in destroying
activated platelets in clots.
The results of these studies will provide insight for the development of nanoparticlebased targeting in vivo.

Materials and Methods:
PRP, WB and gel-filter platelet (GFP) preparation:
GFP, PRP and WB were prepared as described in Chapter 2.

Fibrinogen-conjugated gold-coated magnetite synthesis:
Magnetite nanoparticle synthesis (cFe3O4), gold-coated magnetite nanoparticles,
conjugation of fibrinogen to gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4), gold
nanoparticle synthesis (cAu18), and conjugation of fibrinogen to gold nanoparticles (FGN-cAu18)
were described in Chapter 2.
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Effect of nanoparticle concentration and labeling time on penetration of FGN-cAu18 into clots:
PRP and WB were allowed to form clots at low (1nM) and high (10nM) thrombin
concentrations for 10-15 minutes at 37°C on the microtiter plate reader as described in Chapter 3.
After clots were formed, they were transferred into fresh microcentrifuge tubes that contained
FGN-cAu18 with the concentration adjusted to give OD522= 0.2 or OD522=1.0. FGN-cAu18 were
supplemented with CaCl2 to a final concentration of 2mM. Clots were incubated in FGN-cAu18
for 15 or 60 minutes at 37°C. Then, the clots were washed thoroughly in Tyrode’s buffer with
0.1% BSA three times before fixing in 1% glutaraldehyde in 0.1M HEPES, pH 7.4, for 30
minutes at room temperature (RT).
For visualization of nanoparticles inside of clots, the samples were processed through
standard SEM preparation procedures including post-fixation in 0.05% OsO4, dehydration in a
graded ethanol series, critical point drying, and carbon coating. Samples were analyzed by using
a Hitachi S-4800 FE-SEM operating at 15KV for backscattered electron imaging.
For measuring nanoparticle penetration, after primary fixation with 1% glutaraldehyde,
samples were washed three times with 0.1M HEPES before embedding in OCT. The samples
were frozen on dry ice. The frozen clots were sectioned on a cryostat and the sections were
picked up on poly-L-lysine coated slides. Then, the sections were fixed with 1% glutaraldehyde
for 5 minutes. They were rinsed excessively with Millipore double deionized water (MDDW)
and then treated with a Sigma-Aldrich silver enhancing kit according to the manufacturer’s
directions. The treated sections were then fixed with 2.5% sodium thiosulfate, and then washed
three times with MDDW and air dried overnight. Cover slips were mounted using VectaMount
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medium and analyzed by light microscopy to measure the nanoparticle penetration. Both SEM
preparation and silver enhancement were described in detail in Chapters 2 and 3, respectively.

Oscillating magnetic field device:
A custom made OMF device was constructed in-house and used to heat magnetite
particles. The OMF device was built using a resonant circuit. The system consisted of a handwound inductor coil with water cooling (described below) connected as an autotransformer,
which was paired with a set of suitable fixed capacitors in series and a parallel variable air
dielectric capacitor. The OMF system was powered by an AG Series 1024 RF amplifier with
internal signal generator (T&C Power Conversion, Rochester, NY). The signal generator was
used to produce a 500kHz waveform by using internal power output control to reach the desired
field amplitude.
The air core solenoid or the inductor is the source of an OMF. It was built by wrapping
3.175mm diameter copper tubing (Phillips and Johnston, Glen Ellyn, IL) around a 5cm diameter
glass cylinder for a total of 50 turns. Flowing water ran through the hollow copper tubing,
pulling heat as it wound around the inductor during operation, to prevent overheating during
operation. To provide electrical insulation to prevent short circuiting, the coils were wrapped in
vinyl tape.
In order to tune the OMF circuit, a BK Precision 4017B signal generator was used to
generate a 5volt sinusoidal waveform at 500kHz. The waveform bias was adjusted with the DC
offset voltage. The output power is limited by an internal source resistance of 50Ω. The
frequency and the amplitude range could be selected with pushbuttons on the signal generator.
Since the various combinations of fixed capacitors with a variable capacitor functioned as
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resistors affecting the voltage that could be delivered to the solenoid to which they were
attached, the voltage could be measured and applied to calculate the magnetic flux in the
solenoid using Coulomb’s Law. The strength of magnetic field produced by the OMF was
determined by using a 15-gauge cooper wire that was shaped into a square loop with an area of
1cm2, placed in the middle of the solenoid. The potential across the wire was measured with a
BK Precision 2125A analog oscilloscope. The magnetic field, in tesla (T), can be calculated by
Coulomb’s equation:
B=E/ (2 * π * F * A)
Where B is magnetic field produced in tesla, E is the potential across the copper loop in
volts, F is the frequency of the OMF in hertz and A is the area of the copper loop in square
meters.
Tuning was further refined by adjusting the variable capacitor when the system was
powered by the RF amplifier at 10Watts forward power. Optimal tuning was achieved when the
reflected power was detected at less than 10% of forward power (60,64).

Testing the efficacy of cFe3O4 batches:
The heating capacity of cFe3O4 nanoparticles varies from batch to batch. Therefore, their
capacity to heat and kill cells was tested in a phagocytosis model using the Mus musculus
macrophage cell line RAW 264.7 as previous described (64), with minor modifications. 70,000
cells were allowed to adhere onto 13mm Thermanox® plastic coverslips (NUNC™, NY, USA)
and grown in high glucose Dulbecco’s modified eagle medium (DMEM) (Fisher Scientific,
Gibco™) supplemented with 10% fetal bovine serum (FBS) overnight at 37°C in a 5% CO2
atmosphere. 50μL undiluted cFe3O4 nanoparticles were added to 450μL media and incubated
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with the cells for 30 minutes at RT. As controls, media alone and 18nm gold nanoparticles were
added and incubated in the same manner. Cells were washed twice in Dulbecco’s phosphate
buffered saline (PBS) to remove free nanoparticles, then exposed to the OMF at 500kHz, 8mT
for 1minute. Cell viability was measured by exclusion of 0.04% trypan blue in PBS. Light
micrographs were collected with a Nikon TE2000U inverted light microscope with a CoolSNAP
ES camera (Photometrics) using Metaview software (Molecular Devices).
In some instances, SEM standard preparation was used to further analyze the damage of
the cells. For this, cells were washed with PBS, followed by fixing in 1% glutaraldehyde in 0.1M
HEPES, pH 7.4 for 30 minutes at RT. Then, samples were washed and post-fixed with 0.05%
OsO4 for 15 minutes. Samples were dehydrated using a graded series of ethanol and dried by the
critical point drying procedure. The dried samples were mounted onto SEM stubs with carbon
tape and coated with carbon using a carbon evaporator. Samples were analyzed using a Hitachi
S-4800 FE-SEM operating at 1kV for secondary electron imaging and 15-30kV for backscattered
electron imaging. Batches of cFe3O4 that killed at least 70% of the cells were coated with gold to
be conjugated with fibrinogen and used in hyperthermia experiments.

Hyperthermia of surface activated platelets:
Gel-filtered platelets were supplemented with 2mM CaCl2 and allowed to spread on
Thermanox® coverslips between 10-15 minutes. The spread adhered platelets were then
incubated with FGN-cAu-Fe3O4, or FGN-cAu18, or left unlabeled in Tyrode’s buffer with
0.1%BSA for 15 minutes. Unbound labels were washed off by dunking the coverslips in excess
buffer. Then, the coverslips were washed three times by incubating a drop of buffer on the cover
slips for 5 minutes. The coverslips were covered in buffer and transferred to a 35mm Petri dish,
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then exposed to the OMF at 500kHz, 8mT for 5 x 2.5 minutes bursts with a one-minute cool
down between bursts. Negative controls received no magnetic field exposure and were kept away
from the OMF apparatus. The samples were then washed and processed by SEM standard
preparation methods to observe the morphology of the cells. SEM preparation and analysis were
similar to that described above for testing the efficacy of Fe3O4 in the RAW 264.7 cell line.

Results:
The success of disrupting clots depends on several factors, including the efficiency of
magnetite nanoparticles, having a sufficient amount of nanoparticles accumulated in the interior
of the clot, and the depth of nanoparticle penetration into the interior of the clot. In Chapter 2, it
was demonstrated that increasing the complexity of the clot components challenged the extent to
which nanoparticles could penetrate and concentrate deep inside of the clot. In the most
challenging condition, WB clots formed at high dose of thrombin, the penetration and
concentration of the nanoparticles were limited to the outside of the clot due to the high density
of the fibrin network. Thus, evaluating the effect of varying nanoparticle concentration and
labeling time on nanoparticle penetration into PRP and WB clots formed at different thrombin
concentrations will inform us about the potential of nanoparticle-based targeting performed in
vivo. Additionally, cFe3O4 synthesis remains a challenge because of batch-to-batch variability in
heating capacity of nanoparticles produced. Hence, a faster light microscopy method will be
utilized to confirm the efficacy of cFe3O4 nanoparticles before coating them for targeting
experiments.
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Effect of nanoparticle concentration and labeling time on penetration of FGN-cAu18 into PRP
clots:
When PRP clots formed at low thrombin concentration were incubated a short time (15
minutes) with FGN-cAu18 at low concentration (OD522nm= 0.2), nanoparticles were mainly found
at the periphery of the clot. Some were able to migrate into the interior, but to a limited extent.
The percent nanoparticle penetration was 29% and 15% for Donors 1 and 2, respectively.
When the time of incubation increased to 60 minutes, slightly more FGN-cAu18
nanoparticles were incorporated (Figure 56), and they penetrated deeper into the clots.
Nanoparticle penetration was 30% clots from in both donors. Increasing the FGN-cAu18
concentration (OD522nm= 1.0) led to a slight increase in concentration of FGN-cAu18 at the
periphery of the PRP clot, but did not significantly improve the concentration of FGN-cAu18 in
the interior of the clot at 15 minutes incubation (Figure 56). Nanoparticle penetration was 20%23% in this set of experiments. When both nanoparticle concentration and time of incubation
were increased (OD522nm=1.0 and 60 minutes incubation), both degree of penetration and
concentration of FGN-cAu18 were markedly increased throughout the PRP clots, including at the
deep interior (Figure 56). The percent nanoparticle penetration was calculated at 45% and 41%
for Donor 1 and Donor 2, respectively (Table 9).
For the PRP clots formed at 10nM thrombin, either low nanoparticle concentration and
short time of labeling (OD522nm= 0.2 and 15 minutes) or high nanoparticle concentration and
short time of labeling (OD522nm= 1 and 15 minutes), led to shallow nanoparticle penetration
into the clot. Most of the labeling was accumulated at the edge rather than deep inside the clots
(Figure 57). The short time incubation time combined with either a low or high labeling
concentration showed only 15% and 24% of nanoparticle penetration for Donor 1, and only 25%
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and 10% for Donor 2 (Table 10). Increasing incubation time but not label concentration
(OD522nm= 0.2, and 60 minutes incubation), improved penetration. There were a few more labels
to be found near the center of the clot (Figure 57), but the total amount of label still was still
quite low. Depth of nanoparticle penetration under this condition was 36%-37% for both donors.
When both nanoparticle concentration and incubation time were increased (OD522nm= 1, and 60
minutes incubation), the improvement in nanoparticle concentration was apparent (Figure 57).
The depth of nanoparticle penetration was 28% in Donor 1, and improved to 41% for Donor 2
(Table 10).

Effect of nanoparticle concentration and labeling time on penetration of FGN-cAu18 into WB
clots:
WB clots formed with 1nM thrombin and labeled with a low concentration of
nanoparticles for short time had only a few nanoparticles detected in the interior of the clot
(Figure 58). Most of them were found near the outside of the WB clot. This is reflected by only
14% nanoparticle penetration under these condition for both donors (Table 11). As the time of
labeling increased, nanoparticles moved slightly inwards from the edge toward the interior of the
clot; however, the majority were still accumulated at the periphery. The total number of
nanoparticles appeared to increase, but still was low (Figure 58). Nanoparticle penetration
improved to 21% and 25% for Donors 1 and 2, respectively (Table 11). When the nanoparticle
concentration was increased (OD522nm= 1.0) but the time of incubation remained short (15
minutes), a higher concentration of nanoparticles was found at the periphery of the clot and
nanoparticle penetration was limited to the periphery of the clot (Figure 58). The degree of
nanoparticle penetration remained low and comparable to results using low concentration and
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short time incubation, at 11% and 17% for Donors 1 and Donor 2, respectively (Table 11). When
both concentration and time of incubation were increased (OD522nm= 1.0, and 60 minutes
incubation), the penetration of nanoparticles was nearly to the center of the clot for Donor 1 with
34% nanoparticle penetration; whereas, the nanoparticle migration was more peripheral for
Donor 2 at 21%. The nanoparticle concentration inside of the clots appeared to slightly increase
in both donors, but still remained relatively low (Figure 58).
In the interior of WB clots formed with 10nM thrombin, nanoparticle concentration was
limited and generally difficult to detect (Figure 59). With high FGN-cAu18 concentration and
long incubation time (OD522nm=1, and 60 minutes incubation), a few more nanoparticles were
detected in the interior of the clots (Figure 59). However, the nanoparticle concentration was still
lower than what was observed in 1nM WB clots, and much lower than what was observed in
PRP clots. The percent of nanoparticle penetration increased slightly as the time of incubation
increased to 60 minutes. Between 22% and 26% nanoparticle penetration were obtained for both
donors. Increasing the FGN-cAu18 concentration did not improve the depth of nanoparticle
penetration at the short incubation time. Less than 20% nanoparticle penetration occurred in
Donor 1 and Donor 2 with 15 minutes of labeling (Table 12).

Testing the efficacy of cFe3O4 in heating and killing cells in a phagocytosis model:
The quality of the cFe3O4 nanoparticles plays a critical role in disrupting the clots. Batchto-batch variability in heating capacity is a continuing issue. Thus, a faster light microscopy
model was utilized to test the heating and killing properties of Fe3O4 nanoparticles before coating
them for targeting experiments. Relatively rapid scanning with the light microscope allowed us
to observe the cells’ morphology and viability. When RAW 264.7 cells had no nanoparticles or
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were incubated with the cAu18 nanoparticles, regardless of whether or not they were exposed to
the OMF, the cell density was very high. The cells looked healthy, and firmly adhered. On the
other hand, when RAW 264.7 cells were incubated with cFe3O4 nanoparticles and treated with
the OMF, the majority of the cells had lifted from the coverslip, resulting in a very low density.
More than half of the remaining adherent cells were stained with trypan blue, compared to an
insignificant number of the control cells (all incubation conditions without OMF treatment, and
incubation without nanoparticles or incubation with cAu18 treated with the OMF) (Figure 60). In
backscattered electron images, cells that were incubated with gold nanoparticles appeared very
bright. A less bright but distinct signal came from inside the cells, which indicated cells had
ingested magnetite nanoparticles. The control cells without nanoparticles had a very dim signal
corresponding to granules in the interior of the cell (Figure 61). The backscattered electron signal
is most likely due to OsO4 staining of the granule membranes, with some contribution from the
granule contents. Additionally, secondary electron analysis showed that all samples without
OMF exposure were healthy, well spread, and had no membrane damage. The cells incubated
with cAu18 and no nanoparticles, as expected, show no damage even when they were treated with
the OMF. Cells exposed to both cFe3O4 and the OMF showed extensive cell damage. Frequently,
traces of cells observed as membrane debris were found (Figure 62).

Hyperthermia treatment of surface-activated platelets:
After using the RAW 264.7 cells to test the killing capacity of the cFe3O4 (the magnetite
nanoparticles), cFe3O4 were then coated with gold and conjugated to fibrinogen. After, FGNcAu-Fe3O4 were used to target the surface-activated platelets. First, we observed that the labeling
pattern of FGN-cAu-Fe3O4 was similar to that of FGN-cAu18 on well-spread platelets. The labels
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were found near the granulomere in very high numbers. FGN-cAu18 has higher electron density
under backscatter mode compared to fibrinogen conjugated-gold coated-magnetite nanoparticles,
and thus appeared brighter (Figure 63). Second, we wanted to examine the killing ability of
FGN-cAu-Fe3O4 nanoparticles on the surface-activated platelets under exposure to the OMF.
There was no damage observed on either unlabeled or FGN-cAu18 labeled cells. But there was
membrane damage, and amorphous cell structure was observed in FGN-cAu-Fe3O4 labeled
platelets (Figure 64). All the batches of cFe3O4 nanoparticles tested that showed heating and
killing ability in RAW 264.7 cells also showed killing capacity with surface-activated platelets
after they were coated and conjugated to make FGN-cAu-Fe3O4.

Discussion:
Optimizing the penetration and concentration of nanoparticles in clots and testing the
heating and killing efficacy of magnetite nanoparticles were evaluated in this chapter in order to
improve the chances of successfully disrupting labeled clots when they are exposed to the OMF.
In the PRP clot system, improvement of both nanoparticle penetration and concentration in the
interior of clots occurred as the label concentration and time of incubation were increased. The
WB clots exhibited the same phenomenon. However, the amount of increase in nanoparticle
penetration was minimal, and nanoparticle accessibility was still limited to just the periphery of
the clots, especially in WB clots formed with 10nM thrombin. We also demonstrated the
feasibility of using a faster light microscopy method with RAW 264.7 cells, that allowed us to
predict the heating and killing efficacy of batches of cFe3O4 before coating them with gold and
employing them to target activated platelets in experiments that require lengthy analysis.
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Effect of nanoparticle concentration and labeling time on nanoparticle penetration into clots:
We hypothesized that optimizing the nanoparticle concentration and labeling time would
improve nanoparticle penetration into clots. It was determined that longer labeling time with high
concentration of FGN-cAu18 gave noticeably better outcomes. We were able to observe higher
nanoparticle deposition closer to the center of clots.
We expected that clots formed with high thrombin concentration (10nM) would
challenge nanoparticle penetration more than clots formed with low thrombin concentration
(1nM) in all conditions that we tested. This is, in fact, what we observed. The overall amount of
nanoparticles that penetrated and their concentration inside the 10nM thrombin clots were less
than with 1nM thrombin clots. The thrombin concentration present at the time of clot formation
affects the fibrin structure formed; thereby influencing the permeability of the clot. When a high
thrombin concentration was available during clot formation, more and thinner individual fibers
for a given amount of fibrinogen were generated; while a low thrombin concentration produced
thicker and fewer individual fibers per fibrinogen content (65-67). As a result, the low thrombin
dose allowed formation of a porous and permeable clot; therefore, it was more susceptible to
penetration of FGN-cAu18 into the interior compared to the high thrombin clot that has a dense,
tightly packed network. The data suggested that while FGN-cAu18 nanoparticles were
incorporated into the clot, their migration through the three-dimension fibrin network might be a
rate-limiting determinant for nanoparticle penetration. That means it might be more difficult to
disrupt the high thrombin concentration clot than the low thrombin concentration clot. By
elevating both nanoparticle concentration and time of labeling, low nanoparticle penetration and
concentration issues could be overcome, and we may be able to successfully disrupt even those
clots with a dense fibrin network.
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Differences in clot components could also impact the effect of nanoparticle penetration
into clots. The more complex system (WB clot) remarkably limits nanoparticle penetration,
whereas the less complex system (PRP clot) gives only slight resistance to nanoparticle
penetration. It is likely that the addition of RBCs to fibrin and activated platelets contributed
significantly to the solid matrix, bulk and occlusive nature of whole blood clots, thereby,
enhancing stability. The WB clot was well protected from external permeation, such as the
labeling with FGN-cAu18 nanoparticles or fibrinolysis (68-70). Moreover, due to steric
hindrance, the presence of RBCs could cover or block the access of FGN-cAu18 to interact with
the integrin receptors on the activated platelet surface (70). Additionally, the activated contractile
platelets pulling on fibrin cause the contraction of the blood clot. This results in the compaction
of the RBCs to the core of the clots and redistribution of activated platelets and fibrin toward the
outside of the clot. Consequently, RBCs that gather together in the center of the contracting clot
undergo a shape transformation from their native biconcave shape to polyhedral shape (71,72).
This remarkable event reduces clot permeability because the polyhedral shape is able to
minimize the space between the cells, which help to create an impermeable seal at the site of
vessel injury to prevent bleeding (72,73). However, this biologically important event could
reduce the effectiveness of nanoparticle penetration into WB clots. In the WB clots, especially
those formed at 10nM thrombin concentration, despite the increase of both nanoparticle
concentration and incubation time, the increase of nanoparticle penetration was still minimal, and
the label was only able to migrate and accumulate primarily at the periphery rather than at the
core of the clot. It is likely that WB clots labeled with FGN-cAu-Fe3O4 would be more
challenging to disrupt than labeled PRP clots when they are exposed to the OMF.
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Overall, the effect of nanoparticle penetration could be improved by increasing both
labeling time and concentration in PRP clots, but the effect with WB clots are less promising
especially in clots formed with high thrombin concentration. In vivo, the high thrombin WB clot
would be the most likely type to occur at the site of stroke. Therefore, in order to further increase
the ability of nanoparticle penetration to enhance the chance of successful clot disruption in a
WB system, several approaches are advisable. First, instead of only one application of
nanoparticles, clots could be exposed to nanoparticles multiple times. If the degree of
nanoparticle penetration remains unchanged or only slightly changes, an additional OMF
exposure might be applied between each labeling step. Multiple OMF exposures would disrupt
clots layer by layer, each time exposing a new surface of the clot for repeated labeling. As a
result, we could bring the label to the center of the clot after several rounds of labeling and OMF
treatments. The implication for in vivo applications is that eventually the clot would be small
enough that is would no longer block the vessels, thereby, restoring blood flow. Administration
of tissue plasminogen activator (tPA) synergistically with nanoparticle labeling and OMF
treatment could be another potential approach. With this approach, tPA dissolves fibrin, and
nanoparticle-induced hyperthermia destroys activated platelets of the clots, providing a twopronged strategy for clot disruption.

Testing the efficacy of Fe3O4 in heating and killing cells in a phagocytosis model:
The RAW 264.7 model allows for predicting the heating and killing efficacy of cFe3O4
magnetite nanoparticles. In this study, this cultured macrophage cell line was incubated with
cFe3O4. The macrophages were then exposed to the OMF, and cells that ingested cFe3O4
nanoparticles were damaged as a result of nanoparticle heating. Our experiment demonstrated
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that all of the magnetite nanoparticle batches that killed macrophage cells also damaged surfaceactivated platelets after coating with gold and conjugating with fibrinogen. In the past, SEM
analysis was the only way to confirm the damage done to activated platelets by magnetite
nanoparticles. However, SEM is time consuming, complex procedurally, and labor intensive. A
technique using phagocytic cell cultures and light microscopy could determine the efficacy of
magnetite nanoparticle in a significantly shorter amount of time. Therefore, we could avoid
spending too much time and resources on using an unsuccessful batch of magnetite nanoparticles
in targeting experiments. RAW 264.7 cells served as a good phagocytic model in our hands,
providing a method with intermediate difficulty that can be used to test the efficacy of magnetite
nanoparticles before targeting clots, both in vitro and in vivo.
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Figures and Figure Legends:

Figure 55. TEM micrograph of magnetite nanoparticles produced by coprecipitation method after
3 days aging under argon. The magnetite nanoparticles were dried onto a formvar-coated nickel
grid before imaging by TEM. Coprecipitation produced nanoparticles with a broad size
distribution. ImageJ software was used to measure the size of random 100 random magnetite
nanoparticles. The size of nanoparticles ranged between 3nm and 100nm in diameter. The
population was very heterogeneous, with a coefficient of variation of approximately 32%. The
most common size found in this batch was between 9nm and 13nm in diameter.
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15 mins incubation

[High] FGN-cAu18

[Low] FGN-cAu18

60 mins incubation

Figure 56. Effect of nanoparticle concentration and labeling time on nanoparticle penetration into
PRP clots formed with 1nM thrombin. The images were taken at the interior of the clot where
nanoparticles had penetrated deepest. At low concentration of FGN-cAu18 and short time of
incubation, few nanoparticles were found inside of the clot. When label concentration or time
incubation were increased, more nanoparticles were presented in the interior of the PRP clot.
With both high concentration of FGN-cAu18 and long incubation, the effectiveness of
nanoparticle penetration was improved significantly, indicated by the huge number of
nanoparticles found in the PRP clot. Micrographs were taken under backscattered mode. White
arrows indicated FGN-cAu18. Scale bars equal 10μm.
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60 mins incubation

[High] FGN-cAu18

[Low] FGN-cAu18

15 mins incubation

Figure 57. Effect of nanoparticle concentration and labeling time on nanoparticle penetration into
PRP clots formed at 10nM thrombin. Despite higher labeling concentrations, few nanoparticles
were found, and were found only near the edge of the clots, when they were labeled for 15
minutes. It was very difficult to find nanoparticles at the center of the clots. Increasing the
labeling time appeared to improve nanoparticle concentration in the clot. When the PRP clot was
labeled at high FGN-cAu18 concentration with a long incubation time, the nanoparticle
penetration and concentration inside of the clot were improved significantly. Micrographs were
taken under backscattered mode. White arrows indicate FGN-cAu18. Scale bars equal 10μm.
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PRP clots formed at 1nM thrombin
Clot
Labeling time
diameter
Distance
(mins)
(mm)
migration (mm)

Donor

OD522,
[label]

Percent
penetration (%)

#1

0.2

15

1.9

0.56

29

#1

0.2

60

2

0.6

30

#1

1

15

2.4

0.56

23

#1

1

60

1.5

0.68

45

#2

0.2

15

1.7

0.25

15

#2

0.2

60

2.2

0.67

30

#2

1

15

1.5

0.3

20

#2

1

60

2.7

1.1

41

Table 9. Quantification of nanoparticle penetration in PRP clotted with 1nM thrombin, labeled
with low or high concentration of FGN-cAu18 and incubated for either 15 or 60 minutes. At short
incubation time and low label concentration, the percent nanoparticle penetration was relatively
low. As the incubation time and nanoparticle concentration increased, the percent nanoparticle
penetration increased substantially. Percent penetration was calculated by distance of migration
divided by clot diameter. The data were obtained from light microscopy and silver enhancement
methods.
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PRP clots formed at 10nM thrombin
Clot
Labeling
diameter
Distance
time (mins)
(mm)
migration (mm)

Donor

OD522,
[label]

Percent
penetration (%)

#1

0.2

15

1.5

0.22

15

#1

0.2

60

1.49

0.53

36

#1

1

15

1

0.24

24

#1

1

60

2.5

0.7

28

#2

0.2

15

1.2

0.3

25

#2

0.2

60

1.88

0.69

37

#2

1

15

1.97

0.2

10

#2

1

60

0.75

0.32

43

Table 10. Quantification of nanoparticle penetration in PRP clotted with 10nM thrombin, labeled
with low or high concentration of FGN-cAu18 and incubated for either 15 or 60 minutes. Despite
the higher density clot formed at high thrombin concentration, the percent penetration of
nanoparticles was still increased when the clots were treated with higher nanoparticle
concentration and longer incubation time. Percent penetration was calculated by distance of
migration divided by clot diameter. The data were obtained from light microscopy and silver
enhancement methods.
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15 mins incubation

[High] FGN-cAu18

[Low] FGN-cAu18

60 mins incubation

Figure 58. Effect of nanoparticle concentration and labeling time on nanoparticle penetration into
WB clots formed with 1nM thrombin. Nanoparticles appeared at very low concentration in the
interior of WB clots that were labeled at low FGN-cAu18 concentration and short time of
incubation. When the FGN-cAu18 concentration and incubation time were increased, the effect of
nanoparticle penetration improved slightly. Under these conditions, nanoparticles were still more
likely to be found at the periphery of the clot rather than at the center. Micrographs were taken
under backscattered mode. White arrows indicate FGN-cAu18. Scale bars equal 10μm.
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60 mins incubation

[High] FGN-cAu18

[Low] FGN-cAu18

15 mins incubation

Figure 59. Effect of nanoparticle concentration and labeling time on nanoparticle penetration into
WB clots formed with 10nM thrombin. Under these conditions, finding nanoparticles in the
interior of the clots was rare. Very few nanoparticles were found near the center of the clots that
were labeled at low FGN-cAu18 concentration at the short incubation time. There was a slight
increase of nanoparticle concentration when clots were labeled at high FGN-cAu18 concentration
and long incubation time. However, nanoparticles appeared to be abundant only at the periphery
of the clots. Micrographs were taken under backscattered mode. White arrows indicate FGNcAu18. Scale bars equal 10μm.
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WB clots formed at 1nM thrombin
Clot
Labeling time
diameter
Distance
(mins)
(mm)
migration (mm)

Donor

OD522,
[label]

Percent
penetration (%)

#1

0.2

15

3.5

0.5

14

#1

0.2

60

2.7

0.58

21

#1

1

15

2.8

0.3

11

#1

1

60

3.27

1.1

34

#2

0.2

15

2.8

0.4

14

#2

0.2

60

3.33

0.83

25

#2

1

15

2.4

0.4

17

#2

1

60

3.6

0.75

21

Table 11. Quantification of nanoparticle penetration in WB clotted with 1nM thrombin, labeled
with low or high concentration of FGN-cAu18 and incubated for either 15 or 60 minutes. The
percent of nanoparticle penetration into WB clots was low at the low concentration with short
time of labeling. Increasing the time of incubation improved nanoparticle penetration, while the
effect of increasing nanoparticle concentration was less clear. As expected, nanoparticle
penetration was improved most when both incubation time and label concentration were
increased. Percent penetration was calculated by distance of migration divided by clot diameter.
The data were obtained from light microscopy and silver enhancement methods.

219

WB clots formed at 10nM thrombin
Clot
Labeling
diameter
Distance
time (mins)
(mm)
migration (mm)

Donor

OD522,
[label]

Percent
penetration (%)

#1

0.2

15

3.9

0.45

12

#1

0.2

60

2

0.5

25

#1

1

15

2.79

0.36

13

#1

1

60

2.2

0.48

22

#2

0.2

15

1.66

0.34

20

#2

0.2

60

1.68

0.43

26

#2

1

15

1.94

0.26

13

#2

1

60

2.48

0.62

25

Table 12. Quantification of nanoparticle penetration in WB clotted with 10nM thrombin, labeled
with low or high concentration of FGN-cAu18 and incubated for either 15 or 60 minutes. WB
clots formed at high thrombin concentration posed a significant challenge to nanoparticle
penetration. Thus, even when both label concentration and incubation time were increased,
nanoparticle penetration improved only slightly. Percent penetration was calculated by distance
of penetration divided by clot diameter. The data were obtained from light microscopy and silver
enhancement methods.
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cAu18

cFe3O4

+ OMF

- OMF

Control

Figure 60. Light microscopy analysis of magnetite nanoparticles and oscillating magnetic field
(OMF) treatment in RAW 264.7. In the control and colloidal gold (cAu18) samples, with or
without OMF treatment, cells were viable (indicated by exclusion of trypan blue), adhered, well
spread and present at high density on the surface of the coverslip. However, when the cells were
incubated with colloidal iron oxide (cFe3O4) and exposed to the OMF, the density of adherent
cells was significantly reduced, and many remaining cells had a rounded morphology. Also,
many cells were stained with trypan blue. White and black arrows indicate examples of trypan
blue positive and rounded cells, respectively. Scale bars equal 100μm.
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cAu18

cFe3O4

BEI

SEI

Control

Figure 61. SEM micrographs showing the uptake of magnetite nanoparticles by RAW 264.7. In
the secondary electron images (SEI), the RAW 264.7 cells appeared well spread, healthy and
adhered to the cover slip for all samples. In the backscattered images (BEI), cells that ingested
colloidal gold (cAu18) looked brighter than cells that ingested colloidal magnetite (cFe3O4).
Control cells without any nanoparticles show only minor internal signal from the OsO4 fixative.
Scale bars equal 1μm.
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cAu18

cFe3O4

+OMF

-OMF

Control

Figure 62. SEM micrographs of the RAW 264.7 cells labeled with cAu18 (gold) or cFe3O4
(magnetite) nanoparticles and exposed under the oscillating magnetic field (OMF). Cell
morphology was undamaged in control and cAu18 samples, with or without OMF treatment.
When the cells ingested cFe3O4 nanoparticles and were exposed to the OMF, the cells were
destroyed, and there were bits of membrane and debris left behind. Thus, damage of the cells
depended on both the uptake of cFe3O4 nanoparticles and OMF treatment. Scale bars equals
1μm.
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FGN-cAu18

FGN-cAu-Fe3O4

BEI

SEI

Control

Figure 63. SEM micrographs of surfaced-activated platelets labeled with fibrinogen-conjugated
gold nanoparticles (FGN-cAu18) and fibrinogen-conjugated gold-coated magnetite nanoparticles
(FGN-cAu-Fe3O4). All samples are in the absence of OMF exposure. High numbers of both
FGN-cAu18 and FGN-cAu-Fe3O4 are found around the granulomere of the platelets in secondary
electron images (SEI) and backscattered electron images (BEI). The arrows indicate the
localization of the nanoparticles. Scale bars equal 1μm.
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FGNcAu

FGN-cAuFe O

BEI

SEI

Contr
ol

Figure 64. SEM micrographs of targeted gold and magnetite nanoparticles and OMF killing
surfaced-activated platelets. All samples were exposed to the OMF. In secondary electron images
(SEI), the samples with no label (control) and labeled with fibrinogen-conjugated gold
nanoparticles (FGN-cAu18), showed platelets that were well spread and adherent. No damage
was observed with either the control or FGN-cAu18 treatment. In contrast, the cells died and were
fragmented in the fibrinogen-conjugated gold-coated magnetite nanoparticles (FGN-cAu-Fe3O4)
sample as a result of OMF treatment. The arrows indicate the localization of nanoparticles. Scale
bars equal 1μm.
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Chapter 5- Conclusions
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The holy grail of ischemic stroke treatment is to develop an agent that is highly effective
at reopening the occluded vessel without causing bleeding. To this end, it is important to
remember that hemostasis is a protective, physiologic process of clot formation that prevents
blood loss at the site of injury; whereas, thrombosis is considered to be a pathological condition
due to hemostasis in an exaggerated form. That means thrombosis and hemostasis share a
common mechanism, and appropriate, tight regulation of hemostasis is required to maintain the
delicate balance of normal processes between hemorrhage and thrombosis. Consequently, the
potency of any current antiplatelet strategy inevitably carries a risk of bleeding complications
(1). In this regard, we eagerly seek to develop the potential magic bullet of antiplatelet therapies,
one that is highly effective in treating thrombosis and yields little to no bleeding risk.
Integrin aIIbb3 receptors are highly expressed on platelets and are capable of binding
ligand with high affinity, regulated through distinct conformational changes in the integrin.
Normally, about 80,000 aIIbb3 receptors are expressed on the platelet surface, and further
numbers can mobilize from intracellular stores during platelet activation (2). Upon activation,
aIIbb3 receptors become competent to bind to their ligand fibrinogen. The receptors crosslinked
by the ligand then move through the platelet membrane, internalizing through the open
canalicular system, and concentrating at the center of the platelet (3,4). The binding of fibrinogen
to platelet integrin aIIbb3 receptors has been recognized as a powerful target for antiplatelet
therapy (5). For example, the antibody treatment abciximab can inhibit platelet function through
blockage of fibrinogen binding to platelet integrin aIIbb3 receptors, thereby blocking platelet
aggregation. This has shown effectiveness in reducing platelet aggregation and preventing reocclusion in a clinical setting. However, abciximab does not distinguish between integrin aIIbb3
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receptors on activated and quiescent platelets (1,6). As a result, it has been considered to be
associated with higher bleeding rates in patients with acute ischemic stroke.
We expect our fibrinogen-based targeting to be able to select for activated platelets
involved in thrombi formation while leaving circulating platelets unaffected. Hence, we
proposed that using fibrinogen-conjugated nanoparticle targeting followed by magnetically
induced hyperthermia could be a better option than current antibody treatments in terms of
increasing therapeutic effects through highly localized hyperthermia, and concomitantly reducing
bleeding complications. Building upon our previous work (7), we have demonstrated here that
fibrinogen-conjugated nanoparticles are able to specifically associate with activated platelets in
the presence of plasma fibrinogen and red blood cells (RBCs). However, this method has a few
challenges that might prevent the fibrinogen-conjugated nanoparticles from effectively
interacting with activated platelets in clots that must be considered.
First, plasma fibrinogen can interact with unoccupied aIIbb3 receptors of activated
platelets. At the same time, plasma fibrinogen can strongly associate with our nanoparticle
labels. Thus, we observed that fibrinogen-conjugated nanoparticles heavily bind to fibrin in
preformed platelet-rich plasma (PRP) and whole blood (WB) clots. In fact, the presence of
plasma fibrin(ogen) is unavoidable at the site of an occlusive clot in vivo; thereby, its binding is
likely to inhibit and compete with fibrinogen-conjugated nanoparticles in binding to aIIbb3
receptors of activated platelets. Moreover, the presence and generation of thrombin during clot
formation could be a factor causing a reduction in penetration of fibrinogen-conjugated
nanoparticles into clots. Due to the ability to cleave fibrinogen into fibrin, thrombin possibly can
convert both plasma fibrinogen and conjugated fibrinogen to fibrin. The combination of the
polymerized product of thrombin-cleaved fibrinogen, fibrin within the preformed clot, and
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plasma fibrinogen is likely to have caused steric hindrance and competition that further prevents
the association of fibrinogen-conjugated nanoparticles to their target deep in the interior of the
clot.
To deal with plasma fibrinogen competition in binding to aIIbb3 receptors on activated
platelets and the steric hindrance of fibrin due to thrombin activity, an effective ischemic stroke
treatment could include a co-administration of tissue plasminogen activator (tPA) along with
fibrinogen-conjugated nanoparticles. The tPA will activate the fibrinolysis pathway by lysing
fibrin within the blood clot to promote a reduction in the structural integrity of the blood clot, as
well as reducing the amount of fibrin network surrounding the clot. Consequently, the
fibrinogen-conjugated nanoparticles will have better access to their targets and better opportunity
to produce their desired effects. In addition, fibrinogen-conjugated nanoparticles can integrate
strongly with the fibrin network within a blood clot and may be able to promote clot release by
causing hyperthermia to the fibrin network directly. Even without tPA co-administration,
fibrinogen-conjugated nanoparticle administration may be still able to dissolve the blood clot and
can be considered as a second method to dissolve the blood clot. On the other hand, due to an
ability to associate significantly with fibrinogen-conjugated nanoparticles, fibrin(ogen) can be
considered as another potential site-specific target to treat ischemic stroke. Arterial clots consist
mainly of fibrin and activated platelets (8,9). Thus, if fibrinogen-conjugated nanoparticles can
bind specifically to both protein and cellular components, it might strengthen our targeting
strategy.
We demonstrated that fibrinogen-conjugated nanoparticles do not interact with RBCs.
This implies that our targeting strategy could be specific and safe when administrating in vivo to
treat ischemic stroke. However, the contribution of RBCs to the bulk of occlusive and arterial
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clots at high thrombin concentration is problematic in preventing the binding of the nanoparticle
label to its target aIIbb3 receptors on activated platelets within clots. In WB clots formed at high
thrombin concentration, a meshwork of fibrin and platelet aggregates was observed mostly on
the clot surface, and the interior consisted of closely packed, compressed polyhedral erythrocytes
with very little fibrin and activated platelets present. Despite increasing both nanoparticle
concentration and labeling time, the access of nanoparticle labels was limited to the periphery of
the clot. As a result, under the oscillating magnetic field (OMF), we might expect the disruption
to occur mainly at the periphery of the clot where fibrin and activated platelets were located.
Also, the disruption might not be sufficient to dissolve the clot and restore blood flow as our
method has proposed.
There are a few ways that we can overcome this problem. First, we could label the clot
multiple times with fibrinogen-conjugated nanoparticles. Also, OMF exposure could be applied
after each labeling, if multiple labeling does not improve nanoparticle penetration and
concentration within the clot alone. By doing that, we could slowly shave off clot layers and
eventually, the clot would become small enough that it would no longer obstruct blood flow. As
mentioned above, tPA co-administration could be utilized to further speed up and improve the
labeling process by lysing fibrin within the clot and allowing fibrinogen-conjugated
nanoparticles to interact more easily with their intended platelet targets.
The co-precipitation method is the simplest and easiest way to synthesize magnetite
nanoparticles. However, the synthesis procedure is not robust and commonly produces
nanomaterials with a large size distribution leading to a non-ideal magnetic behavior (10). This
could influence the clot heating and killing ability of magnetite nanoparticles. Using the
phagocytic cell model combined with light microscopy to test the efficacy of magnetite
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nanoparticles is relatively quick. It also provides a reliable way to determine whether or not the
magnetite nanoparticles will be successful in disrupting activated platelets after being coated
with gold and conjugated to fibrinogen. However, improving and refining magnetite nanoparticle
synthesis procedures will need to be a priority because a more robust synthesis would increase
chances of successful clot disruption. To achieve a reproducible magnetite synthesis procedure,
several parameters have to be carefully mastered to keep control over the range of sizes, colloidal
stability, and oxidation surfaces of the magnetite nanoparticles. These include the reaction
temperature (10,11), oxygen presence (12), pH (13,14), ionic force (13,14) and the addition of
stabilizers (15). Another possible contributor affecting hyperthermia damage efficacy of
magnetite nanoparticles is the different morphologies of gold-coated magnetite nanoparticles. In
fact, it is somewhat difficult to control the particle aggregation, uniformity, and thickness of the
gold deposition (16,17). In the future, it may be worth examining whether one particular
nanoparticle morphology preferentially binds to platelets and is responsible for the majority of
localized hyperthermia. Also, examining and characterizing whether different morphologies of
gold-coated magnetite nanoparticles are more easily conjugated to fibrinogen would provide
additional knowledge into designing and synthesizing high-quality magnetite nanoparticles for
use as an agent in treating ischemic stroke.

Future directions:
Our current work demonstrated that it is possible to specifically target activated platelets
in clots by using fibrinogen-conjugated nanoparticles. The next logical step would be using
nanoparticle-induced hyperthermia to disrupt PRP and WB clots in vitro. We anticipate that PRP
clots will be dissolved more readily than WB clots. WB clots may require multiple labeling in
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combination with multiple OMF exposures to acquire sufficient clot disruption. Additionally, we
might encounter that hyperthermia does not generate enough damage to the clot. This could be
due to the superparamagnetic nanoparticles not heating up efficiently at the applied frequency of
500kHz. Further improvements to platelet hyperthermia may come from the optimization of the
frequency of the OMF. Many studies about superparamagnetic nanoparticle heating showed that
frequencies below 500kHz cause better heat generation (18-21). Thus, it is possible that our
fibrinogen-conjugated gold-coated magnetite nanoparticles would heat more efficiently at lower
frequencies.
The essential role of shear stress, produced by the blood flow on arterial thrombus
formation in native human blood, is another aspect that we could explore in future experiments.
In fact, the changing flow and shear rate could facilitate certain organizations and amounts of
blood clot components within clots. The actual efficacy of many antithrombotic agents is flow
and shear dependent (22,23). Since we demonstrated that nanoparticle penetration significantly
relies on clot structure and organization of its components, it is apparent that the efficacy of
magnetite nanoparticle penetration could be flow and shear dependent as well. Moreover, the
current experiments occurred in the absence of flow; therefore, this gives an incomplete
understanding about nanoparticle dosage, and the interaction strength of nanoparticles with the
clot.
It would be interesting to observe fibrinogen-conjugated, gold-coated magnetite
nanoparticles in use as a platelet targeted ischemic stroke treatment in vivo using a murine model
of carotid artery thrombosis. To do that, we would use the ferric chloride-induced injury model
to generate platelet-rich thrombi in murine carotid arteries because the occlusive clots formed
with this method are relatively similar to those seen in human ischemic stroke patients (24-26).
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Then, fibrinogen-conjugated nanoparticles could be injected through the tail vein, with normal
blood circulation distributing the nanoparticles to the activated platelets at the occlusive site.
Alternatively, nanoparticles can be directly administered to the site of an occlusive clot by
catheter. After nanoparticle administration, the mouse would be exposed to the OMF. The
treatment would be monitored by measuring the blood flow through the artery using an
ultrasonic probe. The success of the treatment will be examined and evaluated by electron
microscopy. However, these in vivo experiments have significant technical challenges. First,
microsurgery is not a simple technique. Indeed, when microsurgery is performed on an
anesthetized mouse to expose the carotid artery, any additional damage to the vessel and
surrounding tissue must be avoided. Also, due to the small size of the murine vasculatures,
catheterizing an artery can cause thrombotic events by itself. Therefore, it may not be feasible to
effectively delivery a dose of nanoparticles to the blood clot that will be sufficient to result in
disruption.
There will be many challenges that need to be overcome before our novel treatment for
ischemic stroke, which is specific cell targeting with nanoparticles for hyperthermia, can be
introduced to in vivo applications. However, the meaningful results of our characterization of the
targeting of fibrinogen-conjugated nanoparticles in both PRP and WB clot systems provided
important insights in how to further develop this ischemic stroke treatment. Additionally,
through the development of this novel anti-platelet therapy for ischemic stroke, determining and
optimizing the treatment conditions will be useful not only for targeting platelets, but also other
pathologic cell types such as cancer.
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